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Phagocytes are important players in host exposure to nanomaterials, by 
processing nanomaterials and possibly contributing to host nanotoxicity.  Macrophages in 
particular are believed to be among the “first responders” and primary cell types that 
uptake and process nanoparticles, mediating host biological responses by subsequent 
interactions with inflammatory signal pathways and immune cells.  Thus, it is important 
to understand how nanomaterials are recognized, internalized, trafficked and distributed 
within this cell type and how this cell-based reaction furthers responses in vivo.  This 
dissertation will focus on describing macrophage-based silica nanoparticle exposure, 
mechanisms of uptake, intracellular fate and potential initiation of downstream 
immunological processes, as a function of physicochemical properties such as size, 
surface properties and geometry. Alterations in physicochemical properties, specifically 
geometry of nanomaterials, can influence cellular uptake mechanisms. Specific 
macrophage phenotypes are shown to induce nanoparticle uptake in vitro and in vivo. 
Mechanistic evaluation has provided evidence of cellular machinery inducing 
autonomous antimicrobial defense and cytoplasmic clearance mechanisms such as 
autophagy in response to positively charged silica nanoparticle exposure. Understanding 
nanoparticle macrophage interactions may allow for the development of platforms to 
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Nanomaterials may be capable of directing specific internal cell trafficking and 
processing pathways. Specific trafficking and pathways can, in turn, lead to significant 
advances in overcoming roadblocks to drug delivery, which have prevented many types 
of treatments from becoming viable therapies. Nanoparticles can also be used as antigen 
presentation delivery vehicles, providing new routes of immunostimulation and potential 
vaccination. Despite the potential of engineered nanoparticles to traffic to specific 
intracellular destinations, little is known about the influence of their physicochemical 
properties on complex interactions with the surrounding milieu. To understand how 
nanomaterials are processed in vivo and their translational potential, we must first 
understand nanoparticle cellular uptake and intracellular fates. Cellular uptake and fate 
can be used to predict physiological destinies and engineer more effective multifunctional 
diagnostics and therapeutics. 
Slight alterations in physicochemical properties of nanomaterials can significantly 
influence how they interact with the biological milieu (1-7). The impact of 
physicochemical properties on cellular uptake pathways and intracellular fates is 
important for drug delivery (8-13). Alterations in surface characteristics can produce 
unexpected adverse events, for example induced inflammatory cascades, mitochondrial 
dysfunction and autophagy (4, 6, 14-19).  
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A better understanding of how the interface between host and nanomaterial 
influences uptake, transport, distribution, and initiation of biological mechanistic 
responses will create increased therapeutic benefit and safety of nanomaterials as 
potential delivery agents. While evidence suggests that physicochemical characteristics 
profoundly influence these biological responses, not all characteristics are equally 
important and many responses are not understood. Ideally, one could assess, predict and 
correlate host biological response to various physicochemical characteristics of 
nanomaterials. Phagocytes are believed to initiate host biological responses and may help 
to solve global delivery issues.  
Phagocytes are important players in host exposure to nanomaterials by processing 
and possibly contributing to host toxicity. Macrophages, in particular, are believed to be 
among the first responders and primary cell types that uptake and process nanoparticles. 
Macrophages may also mediate host biological responses by interacting with 
inflammatory signaling pathways and immune cells. Further, in vitro macrophage model 
systems have proven more susceptible to nanoparticle treatment and tend to predict in 
vivo outcomes better than other cellular in vitro systems (3).  
Phagocytes recognize and process nanoparticles in vivo. Clinical data show a 
correlation of increased phagocytic activity with decreased therapeutic efficacy of carrier-
mediated anticancer agents and with increased clearance rates in patients (20, 21). 
Increased residence time of nanomaterials in clearance organs is also generally attributed 
to increased phagocytic recognition in vivo (22-28). Inflammatory gene expression 
upregulation and increases in inflammatory phenotypes occur both in vitro and in vivo 
following nanoparticle exposure (10, 13, 29-38). How nanomaterials are recognized, 
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internalized, trafficked, and distributed within macrophages will help to eliminate this 
inflammatory response in vitro and in vivo.  
The work in this dissertation will focus primarily on correlating macrophage 
responses to engineered silica nanoparticle exposure as a function of nanoparticle 
physicochemical characteristics, where results can be used to manipulate mechanisms of 
uptake and intracellular fate within macrophages. By deriving this basic understanding of 
initiation of biological responses, it will be possible to develop a platform with the ability 
to make either macrophage-targeted or macrophage-invisible systems with specific 
intracellular uptake and fates.  
 
1.2 Hypothesis and Aims of this Dissertation 
The central hypothesis is that engineered silica nanoparticle intracellular uptake 
and fate in macrophages can be manipulated by alterations in geometry and in surface 
characteristics, as discussed in the three aims below. A correlative understanding between 
how physicochemical properties induce macrophage uptake and fate could improve the 
therapeutic effect of drug delivery systems and avoid deleterious effects. This hypothesis 
was tested through three Specific Aims: 
1. Assess the toxicity and intracellular fate of engineered positively charged silica 
nanoparticles as a function of geometry in macrophages. 
2. Evaluate the intracellular uptake of positively charged silica nanoparticles as a 
function of geometry in macrophages. 
3. Investigate the influence of variations in macrophage phenotype on cellular 
uptake and intracellular fate in vitro and in vivo. 
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1.2.1 Specific Aim 1: Assess the toxicity and intracellular fate of 
 engineered positively charged silica nanoparticles as a  
function of geometry in macrophages 
Successful clinical nanoparticle candidates deliver high payloads of therapeutics 
to intended intracellular compartments, increasing efficacy and minimizing potential side 
effects. The understanding of how physicochemical characteristics influence   
intracellular compartment delivery, however, is limited. Within this aim we evaluate the 
intracellular fate of highly positive-charged silica nanoparticles with geometric 
variations, to determine the effect of geometry on intracellular fate. Interestingly, changes 
in geometry did not alter intracellular fate within RAW 264.7 macrophages. In response 
to silica nanoparticle exposure macrophages induced autophagy, which, within this 
context, could follow autonomous antimicrobial defense mechanisms. Autophagic 
mechanisms appear to aid in cellular coping, reduce toxicity, provide potential clearance 
mechanisms and initiate nanoparticle stability in vivo (39). Other groups have shown 
similar fates for highly positive-charged gold nanoparticles, iron oxide, polyplexes and 
dendrimers (40-44). These results suggest that in some cases positively charged particles 
should not be used for targeted intracellular delivery. This is especially true in cases 
where the payload needs to be delivered to a specific intracellular compartment since 
positively charged systems are most likely trafficked to intracellular compartments that 






1.2.2 Specific Aim 2: Evaluate the intracellular uptake of  
positively charged silica nanoparticles as a function of  
geometry in macrophages 
Chapter 4 evaluates the ability of nanoparticle geometry to induce uptake 
mechanisms. The results show that nanoparticle physicochemical characteristics, 
specifically geometry and surface contact area, can be manipulated to induce endocytosis 
and phagocytosis. By inducing pinocytosis/phagocytosis, intracellular fate gene 
expression was altered, which suggests that manipulation of uptake mechanisms of 
nanoparticles could lead to specific intracellular fates (45). For example, endosomal 
compartments have known internal intracellular trafficking receptors, which can be drug 
targets (46). In this case, therapeutic efficacy would benefit from specific uptake and 
endosomal trafficking mechanisms. Such design manipulation would likely enhance 
targeted intracellular delivery. This chapter suggests that altering the geometry or cellular 
surface contact area of the delivery system will enhance design. Therefore, Chapter 4 
suggests directing intracellular uptake mechanisms would be advantageous when 
developing delivery systems in order to influence fate or avoid deleterious effects.  
 In addition Chapters 3 and 4 contain supplemental information on the impact of 
physicochemical characteristics on intracellular uptake and fate in A549 cells. A549 cells 
are a human lung cancer model system, which behaves similarly to RAW 264.7 cells. In 
Chapter 4, A549 cells were compared to primary human lung epithelial cells. Results 
showed that A549 cells did not uptake particles like normal human lung tissue. In 
Chapter 4, RAW 264.7 macrophages, however, did follow similar particle uptake and 
trafficking patterns when compared to normal primary human macrophages. Due to the 
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lack of comparison between normal tissue and A549 cells, I present the data but have 
opted to leave a discussion of that data out of this dissertation.   
 
1.2.3 Specific Aim 3: Investigate the influence of variations in  
macrophage phenotype on cellular uptake and  
intracellular fate in vitro and in vivo 
Macrophages have been shown to alter phenotype and differentiation states as a 
function of their environmental cues in vitro and in vivo (47). The various macrophage 
phenotypes perform different physiological functions in vivo. Therefore it is possible to 
infer that different macrophage phenotypes are likely to exhibit different intracellular 
uptake and fate pathways when interacting with nanoparticles. Chapter 5 explores the 
uptake, toxicity and intracellular fate of nanoparticles within two in vitro macrophage 
polarization models: M1 induced with INF-gamma and LPS, and M2 induced with IL-4. 
Afterwards, the macrophage polarization results are correlated to in vivo systems. 
This exploration found nanoparticle uptake, morphology and cytokine/chemokine 
release are altered by changes in macrophage phenotype. Results suggest that M1 
macrophages are the primary mediators for nanoparticle uptake, while M2 macrophages 
appear to play little to no role. Macrophage residence within splenic and liver tissues 
increases over time. Liver and splenic tissues were also shown to be the primary sites of 
nanoparticle accumulation via quantitative ICP-MS. In vivo, M1 macrophages were 
primarily upregulated and nanoparticles appeared to be accumulating within the vacuoles 
of these cells. This work shows that M1 macrophage-mediated uptake could influence in 
vivo and in vitro silica nanoparticle processing.  
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This final aim demonstrates the importance of selecting for phenotype in in vitro 
studies investigating nanoparticle design. Specifically, Chapter 5 shows a higher 
correlation to in vivo results when utilizing M1 model systems. This system may provide 
an in vitro mechanism to study macrophage avoidance in vivo, helping to improve in vivo 
payload delivery and therapeutic effect. 
This dissertation discusses nanoparticle physicochemical characteristic influence 
on biological interactions. A review of literature relevant to this work is discussed in 
Chapter 2 (48). Chapter 3 discusses the impact of physicochemical characteristics on 
intracellular fate. Chapter 4 discusses the impact of physicochemical characteristics on 
intracellular uptake. Chapter 5 discusses the impact of macrophage phenotype on uptake 
and fate and correlates this to in vivo mechanisms. (39, 45, 49). Across these chapters I 
will explore the possibility of manipulating physicochemical characteristics to influence 
nanoparticle macrophage mediated uptake and intracellular fate. Finally, Chapter 6 will 
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Nanoparticles have substantial clinical potential; they may be capable of directing 
specific internal cell trafficking and processing pathways that could lead to significant 
advances in overcoming roadblocks to drug delivery that have prevented many types of 
treatments from becoming viable therapies. For example, hydrophobic drugs, nucleic 
acids and proteins have been encapsulated within nanoparticles to reduce intracellular 
degradation, increase circulation and improve efficacy. As a result, nanoparticles as 
antigen presentation delivery vehicles have become more popular, providing new routes 
of immunostimulation and potential vaccination. In 2013, 241 companies and institutions 
had, combined, 789 ongoing clinical trials and 103 unique investigational products in 
nanomedicine (1).  
However, despite the great potential and sharp rise in clinical trials and 
investigational products, only 38 products have received FDA-approval across the 60 
years of investigational research (1). The field of nanomedicine faces significant 
challenges related to clinical development when compared to the 32 traditional small 
molecular weight therapeutics the FDA approved in 2012 alone. Nanomaterials face a 
different set of challenges from small molecular weight therapeutics given that 
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nanomaterials are on the same size scale as biologicals, facilitating increased interactions. 
The size scale may also help to explain limitations in clinical translation, probably 
connected to nanoparticle clearance potential. This chapter will discuss nanoparticle 
clearance, the cells responsible, and strategies to attain better retention to improve 
translatability. 
Slight alterations in properties of nanomaterials can significantly influence how 
these materials interact with the biological milieu (1-7). Surface characteristics may also 
produce unexpected adverse biological events, for example, induced inflammatory 
cascades, mitochondrial dysfunction and autophagy (1, 6, 8-14). The impact of drug 
delivery properties is particularly important on cellular uptake pathways and intracellular 
fate destinations (15-21). A better understanding of how the interface between host and 
nanomaterial influences uptake, transport, distribution and initiation of biological 
mechanistic responses is required to assess therapeutic benefit and safety. Ideally, one 
could assess, predict and correlate host biological response to various physicochemical 
characteristics of nanomaterials. Physicochemical characteristics, such as surface 
chemistry, charge, shape and topography profoundly influence uptake, transport, 
distribution and initiation of biological mechanistic responses. However, not all 
characteristics are equally important and few mechanisms are clear. Yet, phagocytes 
appear to play a clear role in modulation of these responses.  
Phagocytes are important players in host mechanistic responses to nanomaterials, 
processing these materials and contributing to host toxicity. Macrophages, in particular, 
are among the “first responders” and primary cell types that uptake and process 
nanoparticles, mediating host biological responses by subsequent interactions with host 
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inflammatory signaling pathways and immune cells. The following examples will help to 
illustrate the need to understand how nanomaterials are recognized, internalized, 
trafficked and distributed within macrophages and how macrophage response influences 
outcomes in vivo. In vitro macrophage model systems have proven more susceptible to 
nanoparticle treatment and tend to predict in vivo outcomes better than their in vitro 
counterparts (4). Clinical data have correlated increased phagocytic activity to decreased 
therapeutic efficacy of nanoconstructs and increased clearance rates in patients (22, 23), 
while increased residence time of nanomaterials in clearance organs is also generally 
attributed to increased phagocytic recognition in vivo (24-30). Following nanoparticle 
exposure, inflammatory gene expression and phenotypes increase both in vitro and in 
vivo (18, 21, 31-40). Macrophages clearly play an essential role in nanoparticle 
processing and neglecting their role could be detrimental to nanoparticle translation.  
In this chapter, I will argue that a majority of the nanoparticle drug delivery and 
imaging literature has neglected the role of macrophages in in vivo nanoparticle 
processing, which has caused deficiencies in nanoparticle design resulting in limited 
clinical translation. Design and translation could be improved by understanding 
macrophage-nanoparticle interactions. This chapter will address failures and success of 
nanomaterials as a function of macrophage nanomaterial interactions with the goal of 







2.1.1 The role of the mononuclear phagocytic system in 
nanoparticle processing 
 The low FDA approval rates, mentioned earlier, of nanoparticle therapeutics and 
diagnostics illustrate the limitation of nanoparticle clinical translation in human patient 
populations. Failure can be attributed to rapid excretion of therapeutics and diagnostics or 
induction of inflammatory responses due to nonspecific recognition and uptake of 
nanoconstructs by macrophages. Rapid excretion limits accumulation at target delivery 
sites and inflammatory responses induce toxicity. 
Clinical trials of IV-administered systems, which represent 120 of these 789 
ongoing clinical trials, illustrate the important role of excretion rates and the important 
clinical role of the mononuclear phagocytic system (MPS) in nanoparticle delivery. 
Successful nanoparticle clinical candidates should deliver high payloads to target sites; 
however, only ~.01% of the total injected dose of drug is delivered to its target site 
(outside of the liver and spleen). The other 99.99% of dose ends up being cleared or 
residing in nonspecific clearance organs (41).  
Current literature attributes this to the rapid association of these nanomedicines 
with elements of the MPS (42). To some extent association of nanoparticles with the 
mononuclear phagocytic system is a function of the opsonization that the particle 
undergoes when exposed to the blood and the recognition of these opsins via the MPS 
(43), particularly Kupffer cells and splenic macrophages. If macrophages are indeed 
responsible for high clearance rates, the disappointing efficacy due to poor delivery of 
active drug payloads to specific targets is likely a result of macrophage-nanoparticle 
recognition and subsequent processing. If delivery vehicles were designed such that they 
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either avoided or harnessed this recognition system, payload delivery and subsequent 
efficacy could be enhanced significantly. However, in order to design appropriate 
systems an understanding is needed of nanoparticle-macrophage interactions both at a 
cellular and a system-wide level. Macrophages recognize opsonized proteins, specific 
surface chemistries, and other surface and biological characteristics marking these 
nanoparticles for clearance and/or toxicological fates. Physicochemical characteristics 
can influence these interactions and may also potentiate toxicological mechanisms. What 
is not understood is how nanoparticle surfaces interact with the biological environment 
and how this interaction influences phagocytic clearance and toxicological fates. 
Developing a correlation between nanoparticle physicochemical characteristics and 
nanoparticle uptake, processing and clearance mechanisms in macrophages would aid the 
design of new, more efficacious and safer nanomaterial platforms. 
While increased clearance capacity and improved circulation rates would be 
beneficial to increasing translation, the future of nanomaterial design needs to focus on 
reducing nanoparticle inflammatory related toxicity. Safer nanoparticle platforms are key 
to ensuring clinical translation and an understanding of MPS-nanoparticle interactions 
could help to design new nanoparticle systems to avoid inflammatory adverse events. 
Orthopedic implant-centered inflammation represents one of the best clinical examples of 
induced MPS-nanoparticle inflammation. Implanted metallic biomaterials, such as those 
utilized in total knee or hip replacements, release nanoparticulates as a result of 
environmental stress placed on the given medical device. Released nanoparticles are 
believed to cause the development of aseptic osteolysis, which is the result of local 
macrophage recruitment, i.e., phagocytosis of the particles shed from the device, and a 
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resulting local inflammatory response (44). Patient hip tissue samples from cases of 
implant-centered inflammation have been examined histopathologically and large 
numbers of CD68-positive foamy macrophage cells were observed in the surrounding 
tissue (44). The increased macrophage populations indicate large local macrophage 
recruitment as a result of implant inflammation. Subsequent gene expression analysis 
illustrated that foamy macrophages are strongly associated with expression of osteolytic 
proteins (44). These findings have been correlated in vitro with macrophage 
inflammatory genomic profiling as a result of particle wear exposure (45). This suggests 
the role of macrophages in the induction of aseptic osteolysis, a chronic local 
inflammatory disorder. This local inflammatory reaction could be indicative of what 
could result in tissue; with a large accumulation of nanoparticles this could facilitate 
similar inflammatory mechanisms. These mechanisms could cause negative 
inflammatory effects in certain tissue accumulation sites, especially clearance organs, 
potentially impacting future nondegradable nanoparticle design for imaging or drug 
delivery systems. 
 
2.1.2 What is a phagocyte/macrophage? 
Understanding the role of macrophages in nanoparticle processing requires a basic 
understanding of macrophage cellular characteristics. What is not well known is how 
these cellular characteristics influence cellular-nanoparticle interactions, required for 
effective design of nanomaterials. Ideally, a correlation would be drawn between 
nanoparticle-macrophage interactions and in vivo delivery fates and toxicity, improving 
circulation, safety and clearance potential of nanomaterials. 
18 
 
  Macrophages are key in vivo components of normal inflammatory and 
immunological processes. Certain forms of this cell type are essential in the destruction 
and removal of deleterious materials, pathogens, and damaged or abnormal tissue from 
the body; these native roles may be used in nanoparticle processing. These cell types also 
play an essential role in wound healing, introducing local angiogenesis and tissue 
remodeling. Macrophages also play a primary role in the macroscale foreign body 
response to engineered biomaterial implants, initiating local fibrosis and unresolved 
inflammation. These pathologies may also be implicated in the in vivo fate of 
nanomaterials. Alterations in the role of macrophages arise from changes in phenotypic 
characteristics, which may also induce variations in nanoparticle interactions.  
Macrophage is a broad classification for a cell type whose phenotype is 
influenced by environmental cues that alter morphology, surface receptor expression and 
function. Phenotypic changes induce variations in interactions with nanoparticles, as 
changing surface receptors and overall function can alter recognition and uptake patterns. 
Understanding macrophage phenotype and lineage may help to identify how to harness 
uptake and recognition patterns. Macrophages had been thought to derive solely from the 
hematopoietic stem cell (HSC) lineage; however, more recent literature in the field of 
developmental biology observed some of these cells in the embryo prior to the 
development of HSC lineage. This suggests that at least a portion of what we currently 
classify as macrophages may be genetically distinct from the hematopoietic progeny, 
suggesting that in order to understand macrophage-nanoparticle interactions one must 
look at multiple phagocytic model systems (46). Experts studying dendritic cells and 
macrophages, both subsets of traditional end point HSC cell types, recently suggested 
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that these subsets are more similar than originally thought (47). These two cell types 
might be phenotypes of the same cell.  
As stated previously, the large variations in morphological features and functional 
roles of this cell type may be due simply to environmental factors. Evidence suggests that 
local microenvironmental factors and cues drastically alter the phenotype and 
differentiation states of macrophages (48). Environmental factors directly impact how 
these cells interact, positively or negatively, with the surrounding tissue and homeostatic 
environment, and also may impact how they process nanomaterials in vivo.  
 
2.1.2.1 Macrophage interaction with extracellular environment 
The response of macrophages to their local external environment has the potential 
to substantially impact how nanomaterials are handled in vivo, understanding this impact 
could improve delivery. The following two studies illustrate the need to understand the 
overall state of macrophages in vivo and how macrophage responses to unrelated factors 
may potentially drastically alter the quiescence and uptake of nanoparticulate drug 
delivery systems, such as systemic inflammation or specific disease states. In the first 
study, local activation of normally quiescent tissue macrophages may rearrange surface 
receptors, which make them more susceptible to nanoparticle recognition, and leads to 
abnormally increased internalization rates in phagosomes (49). Increased clearance rates 
were observed in animals treated with zymosan to activate local macrophages. This 
appears to be opsonization-independent and is enhanced compared to control (50). A 
similar study evaluated the priming effect of INF-gamma on the increased uptake of 
chitin particles in an alveolar macrophage model (49). This priming enhanced uptake 
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within the macrophage system and probably polarized them to a more phagocytic 
phenotype. This heightened phagocytic phenotype would account for the observed 
increase in uptake. 
 
2.1.2.2 Macrophage phenotype and environmental factors 
Macrophage polarization states drastically alter nanoparticle uptake and biological 
response, so understanding this impact could improve delivery. According to the 
Th1/Th2 paradigm, in some cases macrophages can reside within a classically activated 
state (M1) or alternatively activated state (M2). M1s are induced via INF-gamma and are 
what we would normally consider immune-activating phagocytic janitorial cells. M2s are 
induced via IL-4/IL-13 and activate angiogenesis, immune suppression and tissue 
breakdown/remodeling (Figure 2.1). However, the Th1/Th2 model system has proven to 
be overly simplified, as many macrophages lie in a state in-between the M1 and M2, or 
even in an M1/M2 unrelated cellular state. However, the Th1/Th2 system does permit the 
study of how environmental factors can influence nanoparticle processing. For example, 
M1 macrophages provide the most robust and drastic response to titanium particulate 
exposure, when compared to M2s. M1s increased inflammatory cytokine and chemokine 
production, while M2 cells, despite uptaking particles, showed a broad suppressed 
inflammatory response. This difference suggests that microenvironmental factors capable 
of inducing phenotypic changes can influence how cells, particularly macrophages, might 
respond to particulate exposure (38). Suggesting one should use multiple phenotypes in 
in vitro culture model systems to ensure that relevant correlative in vivo information is 
derived. Variations in surface characteristics or adsorbed proteins may alter how 
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Figure 2.1:  Environmental impact on macrophage phenotype and function.  
Environmental cytokines known to induce specific macrophage phenotypes 
are outlined below the arrows. The cytokines/chemokines that are known to 
be released from the specific macrophage phenotypes are outlined below 
the macrophages.  The functions of the phenotype in vivo are outlined to 
the right of the macrophages.	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nanoparticles interact with macrophage phenotypes.  
 
2.1.3 Presentation of nanomaterials to phagocytes 
A host system never sees a bare nanomaterial, due to immediate host protein 
adsorption upon blood or tissue contact (e.g., serum proteins such as IgG, fibrinogen, or 
albumin). As the field of nanomaterials progresses, it becomes essential to understand the 
adsorption process of proteins and what characteristics of nanoparticles initiate desired 
and adverse effects, as well as how presence and conformation of adsorbed proteins 
influences the presentation of nanoparticles to phagocytes. Understanding this 
recognition will help to ensure that nanoparticles are not cleared too rapidly or induce 
adverse toxicological effects. The composition and conformation of proteins adsorbed to 
the surface of nanoparticles influences how nanoparticles interact with macrophage 
surface receptors and mediates phagocytic recognition. Depending on the nature of 
protein adsorption to a surface, conformational changes could occur which can facilitate 
adverse opsonization, initiating phagocytosis and potentially inflammatory reactions. 
Physicochemical characteristics are important mediators of such adsorptive properties. 
Conformational changes in these proteins can result from surface curvature, topography 
and hydrophobicity. These adsorption characteristics allow for the presentation of 
nanoparticles to phagocytes to vary widely, initiating both advantageous and adverse 
events, which could range from bioinvisibility to complement activation resulting in 





2.1.3.1 Surface curvature 
The physicochemical characteristics of the surface of nanoparticles can influence 
protein conformational adsorption to nanomaterials, which can increase or decrease 
phagocytic recognition. If the protein maintains its original conformation, detrimental 
cellular uptake or induced toxicity is unlikely to occur. However if native protein 
confirmation is not maintained, certain epitopes can be exposed and this may initiate 
phagocytic uptake, complement activation, or thrombosis formation. Surface curvature of 
nanoparticles has been proven to stabilize protein conformation (51); however, the degree 
of curvature can drastically affect this stabilization and cause stable and irreversible 
protein denaturation. For example, Vertegel et al. (52) found that lysozyme adsorbs to the 
surface of silica nanomaterials with diameters as small as 4 nm and as large as 100 nm. 
They further observed that smaller nanoparticles with higher surface curvatures retained 
native conformational shapes of lysozyme to a greater degree than larger nanoparticles 
with less surface curvature. Albumin was also observed to retain its native conformation 
on particles with a higher surface curvature while fibrinogen exhibited the opposite effect 
(53). These studies suggest that all protein adsorption onto nanoparticle surfaces could 
potentially be manipulated through controlling surface curvature. While albumin 
adsorption onto large silica nanoparticles does not appear to significantly perturb its 
conformation, macrophage uptake of albumin-coated silica occurs via scavenger surface 
receptors and fibrinogen adsorption of Mac-1 surface recognition (43, 54). Recognition 
of conformationally modified proteins via surface receptors may potentiate faster 





 Similar to surface curvature, surface topography of nanoparticles could cause 
protein adsorption or alterations in protein folding, influencing phagocytic cellular uptake 
(55). Bovine serum albumin (BSA), for example, adsorbs more heavily to rough platinum 
surfaces compared to smooth platinum surfaces (56). Increased BSA adsorption likely 
explains why rough gold nanomaterials have shown reduced uptake when compared to 
smooth gold nanorods and spheres in neuronal microglial cells (31), suggesting that 
uptake might be a function of variations in protein coronas. These spikey gold 
nanoparticles also interact with proteins on neuronal cell surfaces, which seemed to 
facilitate reduced expression of certain proteins, such as granulocyte macrophage colony 
stimulating factor (31). The result of this protein adsorption was a dissipation of 
phagocytic activity of these systems. Further studies could elucidate how to enhance such 
topography to help create “bioinvisible” systems by encouraging adsorption of specific 
proteins in specific conformations.   
 
2.1.3.3 Surface hydrophilicity and hydrophobicity 
 Altering surface hydrophilicity can influence protein adsorption, potentially 
decreasing phagocytic recognition of nanomaterials increasing circulation times. The 
degree of surface hydrophobicity in gold nanoparticles (57) affects the amount of 
albumin adsorbed to nanoparticle surfaces. More hydrophobic nanoparticles exhibit 
increased albumin adsorption, which drastically decreases their cellular uptake when 
compared to hydrophilic systems with less albumin adsorption. Poly(ethylene glycol) 
(PEG) is another common surface modification, used to increase hydrophilicity and 
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reduce nanomaterial recognition. PEG increases the blood half-life of many injected 
materials, leading to decreased macrophage uptake and protein adsorption in a grafting 
density-dependent manner (58). This study illustrates the importance of surface 
hydrophilicity on phagocytic uptake, illustrating that increasing density and 
hydrophilicity helps to reduce uptake and increase circulation to improve translation.  
 The curvature, topography and hydrophobicity of a nanoparticle illustrate only a 
few of the physicochemical characteristics that can be changed to show that 
physicochemical characteristics play an essential role in the adsorption process of 
proteins on the surface of nanomaterials. Other characteristics could potentially alter 
these profiles as well. For a more extensive review on nanoparticle protein adsorption, 
readers are directed to recent reviews on the topic(6, 7). 
 
2.1.4 Phagocytic uptake and intracellular fate 
The mechanisms by which the body handles foreign materials and invading 
pathogens are likely harnessed in nanomaterial processing as well. Understanding how 
the body’s mechanistic processes work may help to identify both how phagocytes 
recognize and process nanomaterials and the reasons for global nanomaterial failure. 
Specifically, reviewing the literature of this native pathogenic processing will likely 
provide insights into how nanomaterials are handled by phagocytes. Understanding of 
phagocytic recognition of nanomaterials will provide the capability to manipulate 
physicochemical characteristics to minimize phagocytic uptake and inflammatory 




2.1.4.1 Recognition of nanoparticles via surface activation 
Many nanomaterial uptake and cellular processing mechanisms parallel normal 
pathogenic processing, suggesting conservation in cellular recognition and pathway 
regulation. A variety of native surface receptors, called pattern-associated recognition 
receptors (PRRs), are able to recognize patterns, for example, on the surfaces of 
pathogens or within damaged tissues (59). Patterns occurring on the surface of pathogens 
are conserved across a variety of microorganisms, termed pathogen-associated molecular 
patterns (PAMPs). PAMPs identify injury or cell death patterns, termed damage-
associated molecular patterns (DAMPs)(60).  DAMPs usually correspond to tissues 
undergoing necrosis and are danger signals that initiate local recruitment of 
immunological cells. Because foreign material, pathogens and deleterious native tissues 
present with patterns recognized by surface receptors on phagocytic cells, nanoparticles 
could also potentially present molecular patterns due to protein adsorption, or due to the 
native material itself from specific physicochemical properties. Further, these patterns 
could potentially initiate inflammatory events mediated by phagocytic cells. Four specific 
macrophage surface receptors, which are phagocytic receptors responsible for 
nanoparticle-mediated cellular uptake, will be highlighted in the following four sections: 








































































2.1.4.1.1 Toll-like receptors and targeting specific intracellular  
destinations 
Toll-like receptors (TLRs) represent a broad first line of defense against 
pathogens and potentially nanomaterials, directing intracellular destinations and 
potentially initiating inflammatory events mediated by phagocytes. Ten TLRs have been 
identified in humans, residing both on the surface of phagocytes (TLRs 1, 2, 4, 5 and 6) 
as well as within intracellular compartments (TLRs 3, 7, 8 and 9) (61). Methods utilizing 
nanoparticulate TLR receptor-targeting have provided efficacy clinically. For example, 
poly(lactic-co-glycolic acid) (PLGA) -encapsulated monophosphoryl lipid A upregulates 
inflammasomes to help rid hosts of pathological infections (62). The inflammasome and 
its subsequent release of IL-1beta are an observed activation state of TLRs. This 
activation state induces inflammatory reactions, which frequently involve the myeloid 
differentiation factor 88 (MyD88) and induction of NF-kappa beta activation, both 
hallmarks of inflammatory induction. However, TLRs have also been linked to 
autophagic processing (TLR4, 2, 3 and 7) (63, 64), a cell survival and inflammatory 
reduction mechanism. These contrasting mechanisms, inflammasome modulation and 
autophagy, suggest that variations in physicochemical characteristics could potentially 
regulate the ultimate fate of nanoparticle systems. For example, carbon nanotubes with 
variations in surface characteristics in the presence of TLR ligands induced 
inflammasome activation and IL-1beta release as a function of dose. However, benzoic 
acid modifications had significantly less activation and release when compared to the raw 
carbon nanoparticles, suggesting surface modification can mitigate the inflammatory 
response, at least to some degree (65). 
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Variations in nanoparticle surface modifications can lead to recognition by 
different TLRs and, via this recognition, alter the intracellular fate of the nanoparticle 
system. For example, modification of PLGA with LPS significantly increases the 
antigen-presenting capacity of these delivery vehicles. LPS is a common contaminant 
arising from bacterial adsorption on nanoparticles and is recognized by TLR4 surface 
receptors and activates inflammasome production (66, 67). The enhanced efficacy of 
these systems results from the TLR4-targeting capabilities of the phagocytes, which 
activate inflammasome and IL-1beta production(68). Similar results have been shown 
with LPS-coated polystyrene particles, helping to support surface recognition (12). TLR4 
has also been involved in the processing of graphene oxide in macrophages(69). 
Graphene oxide, however, has also been implicated in activation of TLR9 and autophagic 
signaling and compartmentalization, yet the surfaces of TLR4 and TLR9 recognized 
systems varied(70). This variation in TLR recognition suggests that, in some cases, one 
could alter the surface of a nanoparticle to direct cellular fate, increasing or decreasing 
payload delivery. 
 
2.1.4.1.2 Mannose/lectin receptors and multivalency effects 
Engineering nanoparticles to engage a number of surface receptors can enhance 
specificity and increase uptake of nanoparticles, enhancing phagocytic recognition and 
potentially phenotypic recognition. Multivalency increases the endocytic effect in 
phagocytes. For example, sugar lectin-mannose macrophage interactions can be 
harnessed with nanoparticulates decorated with large numbers of sugar-like motifs (71, 
72). Mannose-lectin receptors are abundantly expressed on the surface of macrophages. 
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The main function of these receptors is to recognize complex carbohydrates, detecting 
mannose, glucose or sugar structures on pathogenic material and glycoproteins (73). The 
engagement of C-type lectin receptors on macrophages has been used by decorating the 
surface of nanoparticles with large numbers of di-mannose and galactose (74). Multiple 
sugar residues drastically enhanced the inflammatory activation phenotype of the cells 
following nanoparticle uptake, enhancing antigen presentation of the encapsulated 
payload, increasing overall efficacy (74). Similar results have been shown with mannan 
(36) and glycan (75). These examples suggest that by engineering nanoparticles to 
engage a number of specific surface receptors, one can drastically enhance the utility of 
such nanoparticles for delivery of therapeutics. Mathematical modeling of the 
multivalency phenomenon illustrates if ligand density on the surface of the nanoparticles 
is sufficient, membrane wrapping around the nanoparticles would be optimal when their 
diameter ranges between 20-35 nm and ligand density is approximately 80% with a 
minimum coverage of 20% (76). This model suggests that uptake can be altered 
significantly with optimization of surface coverage, because this can facilitate 
energetically favorable membrane wrapping. This phenomenon can be applicable to most 
surface receptor interactions and is not specific to sugars.  
Mannose receptors are unique, however, in that they provide specificity to 
phagocytes and might increase uptake and overall efficacy of nanomaterials. The 
following few examples illustrate the utility of using mannose as a phagocytic target 
receptor to enhance overall payload delivery. Mannan has been used to coat gelatin 
nanoparticles to increase specificity of delivery of didanosine to macrophages for the 
treatment of HIV (77). These  nanoparticles substantially increased the amount of drug 
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delivered to the brain, lymphatics and splenic tissue regions, increasing specificity of 
delivery and decreasing systemic side effects (78). Other mannose targeting strategies 
have been employed to gain similar effects, such as mannose (CD206) surface receptors 
to target Th2 polarized macrophages for certain chronic inflammatory disease states (79, 
80). For example, carbohydrate surface modification was utilized to help direct tumor 
targeting of mesoporous silica nanomaterials for thermoablative therapy, which reduced 
tumor size significantly compared to control in treated animals (81). Specificity towards 
macrophage phenotypic receptors could enhance the delivery of nanoparticles to specific 
disease states. 
 
2.1.4.1.3 Scavenger receptors and initiation of specific subcellular  
events 
Scavenger receptors have been implicated in nonspecific macrophage-
nanoparticle uptake and are in part responsible for in vivo failure due to their capacity for 
increasing phagocytic recognition and decreased circulation potential. These receptors are 
responsible for the recognition and internalization of foreign pathogens, oxidized or 
acetylated native proteins (i.e., low density lipoproteins (LDLs) and maleylated albumin) 
and apopotic cellular debris (82). They also play a primary role in the recognition and 
identification of LPS on gram-negative bacteria and lipoteichoic acid on the surface of 
gram-positive bacteria, which are both common contaminants on the surface of 
nanoparticles (83). Contamination could explain the ubiquitous nature of the recognition 
of nanoparticle uptake in macrophages. When developing nanoparticles for biological 
applications, extensive chromogenic endotoxin testing should be done to ensure that the 
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surfaces are free of LPS in order to reduce macrophage recognition. Macrophages may 
still, however, recognize the native nanoparticle surface. For example, ligands developed 
for targeting scavenger receptors are polyanionic in nature (84), suggesting that 
negatively charged nanomaterials could be taken up via this scavenger receptor 
recognition mechanism. Superparamagnetic iron oxide nanoparticles coated with 
nonaggregated dextran, a polyanionic sugar (Dextran-SPIO) have initiated uptake via SR-
AI/II scavenger receptors (15). This was attributed to the increased polyanionic charge on 
their surface due to iron oxidation, which associates with the positively charged collagen-
rich domain of the scavenger receptor. However, when the particles were coated with a 
proprietary polymer brush, uptake via these receptors was significantly diminished or 
eliminated (15, 17). The elimination of uptake illustrates that surface modifying particles 
can significantly reduce phagocytic recognition and help to improve overall efficacy and 
delivery. 
Scavenger receptors’ recognition and uptake of nanoparticles in macrophages has 
been linked to increased inflammatory events, which initiate nanoparticle-induced 
toxicity. This may be a result of the intended purpose of scavenger receptors, pathogenic 
material recognition which induces an inflammatory reaction as a preservation 
mechanism. For example, silica nanoparticle uptake and subsequent proinflammatory 
cytokine release was drastically reduced following SR-A receptor expression silencing 
(18). This result suggests that nanoparticles could reduce their inflammatory potential if 
the silica nanoparticle surface is modified to decrease SR-A uptake. Scavenger receptors 
also play an essential role in the clearance of cellular apoptotic bodies, and can initiate 
inflammatory pathways as a result of apoptotic uptake. This removal could also help 
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explain how nanoparticles initially taken up via another cell type could ultimately reside 
within macrophages, which could help to link the role of macrophages to systems that are 
not originally uptaken by macrophages. For example, cells that had ingested 
nanomaterials and undergone apoptosis as a result had surface apoptotic markers, which 
could facilitate scavenger receptor-mediated uptake by macrophages. This uptake could 
lead, potentially, to indirectly induced inflammation. Macrophage receptor with 
collagenous structure (MARCO) and scavenger receptor A (SRA) are only a few of the 
surface receptors that both recognize these apoptotic bodies and have the capability of 
recognizing a multitude of PARPs, which could help to induce nanoparticle uptake. 
Studies involving a direct link to macrophage-nanoparticle uptake as a result of 
nanoparticle apoptotic cell death have yet to be performed; however, MARCO has been 
linked to the uptake of polystyrene nanoparticles(85) within alveolar macrophages as 
well as aggregates of iron oxide(86). This MARCO link to polystyrene and iron oxide 
suggests that scavenger receptors are promiscuous. If promiscuity exists, identification of 
which portions of the receptor and what physicochemical characteristics induce 
recognition are required when designing new nanoparticle systems to ensure 
inflammation is reduced. 
 
2.1.4.1.4 Fc Receptors and phenotypic role of uptake 
Fc receptors recognize the Fc region of IgG, one of the most abundant proteins in 
the human body and a vital part of the innate and humoral immune systems. IgG 
adsorption to the surface of nanoparticles is well characterized and in some cases 
represents a large capacity of local protein opsonization on the surface of the 
34 
 
nanomaterial (87-89), suggesting Fc-mediated recognition and increased phagocytic 
response. For example, activation of THP-1 cells (human monocytic cell line) via PMA 
leads to a fourfold increase in uptake of IgG-coated nanoparticles as compared to 
undifferentiated cells. This increase can be explained in part by the fact that adherent 
cellular systems tend to uptake nanoparticles to a much higher extent (90). Surprisingly, 
the nonadherent monocyte-like cells internalized the amine-modified systems more 
rapidly than the adherent macrophage-like cells. The opsonization observed on these 
monocytes appears to be the result of an interaction on the macrophage with an Fc 
receptor, the CD64 receptor (also known as Fc-gamma receptor 1), which induces 
phagocytosis. However, the monocytic cell lines uptake the nanoparticles via a dynamin-
mediated endocytic process (16). An in vivo comparison of the uptake kinetics of 
nanoparticles by monocytes and macrophages would be an important future direction for 
the field. This difference in phagocytic uptake shows the significant differences observed 
in macrophage differentiation and activation states. Understanding which phagocytic 
phenotype outplays others in vivo will play an important role in the design of 
nanomaterials and help to identify toxicity and uptake. 
 
2.1.4.1.5 Comparative importance of macrophage surface receptors 
While all of these receptors influence the uptake of nanoparticles within 
macrophages, Fc and mannose receptors might play a more important role than others. 
Comparative phagocytosis studies have focused on studying rates of uptake between 
scavenger, mannose and Fc receptors. The nanoparticles targeted to the mannose and Fc 
receptors appear to be internalized rapidly, while the scavenger receptors take a 
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significantly longer time (91). This suggests that Fc and mannose receptors are better 
poised to internalize nanoparticles. Fc and mannose receptors may or may not be 
expressed on macrophages, and the levels of expression for each receptor type vary 
widely between polarization and activation states of these cells (91). Additionally, many 
of these macrophage surface receptors have evolved to detect opsonized materials to 
increase nanoparticle uptake and many of the receptors may work in parallel. Thus, 
targeting via directed protein adsorption may be accomplished by understanding protein 
adsorption properties and engineering surfaces such that certain proteins adsorb in 
conformationally appropriate states for receptor recognition. For example, IgG and C3b 
induce phagocytosis through the Fc and complement receptors (91), a strategy which 
could be used to target macrophages directly. However, macrophages still uptake 
nanoparticles in the absence of serum, which suggests these four receptors may natively 
recognize nanomaterials (92). In some cases, proteins can also mask the materials from 
surface receptor recognition (93). An understanding of which proteins and what 
adsorption conformation provide this masking will be important if the goal is 
bioinvisability of the particle.  
 
2.1.4.2 Phagocytic internalization mechanisms 
Payload delivery to specific cellular compartments could enhance efficacy in drug 
delivery. Some drugs act on specific cellular organelles and need to be trafficked 
efficiently while avoiding uptake by detrimental compartments. For example, nucleic 
acids act primarily through nuclear localization. Therefore they will be unsuccessful if 
they are trafficked to autophagosomes or lysosomes instead. The following section 
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outlines the specifics of uptake processes, which will aid in efficient design of 
nanomaterials and increase payload delivery.   
After cellular recognition via pattern recognition receptors, foreign materials must 
be internalized within phagocytes, primarily utilizing cellular cytoskeletal rearrangements 
and vesicle development. These internalization mechanisms can be broadly classified as 
phagocytosis or pinocytosis (Figure 2.3). 
Phagocytosis is a broad definition to describe the actin rearrangement and 
pseudopodial envelopment of large bodies into cells and is a primary mechanism for 
nanoparticle uptake (94). Phagocytosis is usually associated with Fc- and CR-mediated 
receptors, enveloping material in a zipper-like fashion. Only certain classes of cells, 
usually termed “professional phagocytes,” have this type of cytoskeletal rearrangement 
capability. These professional phagocytes include macrophages, neutrophils, dendritic 
cells, monocytes, and in special cases, endothelial and secretory epithelial cells. These 
pseudopodial vesiculations are concurrent with granule movements and subsequent 
granule fusion within the cell. Usually following phagocytosis, the vesicle fuses with 
lysosomal compartments and they undergo a large pH reduction; however, in some 
pathogenic scenarios this fusion is avoided. For example, when M. Tuberculosis or 
Chlamydia are ingested, the phagosomes do not acidify, due to the lack of ATPase and 
LAMP markers, respectively (95). Nanomaterials could utilize similar mechanisms to 
reduce fusion. 
Pinocytosis, in contrast, is present in all mammalian cells and can be in some 
situations responsible for nanoparticle uptake. This mechanism can be classified into 
























































































































































ruffles responsible for .5-5 um internalization) and smaller volume internalization (e.g., 
clathrin and clathrin independent mechanisms 20-500 nm). However, larger volume 
internalization mechanisms rarely occur without clathrin-mediated internalization. 
Macropinocytosis and circular dorsal ruffles are characterized via their large protrusions 
from the membrane and actin-dependent polymerization mechanisms, similar to 
phagocytosis. However, zipper-like phagocytic uptake is absent in these processes. 
Rather cells simply envelop the entire substance into the cytoplasm. This process is 
implicated in the uptake of viruses and macromolecules and potentially nanomaterials. 
Clathrin-mediated endocytosis is probably the most well-known and studied of the 
internalization mechanisms. Scavenger, mannose and TLRs are known induction 
mechanisms for this internalization process. This process involves the formation of 
clathrin pits, which wrap and pinch their cargo into the cell. Once enveloping the cargo, 
these pits are cut via dynamin scission to form internalized vesicles. These vesicles are 
trafficked to early endosomes, followed by acidification and transformation to late 
endosomal vesicles where they are then trafficked to other intracellular destinations 
including lysosomal compartments, a mechanism that nanoparticles could harness.  
Unlike clathrin-mediated endocytosis, which is responsible for internalization of 
size ranges from approximately 100-350 nm, caveolin-mediated endocytosis is 
responsible for 20-100 nm endocytosis, size ranges in which nanomaterials fall. 
Replacing the clathrin bowls are caveolae, which generally reside within lipid raft 
domains. As such, they differ in their internalization mechanism. Rather than membrane 
wrapping this invagination typically appears after completion of a bowl just below the 
surface, ingesting the cargo via membrane dropping. These vesicles are typically 
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transported to the golgi or are excreted from the cell, a mechanism which could be 
harnessed in particular nanoparticle delivery scenarios. Cholera toxin utilizes this 
mechanism advantageously by avoiding lysosomal internalization, a method that could be 
utilized in nanomaterial drug delivery. Other mechanisms exist for these uptake types.  
As outlined above, surface recognition patterns induce uptake via interactions 
with phagocytic receptors, but alterations in physicochemical characteristics such as 
geometry and surface chemistry also can alter uptake patterns and may help to induce 
specific intracellular fate patterns, improving delivery. Geometry and surface chemistry 
will be discussed as a way of highlighting how physicochemical characteristics can 
impact phagocytic recognition and uptake. 
 
2.1.4.2.1 Implications of geometry on cellular uptake 
Geometry can influence nanoparticle internalization mechanisms and may alter 
uptake patterns (19, 96). Utilizing particle replication in nonwetting templates (PRINT) 
technology, which enables the production of nanoparticles with defined size and 
geometry, nanoparticle entry has shown a size-dependent phenomenon impacting 
phagocytic uptake. This geometric uptake phenomenon has been corroborated in other 
types of systems as well (97, 98). Smaller nanoparticles with the capability of interacting 
with lipid rafts tend to be taken up via caveolin-mediated mechanisms (under ~60 nm), 
while nanoparticles within a 60-300 nm size range are taken up via clathrin-mediated 
mechanisms and pinocytosis/phagocytosis generally take over when nanoparticles are 
above 300 nm (19). When particles are above 300 nm and are internalized via 
phagocytosis, geometry has a significant effect on the rate and extent of uptake. 
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Interestingly, the results of these studies revealed an angle dependent uptake pattern: if a 
particle contained an edge with an angle larger than 45 degrees, the nanoparticle was 
unable to be completely phagocytosed, indicating that particles above this size may not 
be internalized. Below this value, the nanoparticle was completely enveloped and 
internalized into cellular compartments (20, 99). Predictions based on computational 
models have suggested that membrane-wrapping in phagocytic processes is dependent on 
the ability to overcome high-energy conformations to obtain an energy-minimized state. 
If an edge angle is too large, for example on a cylindrical particle, the nanoparticle can 
associate with the cellular membrane but membrane wrapping cannot occur due to the 
energetically unfavorable conformation required to temporarily wrap over the sharp edge 
(100). Oblated ellipsoidal particles have more efficient phagocytic internalization 
capability than prolated ellipsoidal particles due to a similar phenomenon (21). Shape has 
a profound effect on the phagocytic uptake processing of particles and suggests that 
computational model-assisted design and geometric alterations could help in the ultimate 
evasion or reduction in phagocytic uptake and processing. Further the toxicological 
implications of this inability to complete membrane wrapping are unknown, and could 
potentially influence macrophage content release. The result might follow similar 
patterns to what is seen in the foreign body response in biomaterial implants and facilitate 
the creation of multinucleated cells and an inflammatory response, or might elicit a 
different mechanism altogether. 
Nonphagocytic processes, such as clathrin-mediated endocytosis, also show 
similar sensitivity to particle geometry and may influence the degree of phagocytic 
uptake, an effect which has been shown both computationally and experimentally (101). 
41 
 
Rod-like nanoparticles with rounded ends are uptaken more rapidly than their true 
cylindrical counterparts, which possess 90 degree edges at their ends (19). In another 
model system, spherical particles were taken up more rapidly than rods (102). 
Additionally, the size of spherical particles drastically alters the mechanism by which 
they are internalized, which has been attributed to membrane wrapping of the particle 
(103). For example, clathrin-mediated invaginations were due to elastic membrane 
deformations, and only particles around 50-200 nm in radius were internalized by this 
mechanism (101, 104). This study suggests that when the nanoparticle radius is greater 
than 200 nm, the cell membrane is unable to form a large enough pit for the particle, 
reducing clathrin-mediated uptake. If clathrin-mediated mechanisms are not involved in 
the uptake of spheres larger than 200 nm, other pinocytic mechanisms such as 
macropinocytosis must take over and enable uptake of the particles. This could be an 
important consideration in understanding uptake capacity. By altering the size and 
geometry of the nanoparticles, one may potentially be able to dictate specific uptake 
mechanisms, consequentially improving delivery.   
 
2.1.4.2.2 The influence of surface functionality on nanoparticle  
uptake 
Surface functionality of nanoparticles may play an important role in the mediation 
of uptake of nanoparticle systems. Specifically, surface charge greatly affects levels of 
cellular uptake, with positively charged materials generally taken up to a greater degree 
than their neutral or negative counterparts (104, 105). This effect has been shown with 
phagocytosis in a macrophage model system (106). This might occur because sialic acid 
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is prominently displayed on the surface of macrophages, resulting in a negative surface 
charge thought to attract positively charged materials, increasing their rates of 
internalization. This was investigated in a study in which alveolar macrophages were 
analyzed for their ability to uptake 50 nm gold nanoparticles following preincubation 
with known sialic acid binding proteins, wheat germ agglutinin and limulus protein (107). 
Under preincubation conditions, negatively charged nanoparticles were taken up at the 
same rate as controls while uptake of the positively charged systems was blocked by the 
pretreatment. Uptake has also been observed in the presence and absence of serum in 
macrophage models. This suggests that surface receptors can and do recognize specific 
surface functionality, and uptake those nanoparticles in a similar fashion to traditional 
foreign pathogenic materials. An understanding of how simple surface chemistries affect 
uptake patterns could be used as a design factor to modify uptake.   
Modification of the surfaces of nanoparticles with ligands that are specific to 
well-known internalization mechanisms can also be utilized to harness specific uptake 
pathways. Clathrin-mediated uptake mechanisms utilizing transferrin or folate are 
commonly used in targeting clinical nanoparticle systems to treat or diagnose cancer, as 
these receptor-ligand interactions are commonly upregulated in cancerous tissue. 
Transferrin-mediated mechanisms have been translated clinically into two liposomal 
formulations, CALAA-01 (108) and MBP-426 (109). Vynfinit is an example of a folate-
targeted chemotherapeutic nanoparticle that is clinically approved for ovarian cancer use 
in Europe (110). While transferrin and folate targeting provide benefit for targeting 
cancer cells specifically, macrophage targeting would benefit from utilization of one of 
the 4 receptors discussed previously. Scavenger receptors, for example, induce clathrin-
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mediated endocytosis, and Fc receptors induce phagocytosis. Specific targeting ligands 
could be engineered to induce the particle’s intracellular uptake. The engineered uptake 
patterns could further induce specific intracellular fates. Phagocytic uptake commonly 
results in localization in phagocytic vesicles with little to no further intracellular 
trafficking; however, pinocytic mechanisms have the potential for delivery to specific 
intracellular compartments. For example, endosomal compartments have known internal 
intracellular trafficking receptors (111), which can be targeted by drugs or endosomal 
escape strategies. Such design manipulation could enhance targeted intracellular 
therapeutic delivery.  
Targeting the phagosomal route may still be advantageous, even if the specificity 
can be inferior to pinocytic uptake mechanisms. Many systems have harnessed this 
uptake mechanism to increase efficacy and improve delivery. For example, the 
propensity of the MPS to phagocytose or engulf foreign material has also aided in the 
development of delivery systems to parasitophorous vacuoles within macrophages. 
Ambisome®, a liposomal form of amphotericine B, an antifungal agent, utilizes toll-like 
receptor targeting to harness parasitophorous targeting mechanisms, thus increasing 
efficacy compared to the free drug alone and reducing local systemic toxicity (112). This 
formulation has been on the market for over 15 years and shows the capacity of 
harnessing phagocytic systems to improve overall delivery. 
 The critical takeaway on nanoparticle design is the understanding that a link can 
be drawn between internalization mechanisms and ultimate intracellular fate. A more 
complex view of intracellular uptake can also help to drive understanding of intracellular 
pathways leading to specific and desirable downstream events. 
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2.1.4.3 Phagocytic nanomaterial processing 
Understanding traditional nanoparticle fates in macrophages, as a result of 
physicochemical properties will allow for direct intracellular delivery improving payload 
efficacy. In turn, the ability to manipulate physicochemical properties can help develop 
engineering mechanisms that home to specific cell compartments. 
 
2.1.4.3.1 Autophagy as a nanoparticle processing mechanism 
Three likely processing events exist for nanomaterials in phagocytes: (1) cell-
autonomous antimicrobial defense mechanisms, (2) native pathogenic or foreign material 
cellular process mechanisms, and (3) opsonization recognition events due to specific 
structural surface similarities with pathogen and foreign materials. Autophagy is an 
example of an innate defense mechanism, with activity against intracellular microbes, 
dysfunctional cellular organelles, and misfolded proteins. Autophagy is induced in 
nanoparticle uptake via pattern recognition receptors (113). Autophagy can lead to 
increases in phagocytic activity, leukocyte migration, and inflammatory responses such 
as specified polarization of immune cells and release of proinflammatory cytokines (113-
119). In some cases, however, autophagy can be beneficial as it provides a cellular 
coping mechanism and reduces the likelihood of toxicity emerging from exposure to 
nanoparticle systems.  
Autophagy is a primary mechanism by which highly positively charged 
nanoparticles are trafficked intracellularly. Postively charged dendrimers, polyplexes, 
gold nanoparticles, iron oxide and silica nanoparticles harness this mechanism (11, 117, 
119-121). However, little to no evidence currently exists linking other surface 
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functionalities to autophagic mechanisms. Other surface chemistries could induce or 
mediate autophagy.  
While autophagy may be beneficial for the reduction of toxicity, it may be 
detrimental to the delivery of cargo, as trafficking of these positively charged systems to 
autophagosomes eliminates the capacity for delivery to other organelles. For example, 
polyplexes are commonly utilized as nucleic acid delivery systems, which by and large 
need to be delivered directly to the nucleus to work effectively. However, if nucleic acid 
delivery systems ultimately reside in autophagic compartments, very little to none of the 
cargo is delivered to the target site, severely limiting efficacy. Fortunately, approaches 
for controlling autophagy with surface modifications of nanoparticles have been 
identified. For example, modifying the surface of MWCNTs with organic compounds can 
help to avoid an autophagic response. A series of LC3-II screening assays illustrated that 
autophagy is highly dependent on surface characteristics in astrocyte and human 
embryonic kidney cell models. They were able to identify certain organic compounds that 
more strongly upregulate autophagy and other organic compounds that appear to have 
little to no effect on mechanistic regulation (122). This suggests that surface chemistry in 
other systems can be manipulated to potentially evade this process. Development of such 
nanoparticles may possibly aid in the design of new materials to modulate downstream 
inflammatory events. In some cases the utilization of autophagy may allow for 
pathogenic removal and, as a result, would represent a promising treatment mechanism. 
Mycobacterium tuberculosis (M.tb.), a pathogen well-known for its survival and 
proliferation within phagosomes, inhibits the development of autophagy within 
macrophages. In alveolar macrophages, PLGA nanoparticles are phagocytized and use 
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rapamycin to induce autophagy, which leads to M.tb. elimination (123). This therapy 
illustrates the importance of understanding the target site of the construct in designing 
new delivery systems. Autophagy in this case enhances efficacy, while as mentioned 
previously in nucleic acid delivery is detrimental to efficacy.  
Autophagosome-like compartments that connect to the cell surface, termed 
surface-connected compartments (SCC), can also process pathogens and foreign 
materials, so may be useful in nanotherapy. SCCs are a series of connected intracellular 
compartments formed when macrophages are subjected to large numbers of highly 
hydrophobic nanoparticles. These SCC compartments serve as a cellular tool to digest 
foreign material and quickly release contents back out to the extracellular space, 
potentially facilitating the degradation of nanomaterials. SCC is observed in uptake of 
LDL, hydrophobic gold and hydroxyapatite particles (124-126). These SCC 
compartments form only when particles are below 500 nm and phagocytosis occurs with 
particles above this size range (124). These compartments are mainly formed through 
actin rearrangement and remain open to the extracellular space while appearing to be 
connected to the plasma membrane. If autophagic compartmentalization and SCC 
formation are linked, this could be a universal phenomenon for macrophage-nanoparticle 
processing and raises the possibility for evolutionarily developed nanoparticle processing 
mechanisms. 
 
2.1.4.3.2 Directed intracellular delivery 
Effective cargo delivery should target specific intracellular organelles and would 
enable site-specific action. After foreign materials are taken up into endosomes or 
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phagosomes, they fuse with lysosomal compartments, which are used by cells to combat 
the foreign material with heavy enzymatic digestion and reduced pH. This fusion allows 
the cells to degrade or remove the pathogen from the environment. However, these 
vesicles also encompass recognition motifs that can traffic ingested material to specific 
cellular compartments (127). These motifs, in turn, can be utilized for site-directed 
delivery. Additionally, systems can be engineered to escape these compartments through 
either peptide motifs or basic surface compositional alteration, such as increasing the 
positive charge on the surface of the nanoparticle to induce lysosomal burst through the 
so-called proton sponge effect (128). After release from the lysosomal compartment, 
delivery vehicles can then be trafficked to a specific intracellular compartment and could 
potentially be advantageous for delivery of bioactive agents. 
Specific strategies would allow for targeted drug delivery systems to the 
mitochondria to induce apoptosis in cancer, alter potassium dysregulation in heart 
abnormalities, and reduce the effects of aging (129). One strategy in mitochondrial 
delivery is to utilize the difference in the local compartmental membrane potential, which 
is significantly lower than the rest of the cellular compartments. By attaching 
mitochondriotropic cationic molecules to the surface of a nanoparticle, for instance 
triphenylphosphonium (TPP), one can harness this membrane potential difference and 
achieve high mitochondrial localization (130, 131). Understanding intracellular fate can 
reduce overall phagocytic toxicity, improving efficacy and reducing translatable failure.  
Peptides have been used to target other specific intracellular compartments such 
as the nucleus and endoplasmic reticulum and could also be advantageous for drug 
delivery (132). The nucleus is a key organelle for delivery of many bioactive agents 
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including nucleic acids. Attachment of nuclear localization signals (NLS), which can be 
recognized via importin protein family members, can mediate nuclear transport 
mechanisms. Doxorubicin-loaded nanoparticles with NLS increase antiproliferative 
effects and the capability for intracellular localization to enhance delivery. These specific 
targeting strategies to subcellular compartments are reviewed elsewhere (133, 134). 
Directing intracellular fate pathways will be important when utilizing engineering 
platforms in order to ensure they do not interfere with uptake mechanisms or alter 
ultimate in vivo circulation and biodistribution.   
Due to the complexity in utilizing these intracellular fate ligands and surface 
characteristics, many researchers choose not to incorporate these properties into their 
nanomaterials. However, materials without directed cellular targets may potentially have 
indirect targeting as a function of physicochemical properties and may elicit toxicity. 
 
2.1.4.3.3 Indirect intracellular targeting and resulting potential 
toxicity 
Knowledge of cellular localization of delivery systems could provide information 
regarding both the intracellular targeting of appended therapeutics, as well as a starting 
point for evaluation of possible mechanisms of toxicity. For example, clues about specific 
cytokine and chemokine release and possible mechanistic dissection of downstream 
effects can be used to predict toxicity if the ultimate intracellular destination of 
nanomaterials is known. If the nanomaterial is left without a specific targeting 
mechanism to a known intracellular location, understanding of toxicological 
consequences becomes difficult as they can differ both from cell type to cell type and in 
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the context of specific environmental factors. 
If a nanoparticle targets the mitochondria nonspecifically it can induce 
mitochondrial dysfunction and nanoparticle toxicity. As mentioned earlier, there is a 
mitochondrial membrane potential, an electron transport chain which provides a proton 
gradient through which ADP is phosphorylated to yield ATP. If mitochondrial membrane 
potential is altered, cytochrome C is produced and apoptosis can be initiated. 
Nonspecifically targeted iron oxide particles and carbon nanotubes home to 
mitochondria, affecting the cellular mechanistic energy machinery and ultimately leading 
to cell death (135, 136). Mitochondrial dysfunction has been observed after treatment 
with silica nanoparticles. In these studies, JC-1 mitochondrial potential assays provide 
evidence that nanoparticle size and surface modification have an effect on the membrane 
potential change. Smaller and more positively charged nanoparticles have increased 
induction of these potential changes (137). Crystalline silica nanoparticles initiate both 
necrotic and apoptotic cell death mechanisms, a result of mitochondrial damage. Early 
stages of toxicity with these particles show phago-lysosmal escape and cellular damage, 
resulting in drastic changes in mitochondrial potential (138). These temporal changes 
resulted in hyperpolarization or depolarization causing apoptotic or necrotic cell death, 
respectively. Such processes are detrimental and facilitate drastic nanoparticle toxicity 
and should be avoided in nanotechnological design and development. The mechanism 
and biological motivation for these processes remain unknown. 
Nanoparticle composition can generate reactive oxygen species (ROS) and cause 
mitochondrial damage in macrophages (14), which in some studies led to gene up-
regulation to induce inflammation. Surface hydroxyl groups can initiate interactions with 
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iron in biological environments to initiate the Fenton reaction, which leads to free radical 
production (139, 140). Increased ROS formation leads to the initiation of an 
inflammatory response. Increased levels of oxidative stress, mitochondrial dysfunction, 
and inflammatory gene expression after nanoparticle treatment have been observed 
during these responses (13, 39, 137, 141, 142). For example, porous silica nanoparticles 
were observed to increase ROS generation and adversely affect ATP and TNF-alpha 
content in macrophages and other hematopoetic cells. These results were more 
pronounced with charged surfaces, particularly positively charged modifications, while 
hydrophilicity played little to no role (143). This surface charge phenomenon suggests 
that in nanoparticle design, highly positively charged systems should be avoided. 
In addition to charge, other surface modifications might warrant nanoparticle 
macrophage avoidance, such as topography. Further environmental nanotoxicity studies 
showed that the crystal size of the nanoparticle significantly affected the induction of 
ROS (141). This is due to the differences in uptake mechanisms, as a result of the size of 
the nanoparticles. Smaller nanoparticles induced increased toxicity compared to larger 
nanoparticles, which could be a function of the increased surface area of the nanoparticle 
systems. This suggests that an optimal size range exists in nanoparticle development, in 
which translational potential is greatest. Porosity also appears to influence inflammatory 
activation. Investigation of nonporous and porous silica nanomaterials demonstrated a 
drastic increase in MAPK, TNF-alpha, Il-1beta and NF-kappa beta production when 
macrophages were subjected to nonporous material, while porous silica yielded no such 
effect (144). Porous materials may have increased biocompatibility. However, epigenetic 
modifications in DNA methylation, a sign of chronic inflammatory activation, have also 
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proven to be present in environmental macrophage exposure to nanoparticulates (145). 
Future studies should help to elucidate exactly which modifications and surface 
characteristics elicit toxicity and will help to direct new nanoparticle design. 
 
2.1.5 In vitro macrophage model systems and their correlation in 
vivo 
Little is known about the mechanisms through which the physicochemical 
characteristics of nanoparticles induce up-regulation of inflammatory genes or in which 
stage of nanoparticle-macrophage interaction inflammatory gene upregualtion happens: 
presentation to biological milieu, cellular contact, or after internalization. An 
understanding of these mechanisms, stages and characteristics would be beneficial when 
designing nanoparticle systems. More importantly, inflammatory gene upregulation upon 
nanoparticle insult needs to be studied in vivo. Macrophage models may help to decode 
these understandings, as many macrophage model systems help to predict inflammatory 
mediated events.   
In vitro macrophage models do appear to correlate well with nanoparticle in vivo 
study results. Studies with isolated primary Kupffer cells assessing toxicity of the uptake 
of quantum dots (146), for example, have shown upregulations of TNF-alpha, Il-1beta 
and IL-6. These studies predicted an acute inflammatory response in vivo, which is 
corroborated by results of in vivo quantum dot experiments (146). Similar results have 
been observed with a multitude of other nanoparticles (146).  
Macrophage model systems appear to be capable of predicting correlations 
between nanoparticle characteristics and inflammatory induction. For example, some 
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nanoparticles induce toxicity in hemopoietic lineages (147). In one study, nanoparticle 
treated primary isolated hemopoeitic cells were compared to traditional monocytic 
immortalized cell lines. The traditional monocytic cell lines (147) show little to no 
toxicity towards antimony oxide nanoparticles; however, the nanoparticles did induce 
significant toxicity within the primary monocytic cell lines. A recently published review 
suggests that macrophage in vitro assays correlate well with in vivo results (4). 
Macrophage phagocytosis assays correlate with in vivo retention in the MPS system. 
Release in vitro of TNF-alpha, IL-1beta and IL-8 from macrophage model systems can, 
for example, accurately predict disseminated intravascular coagulation (DIC) and 
cytokine storm disorders in vivo. Leukocyte proliferation in vitro correlates with 
immunostimulation or immunosuppressive effects. Myelosuppressive potential in vivo 
can be correlated with colony forming unit-granulocyte macrophage assays (4). The 
ability of in vitro assays to predict in vivo results suggests that macrophages are an 
important model system for translation, allowing screening with a lower cost, less time-
intensive model system compared to in vivo models. 
However, in vitro model systems do not always correlate with in vivo results. In 
general, cellular model systems are usually more sensitive than in vivo model systems, 
due to their less complex nature and inability to compensate via homeostatic balances. 
For example, quantum dots are traditionally thought of as highly toxic systems in vitro, 
but in vivo they tend to be tolerated with little to no observable toxicity (148). Similar 
disparities may exist with silica, gold, and iron oxide, emphasizing the importance of 




2.1.6 Phagocyte-nanoparticle interactions in an in vivo context 
 Macrophage processing in vivo is significantly more complex than the in vitro 
environment and can alter tissue residence patterns, disrupt payload target delivery, 
increase clearance or facilitate the induction of toxicity. Understanding how macrophages 
facilitate organ-specific uptake, toxicity and clearance within an in vivo context will help 
to improve clinical translational potential of nanoparticle systems by increasing 
circulation and reducing toxicity.   
Not all macrophages are identical and heterogeneity arises as a function of 
environmental conditioning, and could affect nanoparticle processing. For example, 
Kupffer cells vary phenotypically with regard to tissue location (149, 150). Those cells 
that reside within the portal region have increased levels of scavenger receptors, 
phagocytosis and lysosomal enzyme activity when compared to centrally located cells, 
which have increased cytokine activity (151). In contrast to portal region cells, splenic 
macrophages that reside within the red pulp, white lymphatic pulp and marginal regions 
vary significantly in levels of endocytosis, with marginal zone macrophages having a 
significant increase in MARCO receptors (152). If one could discern between these 
macrophage phenotypes and target recognition mechanisms of specific subpopulations, 
nanosystems could be designed to increase circulation times and deliver to specific tissue 
sites. The potential to control the environment and prime these macrophage sites to 
specific activation states that either present antigens or polarize to specific Th1 or Th2 
states, could be used to increase local wound healing and bactericidal activity. 
 Certain physicochemical characteristics such as size, shape and surface 
modification appear to play an important role in nanoparticle tissue accumulation. For 
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example, size appears to play a significant role in nanoparticle residence in clearance 
organs, specifically the liver and spleen. Splenic meshwork size ranges are between 200-
500 nm. Thus, as blood containing nanoparticles filters through it, nanoparticles that are 
below 200 nm should be able to move freely, increasing circulation times of therapeutics. 
In contrast, nanoparticles above 200 nm may provide spleen-directed targeting. Depletion 
of local macrophages via clondronate in the spleen does not drastically reduce the uptake 
of nanoparticles within this environment, which suggests that physical mesh may play a 
more important role than cellular recognition in local uptake (153). In the case of the 
liver, however, liposomal formulations below 100 nm increase in local uptake in 
hepatocytes and Kupffer cells. This could be due to the small size of liver fenestrations 
(~100-150 nm). These lower nanoparticle sizes appear to have a diffusive penetration 
potential in the liver tissue. The penetration could be enhancing local cellular recognition 
and may lead to increased clearance rates. If longer circulation is preferred in new 
nanoparticle system, an ideal size range should be within 130-200 nm, based on these 
physical tissue parameters (152). 
 
2.1.6.1 Clearance mechanisms and tissue residence 
Ideally after payloads have been delivered to their intended site, nanomaterials 
would be cleared from circulation and would not induce an inflammatory response. Many 
therapeutic nanoparticles that have degradation capabilities or are within a small enough 
size do show clearance through biliary or renal excretion mechanisms helping to facilitate 
this ideal situation. However, studies suggest that even after 2 weeks only limited 
nondegradable nanomaterial clearance occurs, with a majority of dosed nanoparticles 
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(~95%) accumulating in clearance organs (26, 154, 155). The possibility of chronic 
toxicity as a result of nanoparticle accumulation, as is the case with traditional 
biomaterial implants, remains to be seen.    
 
2.1.6.1.1 Size effect on clearance 
Size appears to play a significant role in nanoparticle residence in clearance 
organs. Traditionally particles below 15 nm are thought to be trafficked to the kidney and 
excreted through renal mechanisms. Larger nanoparticles however tend to reside in the 
liver and spleen. For example 25 nm silica nanoparticles are excreted through biliary 
clearance mechanisms at 2 weeks post treatment, at which point little to no toxicity or 
tissue abnormalities were observed (26). Similar results have been shown for 17 nm gold 
nanoparticles (26, 156). However larger nanoparticles do reside within clearance organs 
even past 2 weeks. Forty nanometer gold particles persisted in Kupffer cells of mouse 
and beagle dogs for at least 6 months, and would probably persist for the duration of the 
life of the animal (157, 158). This suggests that to ensure clearance, the nanoparticle 
should be below 25 nm. Larger size ranges and degradation mechanisms need further 
investigation. 
 
2.1.6.1.2 Shape effect on clearance 
Shape appears to mediate tissue macrophage-nanomaterial interactions and to 
influence clearance. For example, short rod-like nanoparticles with an aspect ratio of 1.5 
primarily accumulated in the liver, while rod particles with an aspect ratio of 5 resided 
within the spleen (25). These rod-like nanoparticles were mesoporous systems, which in 
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some cases have the capability of breaking apart into smaller particulate forms. This 
break apart could explain the clearance of these nanoparticles primarily through biliary 
mechanisms; however, modifications to the surface with PEG resulted in slower 
clearance, with longer half-lives and altered distribution states (159). This contradicts 
other studies that suggest PEG modification reduces clearance rates and extends half-
lives (160). Yet, increased clearance may mean reduced recognition by macrophages and 
thus less exposure of delivery systems to degradation mechanisms resulting in increased 
therapeutic efficacy.  
 
2.1.6.1.3 Surface modification effect on clearance 
Surface modification can enhance nanoparticle accumulation and apparent 
clearance mechanisms. Increasing PEG density on the surface of nanoparticles increased 
uptake by Kupffer cells, while decreasing the density showed increased uptake via 
macrophage-like kidney mesangial phagocytes (28). This suggests that altering surface 
modifications of delivery systems could direct specific tissue residence. In addition to 
PEG, other surface modifications have been tested. For example, gold nanoparticles 
surface coated with BSA or GSH and an average of 8.2 nm were evaluated in vivo (161). 
The BSA nanoparticles formed large aggregates and accumulated in the liver and spleen, 
inducing toxicity within these organ systems. However, the GSH-coated nanoparticles 
were quickly recognized via macrophages in the kidney and showed renal excretion, 
which suggests BSA is detrimental to delivery. 
Polymer chain length alterations on the surface of nanomaterials appear to help 
circulation potential suggesting macrophages avoid recognition (29). Polymer brushes of 
57 
 
poly(ethylene glycol) methyl ether methacrylate (PEGMA) ranging in molecular weight 
(MW) from ~50,000-750,000 Da were grafted onto the surface of nanoparticles ranging 
in size between 130 nm-1550 nm. Above 500,000 Da MW limit they observed rapid 
clearance of the nanoparticles. Interestingly, 290 nm silica nanoparticle constructs with 
grafted ~130,000 Da MW polymers had a similar hydrodynamic size to 130 nm 
nanoparticles with ~290,000 Da MW polymers. The larger constructs had higher 
clearance rates when compared to the smaller nanoparticles. This suggests that polymer 
chain length may help to avoid opsonization and recognition via phagocytes.  
Charge also appears to play an important role in the uptake and tissue residence of 
nanoparticle systems. For example, neutral and zwitterionic-gold particles have long 
circulation times, while their positively and negatively charged counterparts exhibited 
reduced circulation rates, probably due to macrophage recognition and association within 
clearance organs (162). Similar results were shown with silica nanoparticles: charged 
systems increased opsonization and clearance rates via biliary mechanisms (163).  
Currently, opsonization directs nanomaterials’ biodistribution and clearance 
mechanisms. An in vitro / in vivo correlation between the amount of protein binding and 
the subsequent degree of phagocytosis by RAW 264.7 mouse macrophage cell lines and 
their retention within organs has been studied (4). Nanoparticles made of poly(vinyl-
pyrrolidone)-block-poly(D,L-lactide) copolymers have increased phagocytosis and 
protein binding. This correlated with the splenic and hepatic residence of these 
nanoparticle systems (164). This residence may suggest that macrophages help to play a 
role in the tissue residence and increased accumulation in clearance organs. A similar 
phenomenon has also been observed with gold nanoparticles (98), helping to support a 
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global nanoparticle macrophage recognition phenomenon that correlates to clearance 
organ residence.  
 
2.1.6.1.4 Hydrophobicity effect on clearance 
Altering the surface hydrophobicity in silica nanoparticles significantly alters 
protein adsorption and subsequent organ distribution (165). Hydrocarbon coatings on 
nanoparticles increase splenic residence; however, when surfaces were coated with 
hydrophobin (a natural fungal hydrophilic coating) nanoparticle residency increased in 
the liver. When protein adsorption on the surface was examined after incubation with 
serum, the hydrophobic coating adsorbed more abundant proteins, such as albumin, IgG 
and fibrinogen. This suggests that protein adsorption plays an essential role in organ 
uptake and recognition. In the development of nanoparticles for biomedical applications, 
an understanding of the kinetics of protein adsorption to the surface of nanoparticles as 
well as the identities of adsorbed proteins will be important, as well as the effects of 
protein adsorption on distribution and ultimate nanoparticle clearance (166). For further 
information on how the protein corona affects biological mechanisms and how to study 
such adsorptive properties readers are directed to the following review (167). 
 
2.1.6.1.5 Effect of long-term tissue residence of nondegradable 
nanoparticle systems 
Recent evidence suggests that long-term nanoparticle residence within clearance 
organs such as the liver and spleen, initiate lesions via infiltration and microgranulation 
of hepatocytes and long-term inflammatory response (27, 168). Inhalation of 
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nanoparticles has also initiated lesions within the lung tissue (169, 170). This suggests 
that rather than clearing nanoparticles, the body has developed a local response to isolate 
these foreign materials from host biological environments. The unanswered question is if 
this local response is initiating adverse chronic inflammatory or immunological 
responses. Even more concerning are local responses that can lead to diseases such as 
cancer and immunological disorders. However, lesion formation has been mitigated, at 
least to some extent, by surface modifications in hydrophobicity and charge. For 
example, lung fibrosis occurs for cationic silica nanoparticles, while those with polar or 
anionic surfaces tended to migrate to the mediastinal lymph nodes (171). This might 
suggest that some drug delivery design principles could avoid such response, decreasing 
toxicity.  
The ultimate fate of nanoparticle systems appears to be primarily within clearance 
organs such as the spleen, liver and kidney. Most evidence linking cellular uptake in vivo 
shows correlations between macrophage uptake and residence within those tissues.  
Important future studies include investigations of (1) which macrophages in those tissues 
are responsible for uptake; (2) how macrophage type affects the surrounding 
environment; and (3), how and if nanoparticle clearance occurs. Macrophages may traffic 
to biliary tracks and dump their contents or themselves, or the harsh intracellular 







2.1.6.2 Adverse toxicological effects in vivo 
Macrophage-nanoparticle interactions in vivo appear to initiate global toxicity, 
and may be a result of indirect activities such as complement and thrombolytic events. 
The interactions which elicit these responses remain unknown, and will be important to 
understand and consider when designing new materials. Complement activation and 
thrombolytic events initiate the release of cytokines and chemokines and promote 
immune and macrophage cellular recruitment, differentiation, and response. Complement 
and thrombolytic responses can be mitigated with variations in surface properties (172, 
173). 
 
2.1.6.2.1 Complement activation upon nanoparticle-blood contact 
Complement activation is a destructive issue for nanoparticles, initiating 
phagocytic uptake and inflammation. For example, liposomal formulations of 
doxorubicin have in some cases caused severe hypersensitivity due to initiation of an 
inflammatory cascade (174). Hydroxyl modifications initiate complement activation, due 
to the interaction with C-reactive protein inducing inflammation. Additionally, iron oxide 
nanoparticles surface-activate C3 and initiate inflammatory mechanisms (175). 
Activation of iC3b by nanoparticles might lead to erythrocyte binding and splenic 
clearance (176, 177). These examples illustrate the need to understand surface 
modifications and how they relate to complement activation that induces inflammation. 
Surface modifications can cause significant differences in the degree of 
complement activation (175). Dextrans have been used as excipients for decades to 
reduce protein adsorption and complement/phagocytic activity, resulting in increased 
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half-life of nanoparticles. Similar methods have been utilized with poly(ethylene glycol) 
(PEG) (8) and other water soluble polymers, under the assumption that these hydrophilic 
brushes decrease the surface reactivity and thermodynamic favorability for adverse 
protein adsorption. While this has been met with some success, protein adsorption within 
these systems is inevitable and only a matter of time for proteins to find an energetically 
favorable conformation to adsorb. Systems similar to these might also potentiate 
dysopsonin binding in vivo, reducing the recognition by the immune system. That said, a 
phagocytic recognition still occurs over time, suggesting that inflammation can result in a 
chronic inflammatory cascade. 
 
2.1.6.2.2 Thrombolytic nanoparticle activation 
Thrombolytic activation is another potential consequence of nanoparticles 
contacting blood. Modulation of surface charge and density can initiate variations in 
clotting mechanisms (178). Specifically, negatively charged nonporous silica 
nanoparticles induce platelet aggregation, but when the same particles were surface-
modified with amines this response was reduced (178) and similar results have been 
shown with carbon nanoparticles (179). Interestingly, increased platelet aggregation has 
been correlated with an increase in particle phagocytosis, suggesting that macrophages 
could ingest the nanoparticle-centered clots and initiate downstream responses (180).  
Aggregation and thrombotic initiation has also been observed with cationic 
dendrimers in blood (181, 182), but not with hydroxyl- or carboxyl-terminated systems. 
This suggests that surface modifications can mitigate thrombolytic events	  to some degree. 
Extensive review of nanoparticle systems and their blood compatibility are summarized 
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elsewhere (183). Delineation of mechanistic details by which surface properties initiate 
thrombogenesis and complement activation, and whether procoagulant properties 
observed with cationic dendrimers extend to other nanoparticle structures such as larger 
nanoparticles, remain to be investigated. The key question is how surface properties 
influence these phenomena and how one can potentially harness such powers in order to 
influence engineering of more effective and safe materials.   
 
2.1.6.3 Toxicological implications of nanoparticle-mediated 
inflammation in vivo 
Global inflammatory effects of nanoparticles may potentially be directly related to 
thrombogenesis and complement initiation; however, the particles may still induce 
inflammation without any contribution from these systems. The current lack of 
understanding of the chronic toxicity of nanoparticles could have serious consequences 
and impede advancement to the clinic when intended exposure is desired. The 
mechanistic details which initiate potentially toxic outcomes remain unknown. For 
example, two iron oxide particles with similar cores but different surface chemistries 
initiated very different responses to cytokine levels of IL-1beta, IL-8 and TNFalpha in 
vivo. One formulation displayed little to no increase, while the other showed significant 
increases. The increased expression levels of these cytokines correlated with an induced 
in vivo cytokine storm, resulting in splenic congestion. Several experimental studies 
showed when nanoparticles are incubated in vitro with PBMCs and MM-6 (monocytic 
and macrophage lines), the increase in cytokine activation directly correlates with toxicity 
in vivo, such as DIC and cytokine storms (4). IL-8 is also upregulated by 4 nm gold 
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nanoparticles (184). However, many reports suggest little to no induction of 
inflammatory cytokines (i.e., gold (185) and iron oxide (186)). A study comparing gold 
and silver nanoparticles found that short-term silver nanoparticle exposure resulted in 
induction of ROS and NF-kappa B signaling, which led to direct increases in TNF-alpha 
and IL-6; however, gold nanoparticles did not exhibit similar profiles over the same time 
period. When exposure time of gold was increased, they did observe a significant 
inflammatory response (37). Additionally, osteolysis might be initiated by NF-kappa B 
induction in response to nanoparticle exposure, because the subsequent induction of IL-8 
helps to induce TNFalpha and IL-6 (40). These examples may suggest that inflammatory 
responses are global nanoparticle phenomena and result after prolonged exposure 
independent of the nanoparticle.  
Numerous studies have investigated how particle size is related to cytokine 
inflammation. For example, 5 nm silver nanoparticles exhibited higher toxicity than 100 
nm silver nanoparticles in macrophages (187). Nanoparticle toxicity might actually be a 
function of surface area exposed to macrophages rather than size (188). This may suggest 
surface interactions are mediating inflammatory events.  
Inflammatory events could be mediated by specific physicochemical properties or 
may be a result of nanoparticles themselves. These inflammatory events could be 
biologically detrimental such as in the case of chronic inflammatory events or could be 
resolved via normal hemostatic balances. Development of a fundamental understanding 
of what long-term exposure to nanoparticle systems does to the host environment is 
imperative, whether the effect is inert or destructive in nature. This information can 
provide an understanding of the safety and design considerations for these materials, yet 
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based on this incomplete picture nanoparticles are being advanced into clinical 
development.  
Acute inflammatory reactions to nanoparticles can have profound effects. For 
example chronic silica exposure is associated with autoimmune diseases and chronic 
inflammatory states (188). Toxicological studies provide evidence that the crystalline 
form of silica induces upregulation of inflammatory and oxidative stress agents, such as 
cytokines, chemokines, reactive oxygen species (ROS), reactive nitrogen species (RNS) 
and nitric oxide (9, 170, 189-191). Most findings were associated with silicosis and lung 
cancer in mine workers (33, 170, 192-194), which are inflammatory events that have 
occurred after chronic exposure to crystalline silica exclusively via the inhaled route. 
However, little information exists on the long-term biological effects of amorphous silica. 
The rate of dissolution, degradation and elimination of amorphous silica are not well 
studied. Degradable forms of silica can potentially reduce these inflammatory events, 
paving the way for their utility in biomedical applications. Molecular silicates are not 
detrimental to the human environment at current levels of exposure, suggesting that 
degradation products could be well-tolerated (195). A prerequisite, however, for 
successful development of degradable constructs is to understand the biological fate of 
the degradation products. 
 
2.1.6.4 Designing systems to reduce phagocytic recognition 
It might be beneficial to facilitate bioinvisibility of nanomaterials to increase 
biocompatibility and reduce macrophage recognition in vivo. PEG and other hydrophilic 
polymers are commonly used in drug delivery to facilitate bioinvisibility. However, these 
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systems are still recognized by the innate immune system, taken up by phagocytes and 
rapidly removed from circulation. Researchers attribute this effect to the formation of 
antibodies against these polymers and other pharmaceutical excipients that are in heavy 
use. The formation of these antibodies can be attributed to the increased use of these 
systems in food additives and many dosage forms (196). Development of these antibodies 
directed towards hydrophilic systems creates immune reactions and increased clearance 
rates, highlighting the learning potential of our own adaptive immune system. This could 
be utilized to our advantage to potentially mask the surface of these systems with self-
identifying proteins. By utilizing pathogenic or eukaryotic mimicry, reduction of 
complement activation and thus local recognition and uptake may be possible. For 
example, factor H is a cofactor for Factor I that mediates C3b cleavage and dissociation 
of the Bb complex inactivating the complement pathway (197). Pathogens that utilize 
Factor H binding in their immune defense mechanisms include HIV-1 and streptococcal 
M6. Researchers have utilized sialic acid, the main component on the surfaces of these 
pathogens, to bind Factor H in helping to evade complement activation and thus immune 
recognition. This component is also over expressed in erythrocytes such that as the 
erythrocytes age they undergo desialyation and initiate complement activation and 
phagocytic destruction (198). 
Another potential surface ligand to aid in long circulation of nanomaterials is 
CD47. CD47 is a marker of self, overexpressed on erythrocytes, that helps them to evade 
the immune system during their long circulation period by binding to the SIRP-alpha 
receptor (199). Pathogens have already identified the utility of this system and 
overexpressed the system on some viruses, such as smallpox (200). The active binding 
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sequence of this protein has been recently identified and attached to the surface of 
nanoparticles with a resulting reduction in uptake via the MPS and drastically increased 
circulation times (201). More information on how nanoparticles interact with the 
complement system can be reviewed elsewhere (197). In general, these results suggest 
that utilization of markers of self can significantly reduce complement activation and 
phagocytic recognition, helping to promote drug delivery safety and efficacy. 
 
2.1.6.5 Clinical nanoparticle-macrophage interactions 
Therapeutic capacity and clearance mechanisms have been linked with 
macrophage activity in clinically relevant nanomaterial therapies. For example, liposomal 
chemotherapeutic formulations have been prescribed clinically on- and off-label for 
decades (e.g., doxil). These formulations exhibit increased plasma half-life as patients’ 
age increases or monocytic activity decreases (Figure 2.4) (22, 23). Decreased levels of 
clearance appear to be a direct result of the decrease in phagocytic response, while 
increased phagocytic activity appears to increase clearance rates (22, 23). This propensity 
for clearance should provide clinical evidence for understanding nanoparticle MPS 
interactions. 	  
Environmental nanoparticle MPS interactions induce well-known inflammatory 
morbidities (169, 202, 203). These mechanistically well understood and clinically 
relevant disease states, including silicosis, mesothelioma and pneumoconiosis, present 
after years of initial exposure. While the characteristics of the environmental particles 
responsible for these diseases differ from what is engineered today, the initial phases of 
these diseases follow similar patterns to what is observed in the acute toxicity studies of 
67 
 
Figure 2.4: Increased monocytic activity in patients decreases AUC. 
This suggests the involvement of macrophages in clearance of 




engineered nanoparticles. These observations include local fibrotic lesions with increased 
recruitment of polymorphonuclear- and antigen-presenting cells, macrophages and 
dendritic cells (203). Some research argues engineered nanomaterials are “inert” and 
attempt to disprove parallels drawn between engineered nanomaterials and traditional 
environmental nanomaterial exposure disease states. This research suggests that large 
aggregates or microparticulates are responsible for these disease states, and that smaller 
nanoscale materials are completely cleared. 	  
Generally, fibrotic mechanisms proceed over larger scales; we have no evidence 
to assume that under certain circumstances smaller nonclearable agents would not elicit 
similar responses (204). For example, tuberculosis (TB) is a chronic inflammatory 
fibrotic disease state, with hallmark macrophage involvement. TB is within the typically 
clearable size range; however, the pathogen is not cleared. To compensate, the body 
initiates fibrotic lesions as the control mechanism (205). The body may utilize similar 
mechanisms for potentially clearable nanomaterials.  
Similar mechanisms could be initiated in other pathogenic or particulate 
exposures in multiple organ systems. For example, silica nanoparticles induce the release 
of inflammatory mediators such as interleukins, tumor necrosis factor alpha, transforming 
growth factor, monocyte chemoattractant proteins, and other inflammatory mediators (35, 
39, 189). After silica nanoparticle treatment direct correlations are observed between the 
release of these factors and migration, proliferation, and differentiation of inflammatory 
and immunological cells (39, 154). These acute inflammatory events reflect potential for 
local recruitment and involvement of phagocytes and eventual development of chronic 
inflammation. How nanoparticles initiate these events and the specific role of surface 
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properties on altering inflammatory mediators and leukocyte infiltration remains 
unknown. Understanding initiation will be particularly important knowledge when 
designing systems that are intended to exhibit long-term residence within organs or 
circulation due to the potential of long term inflammatory affects, which could elicit 
toxicity.  
 
2.1.7 Nanoparticle MPS interactions: Conclusions 
 Nanoparticle based drug delivery and imaging systems have the potential to be the 
next breakthrough for medical science. However, enormous complexity complicates 
understanding how these nanoparticles interact with the biological environment, and in 
the context of this review interaction with macrophages. The ability to engineer 
nanoparticle systems to overcome and avoid the deleterious effects or potentially utilize 
them to our advantage requires more knowledge of how current nanoparticles and 
macrophages interact. As we move forward, consideration of biological pathogenic 
interaction studies, known clinical effects from environmental nanoparticle exposure, and 
the rising studies in the engineered nanoparticle community will be of increased 
importance. Combining this knowledge will help to develop a platform that will provide 
us with the ability to make biocompatible systems with direct target affect including high 







2.2 Synthetic and toxicological characteristics of silica 
nanomaterials for imaging and drug delivery 
applications 
The chemical properties, structural properties, and abundance of silica provide 
unique, and inexpensive synthetic alternatives for product development. In recent years, 
the industrial world has seen a drastic increase in the production of products and 
processes that utilize several forms of silica (206, 207). Silica can now be found in many 
cosmetics, foods, and electronics. Due to its attractive synthetic properties it has become 
an ideal candidate for biomedical applications including but not limited to sensors (208), 
drug and gene delivery systems (209) and contrast agents (210). 
Silica itself is the second most prevalent element in earth and as such is found in 
many living systems. This element can be found naturally or synthetically and is 
classified either as crystalline or amorphous. Crystalline materials are by far the most 
common, as much of the natural element is comprised in quartz, the main component in 
several rock types and sand. While silica is still considered to be nonessential to sustain 
life, it does appear to play an important role in maintaining homeostasis and the health of 
many living organisms (211, 212). As such, it is incorporated into various supplemental 
plant fertilizers to help maintain growth, mineral nutrition, and ward off fungal diseases 
(212, 213). Interestingly, several plant and marine life forms also include cellular 
pathways that are able to take natural elemental forms of silica and process it into an 
alternative organic form (214, 215). The organic form has proven to play a principal role 
in plant and animal life, assisting in structural and developmental characteristics in a 
variety of fashions, such as strengthening of cell walls, bone and cartilage (211, 213). 
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Individuals and animals which lack organic silica as a dietary supplement have shown 
increased risk for cardiovascular disease, osteoporosis, and Alzheimer’s (216, 217). 
Much of this is linked to the ability of silica to interact chemically with native metallic 
ions such as aluminum and iron (216, 218, 219). However it remains unclear at what 
pivotal concentration level and chemical composition silica switches from a beneficial to 
detrimental state.   
Silica exposure has been associated with autoimmune disease and crystalline 
silica has been classified by the International Agency for Research on Cancer as a class 
one carcinogen(188). Numerous toxicological studies provide evidence that the 
crystalline form induces upregulation of inflammatory and oxidative stress agents, such 
as cytokines, chemokines, ROS, RNS, and nitric oxide (9, 170, 189-191). Most of these 
studies are associated with silicosis and lung cancer in mine workers (33, 170, 192-194). 
While amorphous silica does not seem to present the same oral or inhalation risks as 
crystalline silica, the implication of introducing such a material via alternate routes of 
administration remains unknown.  Thus extensive toxicological studies are needed to 
understand the environmental and health impacts of silica nanoparticles.   
This portion of the chapter will address current amorphous silica nanoparticle 
synthesis, preparation, characterization, and subsequent toxicological evaluation. 







2.2.1 Amorphous silica nanoparticle synthesis 
The unique inorganic chemical properties of silica provide an exceptional 
platform from which to build drug delivery and imaging systems. Synthetic sol-gel and 
polymerization methods provide a simple way to produce these nanomaterials in a large 
scale. The advantages of silica nanoparticles include: 
1. Relative chemical and thermal stability    
2. Synthetic control over size and size distribution 
3. Potential to induce alterations in geometry 
4. Ease of surface modification 
5. Ability to control encapsulation of molecules of interest 
6. Economic affordability and ease of scale up 
These advantages will be individually discussed with a focus on implications in toxicity 
and their subsequent potential for drug delivery and imaging applications. 
 
2.2.1.1 Relative chemical and thermal stability  
Silica nanoparticles are generally synthesized via aqueous polymerization of 
silicic acids or through the Stober method which is the utilization of silicon alkoxides and 
their subsequent hydrolysis and condensation (220, 221). The two produce two very 
different core materials, with variations in density. Polymerization tends to permit for 
classically uniform particles, by allowing for full hydrolysis of monomer repeat units 
(222). Stober synthesis or silicon alkoxide nanoparticle formation however is generated 
through cluster aggregation, preventing full hydrolysis and thus a reduction in uniformity 
(Figure 2.5) (195, 221). However with the development of modified Stober methods or 
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Figure 2.5: Stober method of silica nanoparticle synthesis. In the Stober 
method, silica undergoes spontaneous cluster formation which then can 




sol-gel chemistries, one is able to more carefully control synthetic procedures (223). 
Once formed, both of these processes lead to a very stable, relatively inert colloidal 
solution, which cannot be disrupted or degraded without further synthetic modification 
(222). This property is highly sought after in both drug delivery and imaging 
applications, as it provides a protective environment for the encapsulated material and 
assists in the reduction of systemic side effects in the human body. Current alternative 
nanoparticle carriers such as liposomes and micelles have the potential to dissociate in 
vivo and release potentially toxic materials into circulation (224, 225). Additionally, the 
native surface functionality of these particles is a terminal hydroxyl group, which 
provides a relatively hydrophilic surface, a property that is known to reduce systemic 
opsonization and increasing circulation times (226). It remains largely unknown if 
mechanism of toxicity of bare silica nanoparticles is due to hydroxyl functional 
interactions with the physiological environment or other physiochemical interactions. As 
will be shown later the masking of these hydroxyl groups does appear to reduce toxicity 
and hydroxyl groups facilitate functionalization. 
 
2.2.1.2 Synthetic control over size and size distribution 
Both polymerization and the Stober method allow for excellent control over 
polydispersity and size of spherical nanoparticles. By simply controlling the reagent 
concentrations and reaction conditions one can create a wide range of differing spherical 
nanoparticle sizes with a polydispersity index within 5% of the total synthesized particle 
(Figure 2.6) (222, 227).  This provides an advantage over traditional drug delivery and 
imaging contrast agent systems such as random copolymers, liposomal and micellar 
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Figure 2.6: Transmission Electron Microscopy (TEM) images of porous and 
nonporous silica nanoparticles. Images illustrate uniformly synthesized 
porous (A, scale bar 100nm) and nonporous silica nanoparticles (B, scale 





constructs, with potentially higher polydispersities (224, 225).  This leads to increased 
error in loading and dosing, as variability in size ranges can increase or decrease 
encapsulation.  Variation in size distribution can also influence cellular uptake, toxicity 
and biodistribution. This is extremely important as the literature outlines nanoparticle size 
dependent effects on toxicity, biodistrubution and uptake (142, 154, 228). Smaller 
nanoparticles generally have increased uptake and toxicity, mostly contributed to their 
increased surface area or exposure to cell surfaces (Figure 2.7) (142, 229). The ability to 
synthesize silica nanoparticles with defined size and size distribution allows systematic 
correlation of these parameters with cellular uptake, toxicity and biodistribution, which in 
turn enables development of constructs for safe and effective biomedical applications. 
Biodistribution and clearance routes have threshold size ranges which prevent or allow 
for particle accumulation. Thus, this characteristic will be important in engineering or 
designing drug delivery and imaging systems, as changes in size distribution could 
significantly alter targeting strategies and dosing mechanisms.   
Systematic evaluation is not limited to controlled size and monodisperse systems. 
Investigators have also explored other synthetic routes to create other nanoparticles. Beck 
et al. (230) created one of the first most commonly used mesoporous silica nanoparticles, 
with the addition of a surfactant, cetyltrimethylammonium bromide (CTAB), using the 
Stober method. This surfactant facilitates the creation of micelles which are coated by 
initial silica crystals and assists in creating larger gaps during synthetic aggregation 
hydrolysis by inducing hydrophobic interactions. Similar processes have shown to create 
mesoporous nanoparticles via polymerization and acid catalysts (222, 231, 232). 
Alterations in surfactant and polymerization chemistry have allowed for the development 
77 
 
Figure 2.7: Plain silica nanoparticle toxicity is dependent on particle-cell surface 
contact area.  The figure illustrates that at equal surface area, smaller particle size 
yield greater particle number (i.e., for every one 200 nm particle there exist 
sixteen 50 nm particles and for every one 100 nm particle there exist four 50 nm 
particles) and higher toxicity on RAW 264.7 macrophages.  Fifty nanometer 
particles induced the highest toxicity, followed by 100 nm and finally 200 nm.  
Note that if particles are graphed via particle number, larger particles remain 
more toxic due to larger cell surface contact area. A. Demonstrates the toxicity 
profile when plotted against particle number; a larger particle facilitates higher 
toxicity due to larger contact area B. Demonstrates toxicity profile when plotted 
against mass. C. Demonstrates the toxicity profile when plotted against the 
surface area; all particles maintain similar toxicity profiles. Modified data from 




of structurally different pores, significantly altering small molecule diffusion patterns 
(233, 234). The control over these diffusion patterns is key to being able to manipulate 
drug or contrast agent release. By following this process with acid extraction or 
calcination, the surfactant is effectively removed, leaving the amorphous material with 
large pores or holes (235, 236). It is interesting to note that toxicity profiles of some 
porous silica nanomaterials have not shown a significant difference when compared with 
their bare silica counter parts (others have shown opposite effects (237), and some in 
vitro studies have even proven to have a reduction in hemolytic capacity of porous 
materials (219, 238). This reduction could potentially be due to a decreased number of 
hydroxyl groups exposed to erythrocytes in circulation. Such a modification provides 
additional versatility in silica nanoparticles for delivery applications, as it allows for 
variations in functionalization and molecular encapsulation within the pores, which have 
been used potentially for subsequent drug release studies (209, 239).   
 
2.2.1.3 Potential to induce alterations in geometry 
Mesoporous silica synthetic characteristics helped to introduce the production of 
more diverse geometries. Modifications in surfactants, solvents, catalysts, salts, etc. can 
significantly alter the structural characteristics of the nanoparticles (235). Sol-gel solution 
phase chemistries can be altered and generate variations in geometries with a change, as 
little as, an adjustment of the surfactant properties (240). The surfactants introduce a 
unique alteration in the interfacial chemistry, causing significant modifications in 
formation of the solid crystal structure. These changes in the crystal structure facilitate 
changes in the morphological characteristics. For example helical mesoporous silica 
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nanorods have been produced utilizing CTAB and co-surfacant hexanol (241). A variety 
of different morphologies have also emerged utilizing CTAB and the addition of different 
functional silanes, which provide additional functional alterations in the interfacial 
chemistry (235). These examples illustrate exciting synthetic results because one can 
easily manipulate sol-gel principles to introduce dramatically different geometries. These 
geometries have proven to drastically alter toxicity and uptake (240).   
Once the discovery had been made that surfactants could alter crystal and 
chemical bulk structural formations, investigators started experimenting with differences 
in nucleation of the same sol-gel chemistry. Instead of utilizing the base alkoxide or acid 
other inorganic or surface materials were used. Nuraje et al. (242) produced such an 
example of creating variations in geometry utilizing interfacial chemistries. At the 
interface of an organic and aqueous phase, where the aqueous phase contains catalyzing 
ions, one can introduce a silicon alkoxide and subsequently nucleate from that interface 
(Figure 2.8) (242). This effectively creates a face for the geometric nanoparticle, and one 
can alter the shapes obtained by altering the catalyzing ions and organic phase. An 
aqueous sodium hydroxide (NaOH) phase with an organic butanol phase for example will 
generate squares, while an aqueous hydrochloric acid (HCl) phase with an organic 
chloroform phase will generate triangles (Figure 2.9) (242). 
Similarly with utilization of sol-gel chemistries and a template nucleation surface, 
synthetic silica schemes have been developed that provide unique tubular geometries. A 
template synthesis normally involves the introduction and subsequent nucleation of silica 
on the surface of a porous alumina membrane. After the silica has coated the inner layer 
of the membrane, the aluminum is generally dissolved away with phosphoric acid, 
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Figure 2.8: Silica nanoparticle interfacial chemistry. The separation between 
the organic and aqueous phases produces a nucleation interface, where a 
silica nanoparticle can form and precipitate into the aqueous phase.  Diagram 
modified from Nuraje 2007 (238). 
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Figure 2.9: Inner and outer surfaces of silica nanoparticles can be differentially 
activated to increase biocompatibility and include drugs or imaging agents. 
Modified from Nan, 2008 (240). 
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leaving behind tubular or rod-like structures. One can alter the thickness of the tube wall 
by controlling the addition of silica to the reaction (243, 244).  
The addition of another nanoparticle made out of differing materials, such as gold, 
polystyrene or other polymers, can also create a nucleation surface (245-247). The silica 
nanoparticle can grow off of this surface and one can subsequently remove the 
nanoparticle via high temperature burning or desolvation principles. Investigators have 
utilized these hollow silica spheres and rods to encapsulate a variety of different materials 
(239, 248).  
As stated earlier, the development of materials with alterations in geometry could 
potentially influence toxicity, cellular uptake and biodistribution profiles. Recent studies 
with silica nanotubes in MDA-MB231cells (human breast cancer epithelial cells) suggest 
that alterations in nanoparticle surface properties, aspect ratio or size can influence 
cellular uptake (240, 244, 249, 250). Sol-gel mesoporous materials also show significant 
changes in cellular uptake, as mesoporous tubular like structures were not taken up as 
significantly as mesoporous spherical structures (251).    
The use of various geometries of silica in biomedical applications proves to be an 
exciting prospect. First they introduce the ability to potentially change cellular uptake, 
biodistrubution and toxicity profiles. Second they provide unique functionalization 
capabilities where the inner and outer surface can facilitate differential functionalization. 
As one changes the geometry of the nanoparticle, it provides the potential to present 
several surfaces, each with the possibility of a different surface characteristic. For 
example a silica nanotube (SNT) presents an inner and outer surface (Figure 2.9).  One is 
able to functionalize the inner surface of SNTs so that it incorporates hydrophobic agents, 
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while the outer surface is modified with hydrophilic biomolecular agents (243, 244). This 
characteristic will be helpful in drug delivery and imaging systems, as many prospective 
deliverable payloads are hydrophobic and in order to increase circulation, statistical site 
accumulation and biocompatibility of the construct that is delivered, it may be helpful to 
induce hydrophilic surface properties.  
 
2.2.1.4 Ease in surface modification 
Silica nanoparticles have a simple unique surface covered by hydroxyl functional 
groups. This surface can be easily modified via traditional silane chemistry. Silane 
chemistry has become an industry standard and is available commercially. The wide 
array provides the ability to functionalize the surface of these nanoconstructs with a 
broad variety of materials. This initiates surfaces that have much different characteristics 
than their respective silica core. These characteristics can be exploited and increase silica 
nanoconstruct potential for engineering drug delivery and imaging systems.   
Functionalization can be as simple as small molecular weight functional groups 
attached via a silane, such as an amine or a carboxyl, which alters the charge density of 
particles. Charge density has proven to be extremely important to toxicity, distribution 
and uptake in silica nanoparticle constructs (24, 229). Positively charged silica 
nanoparticles were taken up by mesenchymal stem cells via endocytosis to a greater 
extent than plain silica nanoparticles while maintaining low toxicity (252). While these 
functional groups can alter toxicity and biodistribution profiles they also provide the 
option for introduction of more complex surface chemical synthesis.  
Blaaderen et al. (253) have developed a novel fluorescent silica tagging method.  
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By utilizing the spontaneous addition reaction of the amine group of a 3 
(aminopropyl)triethoxysilane (APES) and the thioisocyanate group of a fluorescein 
isothiocyanate (FITC) they were able to create a fluorescent silane group that could be 
easily coupled to the surface of a silica nanomaterial. This group then proceeded to coat 
the silica nanoparticle surface with a tetraethoxysilane (TEOS) which provided the FITC 
with a protective coat that significantly reduced photobleaching (Figure 2.10) (253).  
Subsequently research groups have attached other fluorescent molecules to the surface of 
the nanoparticles and proceeded to assess and compare the potential toxicity of these 
constructs to their bare silica counter-parts (254, 255). It is important to note that these 
groups have found that fluorescent particles have similar toxicity profiles to their bare 
counterparts. The development of this construct was important to translation of these 
nanoparticles to drug delivery and imaging systems. As it is essential that detection 
methods that aid in devolving uptake, toxicity and transport mechanisms should not 
affect the properties of the construct.  
These functional surface modifications have also provided the ability to increase 
circulation times by reducing protein absorption and opsonization with the addition of 
hydrophilic surface groups, such as poly(ethylene glycol) (PEG) and other polymers 
(235, 256-259). Stayton et al. (260) conducted an extensive study investigating the effects 
of specific protein adsorption, on 13.3 nm silica nanoparticles in A549 cells (human lung 
carcinoma cell line). The analysis included hemoglobin, albumin, histone, pre-aggregated 
and complete medium. Protein adsorption differed little from protein to protein. Those 
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Figure 2.10: Fluorescent labeling of silica nanoparticles. Abbreviations: 
tetraethoxysilane (TEOS), ammonium hydroxide (NH4OH), water (H2O), 
ethanol (EtOH), 3-aminopropyltriethoxysilane (APES) and fluorescein 




cultures incubated with single proteins tended to form particle aggregates, while bare 
particles had a higher degree of uptake. Additionally, those particles adsorbed with 
histone tended to have a reduced zeta potential which appeared to correlate with faster 
uptake. The investigators also created particles with a cadmium surface modification 
which appear to reduce toxicity and uptake (260). Furthermore, polymer coatings have 
shown to increase circulation, and significantly reduced particle toxicity on certain cell 
lines (24, 229). It is important to note that proteins adsorbed on the surface of silica 
nanoparticles have significant effect on cellular uptake and distribution (2, 93, 261, 262). 
The protein itself could potentially interact with cell surfaces and thus initiate adverse 
events. For example Chen et al. (263), suggested that nucleoplasmic protein aggregation 
significantly impaired nuclear function, leading to the inhibition of proliferation, 
transcription and replication. Surface modification can alter significantly the interactions 
and thus the protein association with the nanoparticle surface(264). Thus it will be 
important to pay attention to protein adsorption onto silica nanoparticles in the context of 
their biocompatibility, biodistribution and cellular uptake.  
Targeting motifs have also been displayed on the surface of these particles to aid 
in active localized targeting to tumor sites and reduction in nonspecific uptake. Kumar et 
al. (254) created fluorescently labeled particles with transferrin surface modification 
which showed cell internalization within Mia-PaCa (pancreatic cancer cell line) and 
without modification showed no internalization. Additionally, Liong et al. (265) utilized a 
folic acid targeting motif and saw a significant increase in uptake of multimodial silica 
nanoparticles in PANC-1 (pancreatic cancer cell line).  
Surface modification can also play a key role in the development of stimuli 
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sensitive materials. Stimuli sensitivity is a unique property that could provide an 
additional versatility to drug delivery systems. For example, porous silica nanoparticles 
can be utilized to trap drug molecules or imaging agents that are usually systemically 
toxic (265-267). These can be capped with materials such as cadmium sulfate, gold 
nanoparticles, dendrimers, or polymeric supports until they reach the intended site. The 
polymeric support can then initiate release dependent on changes in the local 
environment such as pH or reactive species (Figure 2.11) (268-275). For example, 
Nguyen et al. (273) have developed such a nanovalve for mesoporous nanomaterials 
where the valve is opened and closed via oxidation and reduction reactions. Additionally 
these materials can incorporate enzymatic identification markers to facilitate cleavage of 
the polymeric support (270, 276). These stimuli sensitive nanoparticles have also utilized 
mechanical processes such as magnetic fields to open magnetically capped porous 
materials (277). Stimuli-responsive silica composites can be used in delivery of bioactive 
and imaging agents, or theranostics, where release and/or imaging at the target site is 
desired. 
 
2.2.1.5 Ability to control encapsulation of molecules of interest 
In addition to exceptional surface modification characteristics, one is able to 
utilize the silica sol-gel chemical properties to dope and control encapsulation of other 
molecular agents. Similar to the synthesis of hollow spheres and rods, it is possible to 
stimulate nucleation off of other materials and encapsulate them within silica constructs. 
Such examples are iron oxide, quantum dots and gold (208, 278, 279). These doped 
materials provide useful alternative methods of detection such as fluorescence for 
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Figure 2.11: Encapsulation of payloads by porous silica nanoparticles. Payload 
(contrast agent or drug) can be released depending on environmental stimuli. 




confocal imaging or magnetic dipole capabilities for magnetic resonance imaging (MRI), 
but still retain the benefits of silica properties. Initial toxicity profiles on these materials 
have also proven to be similar to bare silica constructs, however it is important to note 
that some of these materials have shown leaching from the silica core (271). In the 
development of these materials it will be important to ensure that the silica constructs not 
retain toxicity but also any encapsulated leachable material. In addition to the 
encapsulation of imaging agents within these systems, therapeutic molecules have also 
been incorporated (144, 209, 280, 281). 
Composite materials have also been formed utilizing silica (282). These 
composite materials have provided a unique capability of composite silica degradation, 
something that traditional silica nanoparticles do not offer. Park et al. (283) developed a 
complex of several 3-5 nm silica particles within a dextran coating. This composite 
created 130-180 nm constructs that could then be degraded to release the 3-5 nm particles 
which can subsequently be cleared(283). With the development of degradable materials 
the utilization of silica in drug delivery systems is significantly more promising, as 
clearance mechanisms of current silica constructs have still not been devolved.  
Additionally, these composite materials have encapsulated proteins and 
immobilized enzymes within the silica nanoparticle. Investigators have done so by 
prehydrolyzing the silicon alkoxide and then simply adjusting and maintaining a stable 
pH range for which the protein retains stability. This process has provided effective 
doping capabilities without altering the conformation or shape upon release, which is 
extremely important to retaining function. This material provides an interesting approach 
to drug delivery as it helps to reduce degradation potential in circulation (284, 285). 
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These degradation profiles are promising as they provide evidence that inorganic 
materials could be developed with the ability to specify doping and enhanced control 
over therapeutic release rates. 
 
2.2.1.6 Economic affordability and ease of scale up 
Silica nanoparticle systems can be generated and purified with ease in large 
quantities at low cost. This is essential in clinical translation of these materials. 
Pharmaceutical and biomedical corporations are looking to invest in materials which are 
easy to produce and have the capability to present both an enhanced therapeutic benefit, 
as well as economic turnaround. Even with the ease in the synthetic chemistry and 
purification, some additional factors such as characterization and sterilization remain.  
 
2.2.2 Silica nanoparticle characterization 
Once silica nanoparticles are synthesized it is essential to effectively characterize 
the constructs. Size, charge, chemical core and surface composition all need to be 
validated and verified in order to successfully assess and re-evaluate the efficacy and the 
impact on delivery of these constructs. Presented here are only a few methods of 
characterization to illustrate each technique’s pros and cons. Thus the key point is that 
validation must be made through multiple sources.  
 
2.2.2.1 Size 
Size characterization is essential because as previously mentioned factors such as 
cellular uptake, biodistribution and toxicity are dependent on size and surface area.  
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2.2.2.1.1 Dynamic light scattering (DLS) or photon correlation spectroscopy 
This method shines a light source at a solution that contains a colloidal dispersion 
of the sample. The particles in the sample undergo Brownian motion, which creates 
interference in light penetration and introduces scattering of light. The light that is 
scattered is detected and translated into a velocity, which can be back calculated into a 
size. The measurement itself does not serve as a complete characterization of size, as it 
only provides the polydispersity over the total sample and measures the hydrodynamic 
radius rather than the actual particle radius. It is however a less expensive option to assess 
and quantify the size and polydispersity of a nanoparticle sample. The method is also 
helpful in the identification of aggregation of particles, due to surface modification or 
charge instability on the surface (286). 
 
2.2.2.1.2 Transmission electron microscopy (TEM) 
This method is a highly sensitive method that utilizes a beam of electrons emitted 
and passed through a dried sample on a copper grid. An image is generated via the 
detection of the electrons through the sample. These images can then be manually or 
electronically measured to assess the actual size of the particles. Due to the sensitivity of 
the instrument, particles in the single nanometer range can be detected. It is important to 
note that once particles are dried, most nonrigid surface modifications such as polymers 
or peptides are not displayed, due to collapse and nonexistent interaction with a solvent 
system. Thus, the actual size of the particle could potentially be much different than the 
representative image. Additionally, it is extremely difficult to ascertain surface 
topography or visualize porosity of dense materials due to electron penetration (287).  
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2.2.2.1.3 Scanning electron microscopy (SEM) 
SEM utilizes a beam of electrons and detects the secondary or backscattered 
electrons of a metallic coated sample, introduced post sample drying. Due to the 
detection method it is difficult to provide effective resolution for particles much below 50 
nm. However, surface topography can be resolved. Similar to TEM, soft organic 
modifications or materials are undetectable (288). 
 
2.2.2.1.4 Atomic force microscopy (AFM) 
AFM utilizes a dragging probe to probe the surface of a material and detects small 
vibrations, due to surface topography, utilizing a piezo electrode. This method can be 
performed in solution and thus can provide size information on both rigid and nonrigid 
materials. AFMs have been utilized to detect and image at the molecular scale, asserting 
topographical changes within 5 nm (289). However, changes in instrumentation set-up 
and sample preparation can significantly affect resolution (290). 
 
2.2.2.2 Charge 
As stated earlier, charge density plays an important role in directing uptake, 
distribution and toxicity. By controlling charge it is possible to direct the biological fate 
and toxicity of silica nanoparticles. 
 
2.2.2.2.1 Zeta potential  
This is a fast, efficient measurement of the electric potential of a colloidal 
suspension. By passing an electric field through the solution, one is able to detect zeta 
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potential at the interfacial double layer which can then be compared to a point in the bulk 
solution calculating a relative charge solution value. This number is extremely useful in 
the identification of the stability of the solution. Generally zeta potential values between -
20 to +20 do not have enough electrostatic repulsion to be stable colloids, and thus they 
aggregate to create solution stability. Additionally, it can be a useful measurement to 
provide charge interaction comparison between particles and cell surfaces. It is important 
to note that this value is highly dependent on pH and salt concentration, since it measures 
the ions in solution. Thus, when taking zeta potential measurements one must note that 
physiological environments differ significantly from measured values, so the number 
they provide is relative (291).    
 
2.2.2.2.2 Surface composition 
Cell-cell mediated interactions via viable, nonviable, native and foreign materials 
are generally through conformation arrangement or chemical identification. This also 
appears to be the case in nanoparticle interactions, thus surface composition will be key 
in characterization.  
 
2.2.2.2.3 Thermogravimetric analysis (TGA) 
This is measurement based on weight loss due to increases in temperature and 
effectively burning off attached surface materials (i.e., polymers). Modified silica 
samples are heated after a thorough drying process and data is extracted and compared to 
bare silica nanomaterials. Correlations can be drawn between weight loss and average 
amount of material located on surface. This measurement provides evidence that 
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compound(s) exist on the surface. However correlative information is limited to melting 
temperature of the sample, thus it is difficult to discern the actual material (292).   
 
2.2.2.2.4 Nuclear magnetic resonance (NMR) 
This measurement is obtained through the induction of a magnetic field on an 
object. This field provides spin ratios which can then be correlated back to chemical 
structural characteristics, and subsequent molecular identification. The method relies on 
heavy training and can be extremely time consuming based on the surface modification. 
However it provides some of the most accurate and quantifiable information (293). 
 
2.2.2.2.5 Infrared spectroscopy (IR)  
This measurement is obtained by emitting infrared band on a sample and 
recording the absorption of stretching and bending frequencies. This also can be 
correlated back to chemical structural characteristics and subsequent molecular 
identification; yet, limited in quantification (294).  
 
2.2.2.2.6 Traditional fluorescent labeling or chemical substitution 
reactions 
One can tag the surface modification or utilize a reagent that reacts with the 
surface modification to create a product which can then be measured via absorbance or 





2.2.3 Silica nanoparticle preparation for biological evaluation 
Following synthesis and characterization it is essential to effectively sterilize the 
particles in order to validate and verify the safety and efficacy of the constructs. Again 
this proves to be a difficult task for inorganic nanoparticles as many traditional 
sterilization techniques are inefficient, ineffective, or impractical. Without sterilization, 
drug delivery and imaging devices could potentially be contaminated, leading to toxic 
side effects not due to the construct itself but the contamination within the suspension the 
construct exists. For a more comprehensive review detailing experiments evaluating the 
effects of sterilization on nanoparticles the reader is directed elsewhere (296). The 
following briefly outlines the pros and cons of traditional sterilization techniques. 
 
2.2.3.1 Heat and autoclaving 
Traditional silica inorganic particles can be heated at extremely high temperatures 
(~500 C). These temperatures are sufficient to both kill bacteria and burn away 
endotoxins. However, the temperature induced does have the potential to detrimentally 
degrade any surface modifications or molecular encapsulations. A lower temperature 
alternative is autoclavation. However most natural or mimics of natural materials still 
degrade at these temperatures or pressures.  
 
2.2.3.2 Filtration 
Filtration through traditional 200 nm pore filters are sufficient to remove most 
bacteria. However endotoxins still pose a significant problem. Additionally, 200 nm 
pores will only work for particles much smaller than the pore size range and many 
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nonspherical or geometric nanomaterials might be caught up and remain within pores 
themselves.   
 
2.2.3.3 Gamma irradiation 
  Ionizing radiation is emitted on samples to destroy bacteria and alter endotoxin 
formation effectively reducing inflammatory response. However, irradiating samples can 
ionize the sample or destroy surface modifications, which are not desirable. 
 
2.2.3.4 Ethanol 
 Soaking materials within ethanol effectively destroys bacteria. However 
endotoxins remain in solution. Sterilization is one of the determining factors behind 
utilization of any nanotechnology-based construct for clinical applications. Each 
sterilization technique provides both sufficient pros and cons, while a combination of the 
techniques may prove to be ideal. It is important to note that sterilization techniques 
could potentially alter size and agglomeration, so it will be key to ensure technical 
composition is maintained through this process.  
 
2.2.4 Toxicity of silica nanoparticles 
 Limited toxicity profiles exist on amorphous silica nanoparticles. However for use 
of silica nanoparticles in a clinical setting it is imperative that their toxicity in vitro and in 
vivo is carefully evaluated. As previously discussed, size, shape, surface modification and 
composition have proven to affect toxicity, distribution and uptake of silica nanoparticle 
constructs. Outlined here is a brief overview of how these characteristics affect silica 
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nanoparticle interaction with in vitro and in vivo environments. By paying close attention 
to outcomes this review will also attempt to address modifications or utilization of 
particular characteristics to obtain better engineered silica nanoparticles for biomedical 
applications.     
There are two distinct modes of cell death: apoptosis, programmed cell death, and 
necrosis, premature cell death. Cytotoxicity has been indirectly linked to markers of these 
modes of cell death and their subsequent initiation events. Such an example is caspase-3. 
This is an important marker of apoptosis and it has been shown to be up-regulated in 
macrophage cell lines following silica nanoparticle treatment (39). Additionally, other 
modes of cell death can be initiated by other cytotoxic cellular events. The current 
initiation modes of cell death remain uncertain. Is it however certain that if silica 
nanoconstructs are instigating these events, in order to engineer safe and effective 
constructs, causation and subsequent elimination of these events need to be addressed.   
It is important to note that bare silica nanoconstruct toxicity is cell type 
dependent. Thus the route of administration influences alterations in toxicity as well.  
Epithelial cells show very little to no cytotoxic effects when treated with silica 
nanoparticles (Figure 2.12) (297, 298). However, fibroblast cell lines and those cell lines 
with longer population doubling times or lower metabolic rates have been shown to have 
a substantial increase in susceptibility to toxic effects (299). Cells with phagocytic 
activity such as macrophages, and to some degree endothelial cells, appear to be the most 
affected cell types (300). Thus it will be important to pay close attention to the cell 
type(s) which many of these assays are performed on and the mechanisms that induce 
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Figure 2.12: Influence of cell type and surface modification on toxicity.  As shown, 
silica nanoparticle treatment does not induce HCT116 or DU145 epithelial cell 
toxicity, while it does induce RAW 264.7 macrophage toxicity. IC50 values in RAW 
264.7 cells are heavily dependent on surface modification, as amine (N) modified 
particles are more toxic than unmodified and carboxyl modified particles (C).  A) 
Confocal microscopy image of DU145, HCT11 and RAW264.7 cell nucleus stained 
with DRAQ5 and particles labeled with FITC. These images illustrate the relative 
uptake of these particles. RAW264.7 cells show a significant increase in relative 
uptake.  B) RAW 264.7 WST-8 proliferation assay, 100nm plain, carboxyl and amine 
modified particles. C) HCT116 and DU145 WST-8 proliferation assay, 100nm plain, 
carboxyl and amine modified particles, little to no toxicity was observed. Modified 




toxic susceptibility (298). This can ensure that surface or material modifications are 
investigated to avoid cytotoxic mechanisms that are induced by processes like phagocytic 
activity. If toxicity has been identified or suggested it is crucial to determine the 
causation of cellular toxicity.  
 
2.2.4.1 Toxicity via cellular internalization 
Prior to discussion of potential toxicity mechanisms it will be important to address 
how nanoparticles can interact with cells and the most probable modes of internalization. 
Silica nanoparticles display on their surface approximately five hydroxyl functional 
groups per nanometer (301). The very nature of the particles is foreign to the human body 
and as such phagocytosis facilitates another uptake mechanism. Cells can also be 
internalized via caveolin and clathrin-mediated endocytosis, macropinocytosis or 
pinocyotsis (302). Each of these mechanisms generally has a size and surface dependent 
threshold (302).  
The most probable mechanistic route of internalization is via endocytosis 
followed by encapsulation within lysosomal compartments (Figure 2.13) (298, 303, 304). 
It is important to note that the acidic pH of the lysosomal compartment is not sufficient to 
facilitate degradation of these particles. Thus after internalization these constructs have 
the potential to do irreversible cell damage if they are released from cellular 
compartments or internalized into important functional compartments such as the 
mitochrondria. Some literature sources have started to devolve potential silica 
nanoparticle escape routes as well as cellular compartment recycling. It has been 






























































































































































































































be released from late stage lysosomes into the cytoplasm. This has been confirmed via 
fluorescent microscopy and the delocalization of silica nanoparticles with lysosomal or 
endocytic compartments (305).  
Increased cytoplasmic presence can increase cellular compartmental 
encapsulation and damage. One such example is the mitochondria. Chang et al. (299) 
compared the results of an (4,5-Dimethylthiazol-2-Yl)-2,5-Diphenyltetrazolium Bromide 
(MTT), mitochondrial function assay of ~80 nm bare silica to chitosan silica 
nanoparticles, on WS1, CCD-966sk (human skin adherent fibroblasts), MRC-5 (human 
lung adherent fibroblast), A549, MKN-28 (human cancer gastric epithelial), and HT-29   
(human caner colon epithelial) cells. The results indicate that cancer mitochondrial 
function was more resilient to silica nanoparticle treatment. Fibroblast cell lines were 
susceptible to functional damage and chitosan modification significantly reduced toxicity. 
Julien et al. (306), Choi et al. (307) and Malugin et al. (298) found similar toxicity 
results.  
 
2.2.4.2 Toxicity via particle-cell interaction 
Cellular internalization however is not the only possible mechanistic route of 
toxicity. Silica nanoparticle cell interaction could potentially be sufficient to induce 
inflammatory or coagulation cascades, triggering signaling pathways and subsequent 
damage. Some investigators believe that nonspecific silica nanoparticle interaction with 
cells is sufficient to create membrane damage. Lactate dehydrogenase (LDH) or 
membrane integrity assays have supported this hypothesis (299, 308). It however remains 
unclear what initiates this damage. Also the influence of surface functional groups, 
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charge, hydrophobicity and contaminants need to be examined in detail. 
The hydroxyl groups on the surface of the silica nanoparticle can also react with 
native species, such as iron in the Fenton reaction, or cellular receptors. Both modes 
create radicals which induce oxidative stress and reactive oxygen species (ROS) (140). 
Increase in ROS levels can cause oxidation of deoxyribonucleic acid (DNA), protein and 
lipids, induce mitochondrial dysfunction and significantly alter the genes related to the 
inflammatory and apoptotic response. Certain markers play a key role in indication of 
oxidative stress and suggest functional cell damage, such as increases in malondialdehyde 
(MDA) and Thiobarbituric Acid Reactive Substance (TBARS) and decreases in 
glutathione (GSH). MDA and TBARS indicate amplified lipid peroxidation and GSH is a 
ubiquitous sulfhydryl-containing molecule that is responsible for maintaining oxidative 
homeostasis, and does so by reducing cellular oxidation species within the cell. Oxidative 
stress induction via bare silica nanoparticles has been shown to be a potential mechanism 
of cellular toxicity in macrophage, embryonic kidney and bronchoalveolar carcinoma cell 
lines (13, 141, 283). Wang et al. have linked a potential apoptotic cell death mechanism, 
as a result of oxidative stress, with a flow cytometric analysis, by proving that the sub-G1 
population of HEK293 (human embryonic kidney cell) increased, with a G2/M phase 
arrest (309).   
Nanoparticle cellular interaction can also stimulate the release of primary and 
secondary inflammatory mediators, such as cytokines, chemokines, nitric oxide (NO) and 
expression of inflammatory genes (283). Increases in interleukins (such as IL-1beta, IL-6, 
IL-8, IL-10, etc.), tumor necrosis factor alpha (TNF-alpha), transforming growth factor 
(TGF), monocyte chemoattractant proteins (MCP-1), macrophage and inflammatory 
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proteins (MIP-1, MIP-2, etc) and their respective messenger ribonucleic acid (mRNA), 
have been shown to be up-regulated in cell lines in environments post in vivo and in vitro 
with silica nanoparticle treatment (35, 189, 283). Many of these represent inflammatory 
signaling factors which induce cellular migration, proliferation, differentiation and 
apoptosis within the biological environment. Direct correlations can be drawn between 
increases in these inflammatory mediators and increased levels of inflammatory or 
immunological cells (T, B, NK cells) in the local environment post silica nanoparticle 
treatment (34, 283). All of these events are hallmark indications of larger developing 
inflammatory events. Additionally, inflammatory events along with direct particle 
interaction with cell environments can adversely enhance cellular activation and 
subsequently induce thromobogenicity (310). If the induction of these mediators is indeed 
due to surface interaction, covering the surface or hydroxyl groups of the particle with a 
biocompatible material could potentially provide a safe alternative.  
Circulation of bare and modified particles can induce additional interactions with 
other circulating blood cells and investigators have begun to study these implications. As 
stated previously, evidence suggests that bare silica nanoparticles cause the lysis of 
erythrocytes (140). Modes or mechanisms of cell death that have been proposed include 
the induction of reactive oxygen species, or surface electrostatic binding interactions with 
tetra-alkyl ammonium groups (218). It has been shown that the density of hydroxyl 
groups on the surface of silica nanoparticles is directly correlated with the rate of 
hemolysis (140, 311). Slowing et al. (219) reported that mesoporous silica nanoparticles 
maintain safe levels of biocompatibility, with low hemolysis activity. However 
contradictory these reports appear to be, it is interesting to note the impact of surface 
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density and charge on the safety of particular constructs. When designing drug delivery 
or imaging systems, it is important to attempt to minimize hemolysis via surface, bulk or 
geometric modifications to reduce side effects.   
 
2.2.4.3 Toxicity via a combination of particle internalization and 
cellular interaction 
Genotoxicity, chromosomal aberrations and mutagenicity are also extremely 
important factors to consider both in the long term health of the patient and in 
development of these particles. Waters et al. (142) performed a transcriptional analysis on 
a variety of different size ranges of particles, utilizing microarrays on RAW 264.7 
(murine macrophage cell line). This provided evidence of adverse amplification effects 
on the expression of genes that are implicated in inflammatory and stress inducing events, 
such as chemokines and cytokines. Surface area was directly correlated with the level of 
gene expression abnormalities, which suggests inflammatory stimulation rather than 
genotoxicity induction. Similarly, Jin et al. (312) showed that luminescent DNA 
nanomaterials presented little DNA damage, which did not necessarily correlate with 
cytotoxicity levels within A549 cells, suggesting cell death occurs through other 
mechanisms. Similarly Barnes et al. (313) reported that 3T3-L1 (fibroblast like cells) 
incubated with silica nanoparticles produced no genotoxicity evidence within a 
reproducible comet assay which assesses breaks in both single and double stranded DNA. 
These results provide a positive outlook for the application of these materials in drug and 




2.2.4.4 Toxicity via biodistribution and clearance mechanisms 
Due to silica’s inherent inability to degrade, clearance mechanisms and organ 
accumulation are extremely important to evaluate, to ensure the safety of these 
constructs. Borchardt et al. (314) investigated the biodistribution of a variety of different 
surface modified spherical nanoparticles, and found that increasing the hydrophilicity of 
the coatings led to increased intestinal delivery and lower uptake via liver and spleen, 
while increasing the chain length and attaching a butyltrichlorosilane increased muscle 
accumulation and bone marrow delivery, respectively. These investigators have proposed 
that alteration in biodistribution is due to both the hydrophilicity and steric inability for 
proteins or opsins to adsorb to the surface of the silica constructs. Additionally, the study 
introduced the aspect that bare silica has a much slower liver absorption than most 
common drug carriers. It will be important to keep these results in mind in development 
of silica nanoparticles, as this study suggests that size, geometry and surface modification 
could potentially provide directed targeting and initiate elimination in toxicity.   
An important issue is clearance of nanoparticles. Ideally, particles should be 
excreted via the kidney so local liver accumulation does not occur. Liver clearance 
however is acceptable if particles are cleared through hepatobiliary mechanisms. 
Nevertheless, toxicity due to prolonged particle accumulation can still pose a significant 
threat. Burns et al. (278) were able to develop labeled silica nanoparticles of diameters 
3.3 and 6.0 nm and showed complete clearance within 48 hours. He et al. (24) 
demonstrated that 45 nm silica nanoparticles with free hydroxyl, carboxyl and PEG 
modifications were cleared mainly through liver excretion with a high circulation rate for 
PEGylated particles. Additional data pointed to removal via renal routes in addition to 
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hepatobiliary mechanisms, suggesting that particles are statistically able to accumulate 
renally and with modification. Hudson et al. (238) examined rat subcutaneous 
biodistribution and clearance of 180 nm-4 um silica nanoparticles at four days, two- and 
three- months. Significant particle accumulation was found in the subcutaneous nodule at 
four days. However two- and three- month time points showed little to no accumulation. 
Following i.v. injection into mouse models doses above 1 mg per animal were lethal. 
 
2.2.5 Applications of silica nanoparticles in drug delivery and 
imaging 
2.2.5.1 Drug delivery  
Drug delivery is defined by the ability to effectively attach or encapsulate a 
therapeutic payload, deliver the respective payload to a site of interest and finally release 
it at an appropriate therapeutic release rate. Silica nanoconstructs as outlined within the 
chapter have three distinct advantages over traditional delivery constructs: 1. the 
construct itself provides protective stability with which one can both protect and 
encapsulate therapeutics; 2. the physiochemical characteristics of the construct can be 
manipulated to facilitate controlled release rates; and 3. alterations in physiochemical 
characteristics and surface attachment can facilitate targetability and effective 
biocompatibility.  
 
2.2.5.1.1 Protective stability  
Silica nanoparticles provide a unique thermally and chemically stable 
nondegradable environment, which can potentially encapsulate therapeutics. Compared to 
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drug delivery systems such as polymeric micelles, liposomes and water-soluble 
polymeric carriers, silica nanoparticles have some advantages. Unlike silica 
nanoparticles, polymeric carriers may lack masking capabilities, while micelles and 
liposomes suffer from inherent potential dissociative properties due to critical 
concentrations and diminished physiochemical interactions (225). Silica nanoparticles 
provide a means by which to encapsulate hydrophobic molecules that would normally be 
insoluble. Such an example was produced by Liong et al. (265) where a mesoporous 
multimodal imaging phosphonate coated silica nanoparticle with a folic acid targeting 
motif was used to help deliver loaded hydrophobic chemotherapeutics, specifically 
camptothecin and paclitaxel. A significant cellular reduction in viability at 20 ug/mL and 
enhanced cellular uptake with the addition of a folic acid motif were demonstrated. 
Additionally, silica nanoconstructs can provide a platform to stabilize bioactive agents. 
As stated earlier, enzymes have been linked to the surface of silica to help maintain 
activity and facilitate a reduction in degradation. Similarly lipids have been stabilized on 
the surface of these materials. Silica nanoparticle-lipid emulsions were created for oral 
delivery where the silica component provided protection against lipase digestion in the 
gastrointestinal tract and a 15-fold increase in digestion was observed compared to lipid 
emulsions alone (315). 
It is important to note, however, that silica stability also comes with inherent draw 
backs, including but not limited to lack of degradation, and aggregation. The key question 
in the design of novel silica systems for drug delivery will be how they will be cleared 
after systemic administration. As reported earlier investigators are looking at degradation 
chemistries that can help solve this elimination problem. Additionally, because these 
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particles are colloidal suspensions there could potentially be modes of aggregation or 
agglomeration. These could counteract alterations in physiochemical characteristics that 
facilitate directed targeting, such as size or geometry. 
 
2.2.5.1.2 Manipulation of the construct to facilitate controlled 
release rates 
While encapsulating the materials is the first step, release and maintenance of 
effective levels of therapeutics are keys to a successful delivery. Mesoporous silica 
constructs provide a means by which to manipulate drug release rates. Unlike traditional 
polymers which rely on cleavage of therapeutics or complete disassociation via 
hydrolysis or enzymatic mechanisms of micelles or liposomes, mesoporous materials rely 
on physiochemical interactions and their effects on basic diffusion or mass transport 
phenomena. These porous materials can have interconnected large networks of pores that 
can create different diffusion length paths and thus alter diffusion release rates. For 
example, Trewyn et al. (240) and Stromme et al. (234) utilized both spherical and rod like 
mesoporous silica nanoparticles. The spherical particle had ordered aligned pores while 
the rod like particle had a tortuous array of pores. These different constructs were loaded 
with an antibacterial agent that facilitates the destruction of both gram positive and gram 
negative bacteria. The altered pore structures significantly altered the release rates of the 
drug in in vitro bacterial cultures, as the spheres had an enhanced delivery at 48 hours 
after inoculation. This research suggested that pore geometry influences release rates 
where more interconnected networks could allow for longer diffusion paths and thus 
potentially longer release kinetics (240). Additionally, Brohede et al. (233) studied the 
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difference between cylindrical and spherical pores. It was found that diffusion through 
spherical pores was enhanced suggesting that the interconnected pores of cylindrical 
particles facilitate longer diffusion paths. 
 
2.2.5.1.3 Physiochemical characteristics 
Surface functionality is one of the most important aspects in enhancing 
biocompatibility, targeting and release of drugs from silica nanoconstructs. With surface 
functionalization one can potentially reduce or eliminate unwanted toxicity, and influence 
cellular uptake. For example, silica nanoconstructs have been modified with cationic 
residues to facilitate nucleic acid adsorption. These constructs have proven to be effective 
in increasing transfection efficiency of nucleic acids both in vitro and in vivo (316-321). 
Additionally, systemic side effects may be potentially avoided with the addition of 
specific functionalities. Mal et al. (322) have utilized coumarin to coat the pores of the 
mesoporous material and UV light emission at 310 nm to release cholestane and 
phenanthrene. Several groups have utilized redox alternatives, such as gold and 
poly(amido amine) dendrimers (PAMAM) to stimulate pore opening capabilities (269, 
271, 274). Extensive work has been done with spherical mesoporous nanoparticles, where 
the attachment of a variety of different types of stimuli sensitive materials were explored 
that will only initiate release upon specified stimuli within certain physiological 
environments (240). For example a cadmium sulfide cap was utilized to encapsulate 
neurotransmitters within mesoporous silica nanoparticles and as a result of a reducing 
environment disulfide bonds where cleaved and drug was released into circulation (271).    
Active targeting, through the attachment of specified ligand on the surface of the 
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particles has the potential to enhance the delivery of silica nanoparticles. As illustrated 
earlier the attachment of specific ligands (transferrin and folic acid) and their subsequent 
interactions with pancreatic cell receptors have facilitated preferential uptake (254, 265). 
Additionally, as stated earlier in the text, Nan (244) and Trewyn (251) demonstrated that 
geometry can potentially provide preferential uptake. One can extrapolate this in vitro 
data to translation, as more work is done to understand how these active targeting 
characteristics facilitate preferential uptake that reduce systemic side effects. Ultimately, 
combinations of silica with other materials can assist in the creation of an ideal synthetic 
system that combines appropriate biocompatibility, diffusivity, encapsulation and release.   
 
2.2.5.2 Imaging contrast agents 
Noninvasive methods utilizing contrast agents can effectively aid in earlier 
detection of disease states and result in better prognosis for patients. The contrast agents 
need to preferentially differentiate abnormal tissue environments from normal 
physiology, thus enhancing the local signal. As such, successful new imaging agents are 
defined by their capability to enhance sensitivity and resolution. Some challenges in 
toxicity, degradation and stability limit the use of traditional signal enhancing imaging 
constructs. However, if the constructs are concealed in a protective environment, 
translation to human use can be facilitated. Silica nanoparticles show promise in the 
development of contrast agent doped particles, such as those utilized in MRI and optical 
imaging applications. Silica nanoparticles provide a platform which can aid in developing 
these modalities by encapsulating specialized imaging materials, thereby protecting both 
the material and the body, and by enhancing the signal yield.     
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2.2.5.2.1 Encapsulating specialized imaging materials 
Silica nanoparticle synthetic doping provides an ideal platform by which contrast 
agents can be doped into particles. Current contrast agents such as gadolinium (MRI) and 
quantum dots (optical), have an inherent toxicity when placed in physiological 
environments. However, if the material is encapsulated within an environment that 
prevents physiological contact, imaging agents can be developed with improved safety 
and signal intensity. As outlined earlier, gadolinium, iron oxide, quantum dots, gold, 
along with several different types of materials have been successfully incorporated or 
doped within silica constructs (208, 251, 265, 278, 279, 323, 324). Liong et al. (265) 
doped iron oxide constructs within silica nanoparticles and produced tumor localization 
in mouse models. This technology has also been utilized to track single stem cells to aid 
in the identification of the distribution of such cells after injection. Chung et al. (252) 
showed that uptake in mesenchymal stem cells does not alter proliferation, function or 
differentiation and they were able to subsequently image and track single cell migration 
through systemic circulation. Multimodal particles utilizing a combination of doped 
gadolinium and gold nanoparticles provided both MRI and photoacoustic imaging 
(optical) modalities. These systems were studied via uptake in J 774 macrophage cells to 
illustrate the proof of concept. However, as stated earlier, occasional reports have 
suggested that the materials can leak from silica materials (271). As a consequence better 
conjugation or incorporation methods are needed.  
Is it important to note that in addition to being able to protect the body from 
potentially toxic materials, silica nanoparticles can actually enhance and protect the 
contrast agent. For example, as stated earlier, the incorporation of fluorophores within 
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these materials have protected them from degradation and reduced photobleaching (253-
255). Additionally, the incorporation of MRI agents, such as gadolinium, within these 
materials could also reduce the potential dissociation of the agent from the carrier.   
 
2.2.5.2.2 Enhancing the signal yield 
The very premise of contrast agent is to enhance localized signal. Silica 
nanoparticles have two properties that enhance signal generation. The first is the 
capability to incorporate multiple contrast agents within one particle. The second is the 
ability to introduce changes in physiochemical characteristics and surface functionality 
that provide enhanced delivery potential. By delivering contrast agents in high payloads 
to a particular site of interest one can enhance the signal significantly. For example Kim 
et al. (323) developed silica nanoparticles containing gadolinium and a luminescent 
particle, with an attached arginine-glycine-aspartic acid (RGD) functionality. They 
showed little or no uptake in HT-29 (human colon cancer) cells when incubated with 
particles without RGD and a significant amount of uptake when incubated with particles 
with RGD. Additionally, Bickford et al. (325) developed a combination of gold and silica 
to produce a particle with near-infrared light scattering capabilities and attached human 
epidermal growth factor-2 (Her-2) targeting ligand. This nanoparticle proved efficacious 
to both target and image three separate cancer cell lines over expressing Her-2.   
 
2.2.5.3 Theranostics 
Dual modalities are useful in that both treatments and diagnostics can be delivered 
simultaneously. This aids not only in time and cost reduction, but also in identification of 
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localization of each construct. These materials maintain the same advantages and 
limitations outlined in drug delivery and imaging agent sections. The following will 
highlight a few of the examples with the utilization of silica as a theranostic platform. Lee 
et al. (326) combined doxorubicin with iron oxide and dye doped in mesoporous silica 
nanoparticles. Following subcutaneous injection passive targeting of these particles led to 
delivery and successful terminal deoxynucleotidyl transferase dUTP nick end labeling 
(TUNEL) staining or appearance of apoptotic cells within the tumor site. Similarly, Park 
et al. (283) were able to create a luminescent degradable silica nanocomposite that 
incorporated doxorubicin. The relatively nontoxic construct facilitated chemotherapeutic 
release, allowed for optical imaging and assessment of the location of the particles, and 
subsequently degraded which allowed for clearance of the particles.  
The above examples provide evidence of the potential of silica nanoconstructs as 
drug delivery systems, imaging agents, or theranostics.   
 
2.2.6 Unresolved issues and future directions 
As outlined throughout this chapter, silica nanoparticles provide an opportunity 
for drug delivery and imaging. However, it remains unclear what exactly the implications 
are of introducing an inorganic material in a biological environment. A key challenge is 
limited knowledge about mechanisms of toxicity of silica nanoparticles. To facilitate 
clinical translation it will be important to define how silica interacts with the biological 
environment. As with any biomaterial, biocompatibility remains the hallmark concern. 
The material should elicit an appropriate response without adverse effects, locally or 
systemically. Taking this into consideration, the traditional definition of toxicity is only 
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part of this larger picture. As highlighted throughout the chapter these materials do not 
seem to produce much initial or immediate adverse effects, but in vitro and in vivo data 
are not without concerns, as the long term effects still remain unclear. 
The initiation of inflammatory or thrombogenic events could potentially possess 
the greatest risks. It is worth noting that this will be important to understanding the total 
picture of these materials, as their crystalline counterparts, which are considered highly 
toxic, usually do not induce their effects for months to years. So, as one looks to the 
future of silica as a biomedical material, it will be key to maintaining safety, efficacy, and 
degradability while still affording the robust physiochemical properties. To translate 
these materials to clinical applications it is necessary to define a mode of transport, a 
mode of clearance, and a mode of treatment.  
 
2.2.6.1 A defined mode of transport 
Drug delivery and imaging systems are defined by their capacity to accumulate 
locally within diseased tissue. The utilization of SNPs to target these sites via alterations 
in geometry, size, surface modifications, including targeting ligands is still dependent on 
one key factor which is the ability to be transported via the blood stream. This transport 
process is not by any means simplistic or easy to effectively define. Silica nanomaterials 
must circulate long enough to allow targeting mechanisms to be effective. Thus, they 
must inherently escape traditional biological removal mechanisms, such as the innate 
immune system, while still not interfering with the local environment. What is essential 
here is that a surface or structural modification be made so that these materials evade 
phagocytic uptake, protein adsorption, and cellular activation. Overcoming hemolytic 
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concerns is imperative to effective maintenance of circulation and affording accumulation 
at the treatment site. Studies will need to focus on altering the surface chemistry via 
polymeric, protein or mesoporous modification that will aid in this endeavor. 
 
2.2.6.2 A defined mode of clearance 
As has already been stated, it is impossible to create a material that will elicit no 
adverse biological response. However one can create a material that provides limits to the 
induction of such response. One can do so by developing a material that provides quick 
access, treatment and subsequent removal. The previous section reviewed how to provide 
access with limited activation via surface modification. Here the focus will be on how to 
modify these materials so that they can be quickly cleared from the system. This can be 
done via the development of a degradation chemistry or utilization of small particles that 
can be excreted readily through renal or hepatobiliary mechanisms. In engineering and 
developing the chemical degradation of these systems, it will be helpful to consider and 
exploit native biological environments, such as acidic lysosomal compartments. After the 
system has performed its function, it should be removed so that the biological 
environment can return to its functioning hemostatic balance.  
 
2.2.6.3 A defined mode of treatment 
This is probably the most difficult and promising aspect of the design. One must 
carefully investigate the cellular uptake and biodistribution profiles of these systems. 
Rather than tailoring silica nanoparticles to a disease state or mechanism, it might be 
potentially useful to utilize their inherent properties as advantageous. For example since 
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silica nanoparticles appear to be able to escape lysosomal compartments, they could 
potentially help to deliver drugs to the cytoplasm of a cell (305). Or the fact that they 
appear to be taken up preferentially in certain cell types and completely ignored by others 
could potentially be utilized as a delivery advantage rather than a disadvantage (298). 
Additionally, dosing mechanisms of nanoparticle systems may also need to be altered, as 
it is clear that surface area and particle number have significantly different outcomes in 
toxicity profiles.  
 
2.2.7 Silica nanoparticle concluding remarks 
Silica nanoparticles show great promise for biomedical applications. However, if 
these materials are to be clinically translated there is a great need for in depth systematic 
evaluations of the implications of size, geometry, surface and core composition. It will be 
important to delineate and introduce possible solutions for modes of clearance, evasion of 
phagocytic activity, reduction in inflammatory mediator expression, elimination of 
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Macrophages play an important role in nanomedicine processing, and are believed 
to be primarily responsible for uptake and in vivo trafficking. For example, increased 
clinical liposomal chemotherapeutic circulation times correlate with decreased monocyte 
counts at nadir, which suggests the role of macrophages in nanoparticle processing (1, 2). 
Macrophages have also shown an in vivo retention of approximately 75% of iron oxide 
nanoparticles administered (3). Finally, in vitro macrophage nanoparticle cytokine assays 
have direct correlation with the in vivo success of nanoparticle-based therapeutics (4).   
Due to the role of macrophages in nanoparticle processing in vivo, macrophage 
targeting has been harnessed with few clinical examples.  Iron oxide particle uptake by 
macrophages has been utilized to detect inflammatory phenotypes of macrophages both 
in vivo and clinically (3, 5).  AmBisome, a lysosomal formulation of amphotericine B, is 
used clinically as a broad spectrum antifungal. The formulation primarily utilizes toll-like 
receptors to harness parasitophorous targeting mechanisms within macrophages (6).    
Local microenvironmental factors and cues in vivo can alter the phenotype and 




interacts with the surrounding environment including nanomaterial processing (7). Most 
successful clinically targeted macrophage examples are likely targeted specifically 
towards a classically activated macrophage phenotype (M1). For instance, in the clinical 
examples listed above M1s are generally up-regulated. However, M1 phenotypes are only 
one of an unknown number of phenotypes found in vivo (8). We lack a full understanding 
of which macrophage phenotype discovers and uptakes nanoparticle systems. A more 
complete understanding of this would be valuable in the design of new drug delivery 
systems, because one could facilitate a higher specificity towards payload targets.  
The Th1/Th2 paradigm illustrates different activation states and different 
macrophage phenotypes, which could help identify the macrophage phenotype that 
discovers and uptakes nanoparticles (9). M1 macrophages are generally considered 
janitorial cells, responsible for clearing foreign materials, pathogens and, potentially, 
nanomaterials. M1 cells are induced by IFN-gamma and are generally characterized by 
high iNOS, IL-12 release, and high expression of CD80. M1s represent, in general, a Th1 
response and, most likely, an inflammatory-mediated response (10). In contrast, a Th2 
state generally has an up-regulation of alternatively activated (or M2) cells. M2 cells are 
considered wound healing cells, inducing basement membrane breakdown, angiogenesis 
and general tissue repair. These cells are induced by IL-4 and are characterized by high 
arginase, IL-10 release and high expression of CD206 (10). The Th1/Th2 paradigm is a 
simplified immunological model system. Many macrophage phenotypes in vivo lie in 
between these two states and may even reside outside of them (8). However, the Th1/Th2 
model system does represent the complex in vivo biological environment more accurately 




which macrophage phenotype is responsible for nanoparticle processing and overall 
biological response. Additionally, this model may help explain whether a specific 
phenotype is responsible for nanomaterial processing and, if so, whether we can select for 
specific target phenotypes to harness therapeutic responses.   
Evidence suggests variations in nanomaterial properties can alter macrophage 
uptake and initiate either Th1 or Th2 responses, which appear to be directly dependent on 
the nanomaterial property. Clinically, environmental exposure to nanomaterials correlates 
directly to induced autoimmune disorders such as scleroderma and rheumatoid arthritis. 
These disease states are generally classified as a Th1 response, suggesting the 
involvement of M1 phenotypes (11). In line with these findings, silica and titanium 
nanoparticles have been shown to induce M1 phenotypes in vivo, significantly regulating 
inflammatory mechanisms (12, 13). However, a recent study revealed that alternatively 
activated macrophage M2 phenotypes in vitro and in vivo took up 300nm PRINT™ 
nanoparticles to a higher extent than M1 phenotypes (14). In contrast, 200-600nm 
poly(lactic acid) particles induced a Th1 response while 2-8µm particles showed a Th2 
response (15). Poly(lactic-co-glycolic) acid (PLGA) nanoparticles showed a Th1 
response even after priming in vivo for a Th2 response (16). Interestingly, environmental 
exposure to crystalline silica has also been linked to silicosis, a disease characterized by 
fibrosis and a general Th2 response (17). Injection of silica has also shown increased 
levels of IgG2a and IgE within serum indicating increased presence of antibodies (18). 
The increased presence of antibodies suggests the adjuvant properties of these systems, 
an M2 mediated-response. However, research has shown an inability to induce an M2 




particles and, to a limited degree, this effect is observed with silica (19). In general, 
evidence suggests nanoparticle characteristics and testing environments can drastically 
affect the uptake and response within macrophage systems.   
Direct correlations between nanoparticle surface modifications have altered 
macrophages responses, specifically with varied phenotypic uptake. Surface modification 
of iron oxide particles with CD86 and CD206 shows targeting of M1 and M2 
macrophages, respectively (20). This modification and uptake shows nanoparticle 
characteristics can be altered to target specific macrophage phenotypes, which could be 
used in therapeutic applications. Surface alterations may also help explain the wide 
variations in reported literature in the systemic immunological response of nanoparticle 
systems. Surface properties may help to induce specific uptake and internalization.  
A correlation should be drawn between variations in nanomaterial properties and 
how these properties interact with the biological environment to induce either a Th1 or 
Th2 response.  We believe that stober silica nanoparticle systems, a commonly used pre-
clinical nanomedical agent, interact with the biological environment and initiate an M1 
phenotypic response in vitro and in vivo. Macrophage phenotype expression is dependent 
on disease state; understanding the phenotype that specific nanomaterial characteristics 
target will help to derive a better functional design platform for drug delivery systems.   
 
5.2 Materials and Methods 
5.2.1 Particle synthesis and characterization 
Spherical silica nanoparticles were prepared by previously reported modified 




isothiocyanate (FITC) to assess cellular uptake. The constructs were sterilized by dry 
autoclaving. Transmission electron microscopy (TEM) images were taken on a Phillips, 
TECHAI F2 (Hillsboro, OR) at an accelerating voltage of 80 kV. TEM samples were 
created by evaporating droplets of particles suspended in deionized water off copper 
grids. After micrograph collection, nanoconstruct size was measured utilizing Adobe 
Photoshop’s pixilation ruler measurement tool (Adobe, San Jose, CA). At minimum the 
sizes of 300 particles of each type were measured. Particle zeta potential of SNPs 
dispersed in DI water at a concentration of 1.0 mg/ml was measured using a Malvern 
Instruments Zetasizer Nano ZS (Westborough, MA). SNPs (50 or 25 mg/ml) were 
sonicated, vortexed and the final particle dispersions were prepared immediately before 
use from common stock in culture medium and vortexed before application to the culture 
cells. All particles were tested for endotoxin levels prior to cellular incubation; levels 
were below FDA recommended .05 EU/mL.  
 
5.2.2 In vitro methods 
5.2.2.1 Cell culture 
RAW 264.7 murine macrophages were obtained from ATCC (Manassas, 
Virginia) and maintained in RPMI media supplemented with 10% FBS, at passage 
numbers 5-25. Cell cultures were incubated at 37°C in 5% CO2 and 95% humidified air 







5.2.2.2 Cell polarization and confirmation 
Cells were seeded and allowed to adhere overnight at 37°C in 5% CO2. The 
following day the cells were treated with a M1 cocktail that consisted of LPS (100ng/mL) 
and IFN-gamma (300 units/mL), a M2 cocktail of IL-4 (10 units/mL) or an unpolarized 
cocktail with no additives (Sigma-Aldrich, St. Louis, MO). All cocktails were diluted in 
fresh media. The cells were incubated for 18 hours to obtain sufficient polarization. To 
confirm polarization, IL-10 and IL-12 were quantified via BD Cytokine Flow Cytometry 
protocol and colormetrically for arginase and nitric oxide (described below).  
 
5.2.2.3 Arginase and nitric oxide evaluation 
Following cellular polarization in 96 well plates, cells were treated for 24 hours 
with a range of silica nanoparticle concentrations (5-250 ug/mL). The colorimetric 
protocols of Classen et al. for the Griess reagent (detection of nitric oxide) and a urea 
assay (detection of arginase) were followed (23).  
 
5.2.2.4 Cellular proliferation 
Following polarization, cells were exposed to a range of concentrations (5-250 
ug/mL) of silica nanoparticles for 72 hours. Relative cell viability was assessed by 
utilizing a water-soluble tetrazolium salt, WST-8 [2-(2-methoxy-4-nitrophenyl)-3-(4-
nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium, monosodium salt], the key 






5.2.2.5 Cell uptake, visualization and quantification 
The uptake of silica nanoparticles by cultured cells was visualized by confocal 
microscopy. Cells were grown on 24 well imaging plates at a density of ~9000 cells/cm2 
polarized and incubated for 24 hours with 37.5 µg/ml FITC labeled silica nanoconstructs. 
After incubation, cells were fixed with 4% formalin in PBS. Cell nuclei were stained with 
2.5 µM 4′,6-diamidino-2-phenylindole (DAPI) according to the manufacturer's protocol. 
(CLSM) Olympus FluoView® FV1000 (Olympus America Corp., Center Valley, PA). 
The intensity of the laser beam and the photodetector sensitivity were kept constant in 
order to compare the relative fluorescence intensities between experiments. Z stacks were 
collected and used for 3D reconstruction and visualization of intracellular particle 
localization. All image acquisitions and analyses were performed using FluoView 2.0 
software.  
Flow cytometry was used to quantify the amount of nanoparticle uptake. Cells 
were grown on 12 well plates at a density of ~15,000 cells/cm2 polarized and incubated 
with 37.5 µg/ml FITC labeled silica nanoconstructs for 24 hours. Following incubation, 
cells were scraped to obtain a single cell suspension. Cells were suspended in PBS 
containing 1% BSA and analysis was performed on a FACSCalibur (BD Biosciences). 
Emitted light resulting from FITC-labeled nanoparticles was detected by the FL-2 
detector. To calculate the background fluorescence of unlabeled cells, cells without any 
addition of nanoparticles were carried along as a negative control in every measurement. 
For whole-cell analysis 10,000 cells were counted. Data analysis was performed with BD 





5.2.2.6 Cellular autophagy 
Coverslips were seeded at a density of ~9000 cells/cm2, polarized with 
polarization cocktails for 24 hours. Following polarization cells were incubated for 24 
hours with 37.5 µg/ml FITC labeled silica nanoconstructs. After incubation cells were 
fixed, permeabilized via triton-X and stained intracellularly for LC3-IIb (Molecular 
Probes). Both colocalization and cellular internalization were visualized with confocal 
microscopy.  
 
5.2.2.7 Cellular co-localization 
Six well plates were seeded at a density of ~9000 cells/cm2 and polarized to either 
M1 or M2 phenotypes. Following polarization, wells were scraped, 1 well containing M1 
polarized cells and 1 well containing M2 polarized cells were seeded on glass coverslips 
and allowed to adhere overnight. Prior to scrapping M1 cells were preincubated with DiD 
(M1) to mark the phenotype and M2 cells were left unstained (Molecular Probes). 
Following adhesion these co-cultures were treated for 24 hours with 37.5 µg/ml FITC 
labeled silica nanoconstructs. After incubation cells were fixed, and stained with DAPI.  
Cellular internalization was visualized with confocal microscopy. 
 
5.2.2.8 Transmission electron microscopy 
The uptake of silica constructs by cultured cells was assessed by transmission 
electron microscopy. Cells were seeded on 6 well plates containing 1x1 cm ACLAR 
plastic at a density of ~9000 cells/cm2, polarized and after an overnight incubation, 37.5 




hours after which they were washed with PBS and fixed with a 2.5% glutaraldehyde and 
1% formaldehyde in 0.1M sodium cacodylate buffer with sucrose and calcium chloride. 
Cells were stained with uranyl acetate for 45 minutes at room temperature and TEM 
images were taken with a Phillips, TECHAI F2 TEM (Hillsboro, OR, USA) at an 
accelerating voltage of 80 kV. 
 
5.2.3 In vivo methods 
5.2.3.1 Animal handing 
All animal experiments were performed in accordance with the Institutional 
Animal Care and Use Committee (IACUC) guidelines of The University of Utah. Adult 
female CD-1 mouse injections were administered via the tail vein at 20 mg/kg of 
hydroxyl nanoparticle formulations with a max injection volume of 200 ul. Saline 
administration was used as a negative control. Mice were sacrificed at one- and four- 
week time points and organs analyzed. N=5 for all studies.  
 
5.2.3.2 Biodistribution and clearance 
At necropsy, organs were collected, isolated and weighed. Organs subsequently 
underwent acid digestion with aqua regia at 80 C. Following complete organic digestion, 
the solution was suspended in 5% trace metal-grade nitric acid and HF was added to the 
solution to dissolve and stabilize the silica content. This solution was analyzed via 
inductively coupled plasma mass spectrometry (ICP-MS), and quantified against a silica 






 Following necropsy organs were fixed in 4% fresh paraformaldehyde. Samples 
were dehydrated, paraffin-embedded and cut into 4µm thick sections. Sections were 
stained hematoxylin and eosin. Immunohistochemical staining was performed on air-
dried room temperature sections, placed in a 60 C oven to melt the paraffin. Sections 
were deparaffinized with EZ Prep solution (Ventana Medical Systems). In the case of 
iNOS and Arginase sections were pretreated with CC1 (Cell Conditioner 1, pH 8.0) and 
F4/80 was digested with Protease 2. Primary antibodies were applied (iNOS: 1:50 for 2 
hours, Arginase 1:800 for 1 hour, F4/80 1:200 for 2 hours) (Thermo Scientific and 
Abcam). Slides were detected using the IView DAB detection kit (Ventana Medical 
Systems), which is a Streptavidin-HRP system, utilizing DAB (3-3’ diaminobenzidine) as 
the chromogen and counterstained with hematoxylin. Sections were washed with DI 
water, dipped in iodine followed by sodium thiosulfate and dehydrated in graded alcohols 
cleared with xylene and coverslipped. Immunofluorescence was similarly performed with 
primary antibody incubation (C68 1:100 for 2hours, CD206 1:50 for 2 hours, LC3-IIb 
1:100 for 1 hour) and subsequent secondary detection (Alexa Fluor 647) (Molecular 
Probes).   
 Immunofluorescence was imaged on an Olympus 1×50 inverted microscope. 
Quantification and visualization were performed utilizing an ImageJ plug-in described 
elsewhere. Immunohistochemical staining was visualized utilizing an Aperio slide 






5.2.3.4 Transmission electron microscopy 
The uptake of silica constructs within organs was assessed by transmission 
electron microscopy. Organs were fixed with a 2.5% glutaraldehyde and 1% 
formaldehyde in 0.1M sodium cacodylate buffer with sucrose and calcium chloride. Cells 
were stained with uranyl acetate for 45 minutes at room temperature and TEM images 
were taken with a Phillips, TECHAI F2 TEM (Hillsboro, OR, USA) at an accelerating 
voltage of 80 kV. 
 
5.3 Results 
5.3.1 Silica nanoparticle synthesis and characterization 
FITC-labeled silica nanoparticles 130nm in diameter were synthesized and 
characterized via DLS, zeta potential, IR and TGA (Table 5.1).  Characterization of 
particle stability in serum was assessed and confirmed that nanoparticles were in 
suspension. After verification of synthesis and stability, the particles were utilized to 
investigate the influence of uptake in M1 and M2 polarized macrophages in vitro and in 
vivo.   
 
5.3.2 Polarization of M1 and M2 macrophages in vitro 
RAW 264.7 macrophages were polarized to M1 and M2 phenotypes utilizing 
traditional cytokine cocktails, IFN-gamma/LPS and IL-4, respectively (Figure 2.1). M1 
polarized macrophages exhibited expected morphological changes such as enhanced 
intracellular vacuoles and 5x increase in size when compared to M2 cells which exhibited 








Figure 5.1.  Confirmation of macrophage polarization. Macrophages 
were polarized into M1 and M2 phenotypes and this polarization was 
confirmed morphologically and by cytokine excretions. A) i) TEM 
images of the morphology of unpolarized macrophages. ii) TEM 
image of the morphology of M2 polarized macrophages.  M2s retains 
a similar size to unpolarized macrophages with a spindle like 
morphology. iii) TEM image of the morphology of M1 polarized 
macrophages. M1s increase drastically in size (~2-5x) and has a 
drastic increase in vacuoles.  B) Confirmation of hallmark M1 and M2 
cytokines show a statistical significant increase in IL-12 in M1s and 
IL-10 in M2s when compared to their unpolarized and oppositely 
polarized counterparts, as expected. Statistical difference from control 
determined via paired t-test, p value < .05 are indicated by a *, p 





iNOS and IL-12 were present in M1 polarization states and absent in M2. M2 states 
exhibited arginase and IL-10 but these cytokines were absent in M1 polarization (Figure 
5.1b and Figure 5.2b,c). The cytokine and morphological results confirmed RAW 264.7 
polarization into M1 and M2 phenotypes. The confirmed polarized macrophages were 
utilized in in vitro testing.  
Nanoparticles were incubated with unpolarized RAW 264.7 cells, M1, and M2 
polarization states for 72 hours (~2 population doubling times) to assess the relative 
influence of nanoparticle treatment on overall function and proliferation capacity. 
Nanoparticle solutions affected proliferation status in M2 and unpolarized cells, with 
higher concentrations exhibiting more pronounced toxicity (Figure 5.2a). The 
nanoparticle concentrations tested did not appear to affect M1 proliferation.   
We observed little to no effect on hallmark M1 and M2 markers, iNOS and 
arginase, after nanoparticle treatment at a variety of concentrations (Figure 5.2b and 
5.2c). 
In an attempt to understand proliferative effects, we sought to investigate and 
quantify the degree of nanoparticle uptake within these polarization states. As such, 
nanoparticles were incubated with M1, M2 and unpolarized macrophages, and the 
relative level of uptake was assessed and quantified via FACS, and confirmed via 
confocal microscopy (Figure 5.3 and 5.4).  Nanoparticles were taken up to a greater 
extent in M1 macrophages when compared to M2 and unpolarized macrophage 
phenotypes. In order to compensate for potential data aberrations related to the 
significantly different cell size between M1 and M2 cells (40um vs. 10um, respectively), 




Figure 5.2. Macrophage viability and cytokine excretion after nanoparticle 
treatment. A) Macrophage viability following nanoparticle treatment. 
Unpolarized and M2 cells showed a statistically significant decreased viability 
with increasing nanoparticle concentration.  M1 cells however appeared to be 
statistically unaffected by nanoparticle treatment. B) iNOS did not appear to be 
significantly affected by any nanoparticle treatment. M1 cells exhibited a 
statistically significant higher native expression, as expected.  C) Arginase 
activity was not significantly affected by nanoparticle treatment. M2 cells 
exhibited a statistically significant higher native expression, as expected. 
Statistical difference from control determined via paired t-test, p value < .05 
indicated with a *, p values > .05 were determined insignificant.  
































































































































































































































































































































Figure 5.4. A more representative confocal image of nanoparticle uptake in 




increase in overall uptake. 
The conflicting uptake and proliferation results led us to ask if internalization 
mechanisms within these polarization states were altered. To visualize nanoparticle 
localization within polarization states, TEM images were taken of macrophages 
incubated with nanoparticles (Figure 5.5). A large accumulation of nanoparticles was 
observed in the vacuoles of M1 macrophages. Very few vacuoles were observed in M2 
cells, and the vacuoles displayed reduced nanoparticle association and vesicular 
definition. Similar results to M2 macrophages were observed for unpolarized cells. 
Mechanisms of particle intracellular fate were investigated in macropahges. We 
previously identified intracellular fate, consistent with autophagic activity after treatment 
with amine modified particles in unpolarized cells (24). We investigated whether similar 
internalization was observed in M1 and M2 polarized cells. A high upregulation of 
autophagic activity in M2 and unpolarized macrophages was observed (Figure 5.5, 5.6). 
M1 cells exhibited little to no autophagy in any treatment group.  
M1 cells have a higher affinity for nanoparticles in isolated culture; however, in 
vivo polarization states are mixed and an investigation with a co-culture may mimic in 
vivo environments better. We investigated if both macrophages were cultured together 
whether an affinity for one macrophage over the other would still be present. We 
observed an increase in particle accumulation in M1 macrophages (Figure 5.7).   
 
5.3.3 In vivo nanoparticle effect 
After observing an increase in nanoparticle uptake in M1 macrophages in both 




Figure 5.5. Morphological features of macrophages after nanoparticle treatment. 
Autophagy is observed within macrophage populations after nanoparticle 
treatment. Left) TEM images of nanoparticle uptake in M1 and M2 cells. 
Nanoparticles resided within increased vacuolization in M1 cells. M2 cells 
appeared to have less uptake and decreased vacuolization.  Right) Levels of 
autophagic activation after nanoparticle treatment in polarized macrophage cells.  
M2 and unpolarized cells had drastic increases in autophagy, while M1 cells only 
showed a slight increase, suggesting differing internalization and intracellular fate 




Figure 5.6. Confocal images of induction of autophagy after nanoparticle 
treatment. High amounts of autophagy were observed in M2 and unpolarized 
cells when compared to control and M1 cells.  Staining is observed in the 
perinuclear region which may give the nucleus the appearance of localized 
stain. However it may also be concentrated within that region due to 















































































































































































































































































































with an in vivo system. Adult CD-1 mice were injected with each nanoparticle 
formulation, and the effects of these systems after 1 and 4 weeks were observed. As 
expected with nondegradable nanoparticle systems, we observed high accumulation in 
the liver and spleen and very little association with other organs (Figure 5.8). While 
uptake and residence of nanoparticles were significantly increased within the liver and 
spleen, animals did not have any weight loss or gain over time compared to control 
animals, suggesting minimal toxic effects of these systems (Figure 5.9). 
Following these observations, we wanted to see if accumulation and residence of 
these nanoparticles within the spleen or liver caused any great duress on the tissue. H&E 
staining did not show toxicity (Figure 5.10); however, slight variations in cell content and 
morphology within the spleen and liver were observed. The spleen showed a slight but 
not significant increase in inflammatory cells, formation of multinucleated cells, and very 
slight destruction of lymphatic foci from 1 to 4 weeks (Figure 5.11). The liver showed a 
slight but not significant increase in hydropic degeneration or vacuolization and increased 
levels of inflammatory cells from 1 to 4 weeks (Figure 5.12). Overall, we observed little 
to no toxicity or induced inflammation in vivo after nanoparticle treatment.   
The observation of a slight increase in inflammatory mediated cells in H&E 
staining led us to investigate the potential of increased levels of macrophages over time 
within these tissues. We observed a drastic increase in CD68 expression, a lysosomal 
marker within the liver from 1 to 4 weeks, suggesting the increase in residence of 
macrophages with lysosomal-like compartments (Figure 5.13).   
 Confirmation of increased macrophage residence and identification of the 




Figure 5.8  Silica nanoparticle organ accumulation, as determined via 
quantitative ICP-MS. Data have been normalized to organ weight to account 
for aberrations, and additionally were also normalized to brain weight and no 
observable differences occurred. We observed accumulation of silica 
nanoparticles primarily in splenic and hepatic tissues, with minimal 
accumulation in other organs. Silica was retained within these organs at 
statistically similar levels out to 4 week time points. Statistical difference 
from control determined via paired t-test, p value < .05 indicated with a *, p 








Figure 5.9. Animal weights as a function of silica nanoparticle treatment and 
time. Little to no change in overall animal weight was observed across groups 
when compared to saline control, suggesting minimal toxic effects due to 
silica treatment. Statistical difference from control determined via paired t-




Figure 5.10 H&E images of heart (top), kidney (middle) and lung (bottom) 
tissues of animals treated with silica nanoparticles at 1 and 4 weeks.  Tissue 
exhibited no response to silica treatment, suggesting limited toxicity within 




Figure 5.11 H&E images of liver tissue of animals treated with silica 
nanoparticles at 1 and 4 weeks. Increased levels of vacuolization 
(increased white space) are present in the liver at both 1 and 4 weeks. 





Figure 5.12 H&E images of spleen tissue of animals treated with silica 
nanoparticles at 1 and 4 weeks. Increased levels of macrophages and 
multinucleated cells are present in the spleen at both 1 and 4 weeks. 
However, overall inflammatory effects are minimal, as a function of 




Figure 5.13 Immunofluorescence of liver tissues stained with CD68. 
CD68 is a lysosomal marker that is useful in identification of increased 
levels of macrophages. This image suggests that we have a drastic 




tissue staining with F4/80 (an M1 marker), iNOS (an M1 marker) and arginase (an M2 
marker). We observed an upregulation of F4/80 and iNOS in the liver and spleen (Figure 
5.14 and Figure 5.15). These M1 markers were patchy; staining was not uniform 
throughout the tissue. To quantify the level of upregulation a complete organ slide scan 
and colorimetric deconvolution were performed, increased F4/80 and iNOS were 
observed in liver tissues. Increases in these M1 markers suggest that M1 macrophages 
play an important role in the response to these nanoparticle systems. We observed no 
upregulation in arginase (Figure 5.16) in any tissue. CD206 (M2 marker) and autophagic 
markers were also utilized, and we observed little to no overall increase in staining (data 
not shown). 
We sought to determine whether M1 macrophage upregulation was a result of 
recruitment as a reaction to nanoparticle residence or if proliferation of macrophages was 
a direct result of macrophage uptake of nanoparticles. We performed TEM on liver and 




5.4.1 Polarization of M1 and M2 macrophages in vitro 
M1 cells appear to show minimal toxic effects when treated with nanoparticles, 
even at very high concentrations. M1 cells also uptake nanoparticles to the greatest 
degree, despite showing the lowest toxicity. This may suggest that polarizing cells to an 
M1 state induces a coping mechanism, for foreign matter, which helps the cell to avoid 
interference with the rest of the cellular machinery and phenotypic state. This may be due 




Figure 5.14 Liver and splenic tissues stained for F4/80. An observable increase 
is shown in treatment groups of the F4/80 stain. This is a macrophage marker 





Figure 5.15 Liver and splenic tissues stained for iNOS. An observable 
increase is shown in treatment groups. This is a marker for M1 macrophages, 
and may suggest increased levels of macrophages present in the tissue, as 
observed via CD68 and F4/80 are M1 macrophages. However iNOS is 





Figure 5.16 Liver and splenic tissues stained for arginase.  No observable 
increase is seen across treatment groups. Arginase is a marker for M2 cells, 
which may suggest that M2 cells are not related to the macrophage response 




Figure 5.17. TEM images of nanoparticles residing within macrophages of the 




this is thought to help support cell survival and increase phagocytosis (25). Globally, this 
behavior is not surprising, as characteristically the M1 phenotype is thought to remove 
foreign materials and pathogens from the local environment, which is likely to leave the 
cell, in most cases, unaffected.  
Unlike M1 cells, M2 and unpolarized cells exhibit a toxic effect at higher 
nanoparticle treatment concentrations, despite reduction in overall uptake. The effect 
appears to be at consistent concentrations between M2 and unpolarized cells, which may 
suggest they process the materials in a similar manner. However, the mechanism of 
toxicity remains to be studied. Future analysis such as the use of RNAseq will be 
essential to understand how nanoparticles interact with the cellular machinery. These 
studies will help ensure that interactions do not alter the function and polarization states 
of these cell types, and to determine toxicity related mechanisms. 
 
5.4.2 Uptake of nanoparticles in M1 and M2 cells 
Clear M1-specific uptake suggests that M1 cells have a higher affinity for taking 
up these nanoparticle systems. This may be explained by increased levels of SR-AI/II and 
MARCO scavanger receptors on M1 macrophages, which are known to bind a variety of 
polyanionic materials promiscuously in vivo (26). The collagen-like domain incorporated 
within both SR-AI and SR-AII bind the anionic hydroxyl surface of silica (27). The 
SRCR domain of MARCO has also been implicated in silica binding (28). The increased 
levels of scavenger receptors and their high affinity for hydroxyl terminated groups may 





The morphological features identified within the TEM images may suggest 
differing intracellular fate for nanoparticle systems within M1 and M2 cells. Previously, 
we have observed clathrin-mediated endocytosis for spherical particles of similar sizes in 
unpolarized cells (29).  M2 cells may utilize similar internalization mechanisms. M1 
cells, however, may harness phagocytic mechanisms. These two varied uptake 
mechanisms can lead to very different internalization fates and also varied capacity to 
reach internal cellular machinery. Phagocytic vacuoles tend to be an end stage, while 
clathrin-mediated endocytic vesicles can lead to variations in cellular organelle dispersion 
and, ultimately, intracellular fate. This may help to explain why we observe increased 
autophagic vesicles in unpolarized and M2 macrophages and decreased vesicles in M1 
cells.    
Varied LC-3II or autophagic expression levels might also be explained by 
phenotypic differences. Autophagy is also known to be decreased in cells with 
upregulated phagocytosis, a known feature of M1 macrophages (30). This decreased 
autophagic phenomenon in M1 cells may suggest that these macrophages mediate 
phagocytosis in M1 cells, while uptake via M2 and unpolarized macrophages is mediated 
through another mechanism. These variations in intracellular fate could help to explain 
variations in cellular nanoparticle processing behavior.  
Intracellular fate may also help to explain variations in proliferation. 
Nanoparticles appear to be internalized and trafficked to autophagic vesicles in 
unpolarized and M2 cells. This internalization may alter proliferative capacity within M2 
and unpolarized cells. M1 cells do not appear to utilize similar internalization or fate 




understand if autophagy is a global effect for all nanoparticle surface modifications and if 
autophagy helps to facilitate toxicity related mechanisms.  
Our results indicate that M1s clearly outcompete M2 uptake both in isolated, as 
well as co-culture. Understanding this phenomenon might be useful when designing 
future in vitro assays and globally understanding nanoparticle processing. The results 
may help to correlate in vitro results to a greater extent in vivo. Understanding that M1s 
are the primary phenotype which uptake these nanoparticle systems could help to explain 
downstream physiological effects, such as the induction of inflammation or the 
recruitment of other immunological cell types. 
 
5.4.3 In vivo nanoparticle effect 
We observed minimal toxic effects after nanoparticle treatment, which may 
suggest that the cells which ingest nanoparticles in vivo may potentially be providing a 
cellular coping effect helping to preserve the local tissue from further nanoparticle 
damage. We observed similar results with M1 systems in vitro. In future studies it will be 
important to investigate protein expression patterns within the liver and spleen to see if 
similar in vitro and in vivo protective profiles are observed. These protective profiles 
might also be initiating factors for more chronic inflammatory responses. Future 
directions should allow for increased time point analysis.  
Increase levels of inflammatory cells, destruction of lympatics and increased 
vacuoles suggested the involvement of macrophages and potential induction of 
inflammatory mediated mechanisms. Hydropic degeneration is also a sign of 




in vitro and can be detrimental in longer terms (31). These studies were only carried out 
to 4 weeks, it will be essential in nanoparticle development to carry such studies out to at 
least a year to characteristically identify if inflammatory cell infiltration, tissue 
destruction and vacuolization persists and if it potentiates further downstream issues.  
Drastic increases in lysosomes (CD68) in the liver may help to explain decreased 
levels of silica in some tissues and may help to support downstream inflammation. Silica 
may potentially be trafficked to this site, and cleared or stored in or around biliary tracts. 
It is important to note that CD68 is a lysosomal marker that is observed in cell types other 
than macrophages and one cannot discern between M1 and M2 polarization states with 
this marker.  One can only assume that the macrophages or cells that have been stained 
are activated to a lysomal or inflammatory like state, which could potentially be harmful 
to the animal in chronic situations.    
Increased levels of F4/80, iNOS and CD68 are indicative of primarily activated 
M1 macrophage involvement. Limited to no increase in arginase, CD206 or LC3-bII 
suggests M2 macrophages play little to no role in the overall response to these 
nanoparticle systems. However, local uptake of nanoparticles may potentiate a Th1 
response and thus increased M1 cells. Increased M1 response may be a result of 
nanoparticle uptake and not necessarily completely responsible for uptake themselves. 
Increased M1 and Th1 responses are not surprising, as M1 macrophages are 
traditionally involved in biological processing of nanoparticles. Crystalline silica has 
been linked as an adjuvant to induce autoimmune disorders (32) such as scleroderma, a 
Th1 response. Hydroxyl groups are also known to differentiate dendritic cells and 




phenotypes in vivo (33, 34). MARCO, a scavenger receptor found on M1 cells, has been 
shown to increase nanoparticle uptake. This is also a receptor that is overexpressed on the 
Kupffer cells of the liver and within the red pulp of the spleen. Scavenger receptor 
response has also been shown in vivo to increase M1 response, as SR-A knockouts have 
shown reduced inflammatory M1 phenotypes (35). TLRs have been shown to act in 
cooperation with scavenger receptors inducing inflammatory like phenotypes with 
increased levels of IL-12 and IFN-gamma (M1 cytokines). Induced M1 phenotypes have 
shown to be overloaded with iron oxide particles in vivo (36). Hydroxyl modifications 
induce complement mediated events which could facilitate specific uptake in M1 
macrophages. The evidence presented here and within literature may suggest that silica 
could induce a Th1 response as a result of nanoparticle uptake within these tissues. 
Our TEM results show images that provide clear evidence for nanoparticles 
affinity for macrophages in vivo. This may also suggest further that nanoparticles may 
have an affinity towards M1 phenotypes, however future quantification is necessary to 
draw these specific conclusions. Quantification of macrophage uptake versus other cell 
type uptake will be important in future studies. 
 
5.5 Conclusions and Future Directions 
Macrophage phenotype and the surface modification on nanoparticles both play 
an important role in in vitro and in vivo processing. Our research demonstrates that 
characteristics of stober silica nanoparticle systems, a commonly used preclinical 
nanomedical agent, interact with the biological environment and initiate an M1 




higher affinity for nanoparticles in vitro and may potentially regulate organ-level uptake 
and response in vivo. Uptake within M1 phenotypes may provide a protective effect or 
initiate long term chronic responses in vitro and in vivo. Coping and chronic response 
mechanisms will need further justification and mechanistic evaluation. Surface of 
nanoparticles may potentially play a role in cellular uptake, increased circulation, and 
clearance. The increased levels of M1 uptake in vitro and in vivo may also suggest that 
multiple macrophage phenotypic model systems must be used in vitro to understand 
potential effects of nanoparticles in vivo.  Variations in nanoparticle physicochemical 
characteristics could alter how the nanoparticle interacts with macrophages, changing the 
phenotype that uptakes the nanoparticle and as a direct result of that phenotypic uptake 
changing the physiological response. For example, if M2 macrophages instead up took 
silica nanoparticles to a higher extent, it may have instead elicited a Th2 response and we 
would have observed very different physiological patterns. It will be imperative in the 
future to pay attention to which particles are taken up by which phenotypes, as 
nanoparticle processing could initiate detrimental chronic responses dependent on the 
phenotypic uptake. Additionally, this could have therapeutic implications as differing 
disease states have variations in macrophage phenotypic responses. 
Macrophage phenotype targeting and response could be useful therapeutically. 
The results of this study may suggest that hydroxyl terminated silica nanoparticles could 
be utilized to target M1 macrophages in vivo. Such a strategy could potentially be utilized 
in the design of a treatment for neurodegenerative disorders, where an upregulation of 
M1 phenotypes is destructive to surrounding tissue. If one could target this phenotype 




example, in cases of spinal cord injury, an upregulation of M1 polarized macrophages is 
observed which could be preventing M2 cells from repairing the local environment (37). 
M1 phenotypes have been also implicated in the development of multiple sclerosis, and 
M2 suppression has been implicated in relapse of MS suggesting targeting of these 
phenotypes could present with therapeutic advantage (38).  However, it is imperative 
even within disease states to understand the overall chronic implications of nanoparticle 
treatment and therefore the potential of these systems. 
Overall, this research highlights the need to study nanoparticle uptake in a variety 
of macrophage phenotypes to help understand in vivo physiological responses. We have 
shown a drastic uptake in M1 phenotypes and an increase in macrophages in vivo. These 
studies have only been carried out to 4 weeks, and the early results here suggest that 
chronic studies will need to be performed to understand if immunological or chronic 






1. Caron WP, Lay JC, Fong AM, La-Beck NM, Kumar P, Newman SE, et al. 
Translational studies of phenotypic probes for the mononuclear phagocyte system and 
liposomal pharmacology. J Pharmacol Exp Ther. 2013;347(3):599-606. 
 
2. Caron WP, Song G, Kumar P, Rawal S, Zamboni WC. Interpatient 
pharmacokinetic and pharmacodynamic variability of carrier-mediated anticancer agents. 
Clinical Pharmacology and Therapeutics. 2012;91(5):802-12. 
 
3. Nahrendorf M, Zhang H, Hembrador S, Panizzi P, Sosnovik DE, Aikawa E, et al. 
Nanoparticle PET-CT imaging of macrophages in inflammatory atherosclerosis. 
Circulation. 2008;117(3):379-87. 
 
4. Dobrovolskaia MA, McNeil SE. Understanding the correlation between in vitro 
and in vivo immunotoxicity tests for nanomedicines. J Control Release. 2013;172(2):456-
66. 
 
5. Trivedi R, U-King-Im J, Graves M, Kirkpatrick P, Gillard J. Noninvasive imaging 
of carotid plaque inflammation. Neurology. 2004;63(1):187-8. 
 
6. Wingard JR, White MH, Anaissie E, Raffalli J, Goodman J, Arrieta A, et al. A 
randomized, double-blind comparative trial evaluating the safety of liposomal 
amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile 
neutropenia. L Amph/ABLC Collaborative Study Group. Clin Infect Dis. 
2000;31(5):1155-63. 
 
7. Cassetta L, Cassol E, Poli G. Macrophage polarization in health and disease. The 
Scientific World Journal. 2011;11:2391-402. 
 
8. Wynn TA, Chawla A, Pollard JW. Macrophage biology in development, 
homeostasis and disease. Nature. 2013;496(7446):445-55. 
 
9. Romagnani S. The Th1/Th2 paradigm. Immunology Today. 1997;18(6):263-6. 
 
10. Mantovani A, Sica A, Locati M. Macrophage polarization comes of age. 
Immunity. 2005;23(4):344-6. 
 
11. Cooper GS, Miller FW, Germolec DR. Occupational exposures and autoimmune 
diseases. International Immunopharmacology. 2002;2(2):303-13. 
 
12. Lucarelli M, Gatti AM, Savarino G, Quattroni P, Martinelli L, Monari E, et al. 
Innate defense functions of macrophages can be biased by nano-sized ceramic and 
metallic particles. European Cytokine Network. 2004;15(4):339-46. 
 




Immunomodulation and T helper TH(1)/TH(2) response polarization by CeO(2) and 
TiO(2) nanoparticles. PLoS One. 2013;8(5):e62816. 
 
14. Jones SW, Roberts RA, Robbins GR, Perry JL, Kai MP, Chen K, et al. 
Nanoparticle clearance is governed by Th1/Th2 immunity and strain background. The 
Journal of Clinical Investigation. 2013;123(7):3061-73. 
 
15. Kanchan V, Panda AK. Interactions of antigen-loaded polylactide particles with 
macrophages and their correlation with the immune response. Biomaterials. 
2007;28(35):5344-57. 
 
16. Lutsiak M, Kwon GS, Samuel J. Biodegradable nanoparticle delivery of a Th2 
biased peptide for induction of Th1 immune responses. Journal of Pharmacy and 
Pharmacology. 2006;58(6):739-47. 
 
17. Barbarin V, Xing Z, Delos M, Lison D, Huaux F. Pulmonary overexpression of 
IL-10 augments lung fibrosis and Th2 responses induced by silica particles. American 
Journal of Physiology-Lung Cellular and Molecular Physiology. 2005;288(5):L841-L8. 
 
18. Granum B, Gaarder PI, Groeng E-C, Leikvold R-B, Namork E, Løvik M. Fine 
particles of widely different composition have an adjuvant effect on the production of 
allergen-specific antibodies. Toxicology Letters. 2001;118(3):171-81. 
 
19. Kodali V, Littke MH, Tilton SC, Teeguarden JG, Shi L, Frevert CW, et al. 
Dysregulation of Macrophage Activation Profiles by Engineered Nanoparticles. ACS 
Nano. 2013;7(8):6997-7010. 
 
20. Al Faraj A, Shaik AS, Afzal S, Al Sayed B, Halwani R. MR imaging and 
targeting of a specific alveolar macrophage subpopulation in LPS-induced COPD animal 
model using antibody-conjugated magnetic nanoparticles. International Journal of 
Nanomedicine. 2014;9:1491-9. 
 
21. Stöber W, Fink A, Bohn E. Controlled growth of monodisperse silica spheres in 
the micro size range. Journal of Colloids and Interface Science. 1968;26:62-9. 
 
22. Blaaderen A, Vrji A. Synthesis and characterization of colloidal dispersions of 
fluorescent silica spheres. Langmuir. 1992;8:2921-31. 
 
23. Classen A, Lloberas J, Celada A. Macrophage activation: classical vs. alternative.  
Macrophages and Dendritic Cells: Springer; 2009. p. 29-43. 
 
24. Herd HL, Malugin A, Ghandehari H. Silica nanoconstruct cellular toleration 
threshold in vitro. J Control Release. 2011;153(1):40-8. 
 






26. Platt N, Gordon S. Scavenger receptors: diverse activities and promiscuous 
binding of polyanionic ligands. Chemistry & Biology. 1998;5(8):R193-R203. 
 
27. Chao SK, Hamilton RF, Pfau JC, Holian A. Cell surface regulation of silica-
induced apoptosis by the SR-A scavenger receptor in a murine lung macrophage cell line 
(MH-S). Toxicology and Applied Pharmacology. 2001;174(1):10-6. 
 
28. Hamilton Jr RF, Thakur SA, Holian A. Silica binding and toxicity in alveolar 
macrophages. Free Radical Biology and Medicine. 2008;44(7):1246-58. 
 
29. Herd H, Daum N, Jones AT, Huwer H, Ghandehari H, Lehr CM. Nanoparticle 
geometry and surface orientation influence mode of cellular uptake. ACS Nano. 
2013;7(3):1961-73. 
 
30. Shintani T, Klionsky DJ. Autophagy in health and disease: a double-edged sword. 
Science. 2004;306(5698):990-5. 
 
31. Malugin A, Ghandehari H. Caspase 3 independent cell death induced by 
amorphous silica nanoparticles. Nanoscience and Nanotechnology Letters. 
2011;3(3):309-13. 
 
32. Haustein U-F, Ziegler V, Herrmann K, Mehlhorn J, Schmidt C. Silica-induced 
scleroderma. Journal of the American Academy of Dermatology. 1990;22(3):444-8. 
 
33. Bartneck M, Keul HA, Wambach M, Bornemann J, Gbureck U, Chatain N, et al. 
Effects of nanoparticle surface-coupled peptides, functional endgroups, and charge on 
intracellular distribution and functionality of human primary reticuloendothelial cells. 
Nanomedicine: Nanotechnology, Biology and Medicine. 2012;8(8):1282-92. 
 
34. Yang D, Zhao Y, Guo H, Li Y, Tewary P, Xing G, et al. [Gd@ C82 (OH) 22] n 
Nanoparticles Induce Dendritic Cell Maturation and Activate Th1 Immune Responses. 
ACS nano. 2010;4(2):1178-86. 
 
35. Xu Y, Qian L, Zong G, Ma K, Zhu X, Zhang H, et al. Class A scavenger receptor 
promotes cerebral ischemic injury by pivoting microglia/macrophage polarization. 
Neuroscience. 2012;218:35-48. 
 
36. Sindrilaru A, Peters T, Wieschalka S, Baican C, Baican A, Peter H, et al. An 
unrestrained proinflammatory M1 macrophage population induced by iron impairs 
wound healing in humans and mice. The Journal of Clinical Investigation. 
2011;121(3):985. 
 
37. Kigerl KA, Gensel JC, Ankeny DP, Alexander JK, Donnelly DJ, Popovich PG. 
Identification of two distinct macrophage subsets with divergent effects causing either 






38. Mikita J, Dubourdieu-Cassagno N, Deloire MS, Vekris A, Biran M, Raffard G, et 
al. Altered M1/M2 activation patterns of monocytes in severe relapsing experimental rat 
model of multiple sclerosis. Amelioration of clinical status by M2 activated monocyte 












CONCLUSIONS AND FUTURE DIRECTIONS 
 
 
This dissertation explores how the geometry, charge and surface modification of 
nanoparticles influence intracellular fate and uptake within macrophages.    
 
6.1 Conclusions 
6.1.1 Aim 1 conclusions 
In Chapter 3, positively charged silica nanoparticles were shown to induce 
autophagy, a cellular toleration and coping mechanism, within RAW 264.7 macrophages.  
Inclusion in autophagic vesicles was irrespective of size and shape of the nanoparticle 
systems. Similar fates for other highly positively charged systems have been observed (1, 
2). If payload delivery to a specific cellular compartment is required, autophagic 
compartmentalization will be detrimental. It will be imperative to keep this in mind 
especially when designing systems that require delivery to a specific intracellular 
compartment for efficacy.  
 
6.1.2 Aim 2 conclusions 
In Chapter 4, the influence of physicochemical characteristics on uptake 
mechanisms in macrophages was shown within RAW 264.7 cells and isolated primary 




of nanoparticle systems. Within this chapter the important role that geometry can play in 
the uptake of silica nanoparticle systems was also shown. Manipulation of geometry 
induced specific uptake mechanisms. Within the size ranges studied, highly positively 
charged materials appeared primarily to undergo clathrin-mediated endocytosis for 
~200nm spherical nanoparticles, while adjusting the geometry and size of these systems 
to ~1 um switched the primary uptake mechanism to macropinocytosis or phagocytosis 
with limited uptake of all nanoparticles in both systems. This chapter illustrates the 
capability to manipulate geometry to facilitate specific uptake mechanisms. In the design 
of systems for drug delivery intracellular payload delivery is highly dependent on the 
initial stages of uptake. Ultimate fate of the nanoconstruct could be determined via 
sequestration into compartments early on, ending the fate of the payload in vesicles 
which do not provide opportunity for delivery. 
 
6.1.3 Aim 3 conclusions 
In Chapter 5, the impact of macrophage phenotype on uptake was explored in vivo 
and in vitro. This chapter illustrates the importance of macrophage polarization state on 
studying and understanding the interactions of physicochemical characteristics with 
biological systems. M1 polarized macrophages took up silica nanoparticles to a higher 
extent than unpolarized or M2 macrophages. Unlike M2 and unpolarized macrophages, 
M1 polarized cells did not exhibit toxicity after nanoparticle treatment. This was 
consistent with in vivo findings, as nanoparticles resided within macrophages of clearance 
organs, liver and spleen, with little to no observed toxicity. Markers specific for M1-type 




these organs, suggesting the proliferative role of this phenotype in processing of the 
nanoparticles. The importance of surface chemistry on aggregation potential and initial 
biodistribution was observed. However ultimately all silica nanoparticles underwent the 
same processing. The chapter highlights the importance of the in vitro macrophage model 
system on understanding the fate of nanoparticles.  
Chapter 5 concludes by suggesting in vitro macrophage model systems may be 
capable of targeting specific phenotypes of macrophages, which may be useful in 
targeting pathogenically loaded macrophages or macrophages involved in immunological 
disorders. M1 phenotypes traditionally retain bacteria and pathogenic material within 
their cellular compartments. M1 targeting mechanisms may enhance the delivery of 
bactericidal materials. Additionally, M1 phenotypes are overexpressed in chronic 
debilitating immunological diseases such as MS and RA (3), targeted removal may 
provide therapeutic effect.  
 
6.1.4 Dissertation conclusions 
This dissertation illustrates the importance of macrophages in nanoparticle 
processing and suggests that M1 phenotypes of macrophages are more important than 
other phenotypes. This dissertation claims that macrophages not only uptake 
nanoparticles to a great extent but also appear to have global coping mechanisms to 
handle that uptake. Positively charged nanomaterials initiate autophagy within some 
macrophages to facilitate this coping mechanism. Physicochemical characteristics have 
been shown to drastically alter macrophage nanoparticle interactions. Finally, 




mechanisms. In designing of nanomaterials for drug delivery it will be important to 
consider these conclusions. 
 
6.2 Future directions 
6.2.1 Outline and explanation of future directions 
Early evidence suggests that innate immune functions, specifically cell 
autonomous processes utilized by cellular machinery in pathogen processing, are 
initiating inflammatory mediated events after systemic and oral nanoparticle treatments 
(4-15). Evidence in Chapters 3-5, as well as my lab’s collaborative work, suggests that 
autophagic mechanisms in phagocytic lines are up-regulating inflammatory genes, 
affecting cellular machinery, initiating fibrotic-like encapsulation and chronic 
inflammation (16-20).  The collaborative work also highlighted evidence demonstrating 
that NP surface characteristics significantly influence cellular in vitro and in vivo 
inflammatory responses (18-21). The ultimate goal of this future direction section is to 
understand how nanoparticles can be designed and modified to reduce inflammatory 
mediated events. 
Our lab has yet to expand upon the evidence that demonstrates correlations 
between specific inflammatory mediated mechanisms and surface characteristics. I 
believe it is possible to modulate the levels and potentially the mechanisms of inducing 
inflammation by modulating the surface characteristics. In this chapter, I propose to 
modulate SNP surface curvature, surface functionality, porosity and degradability to 
influence inflammatory mechanisms (increase inflammatory protein cascades, autophagy, 




surface curvature affect the protein adsorption to SNP, intracellular uptake mechanisms 
and the ultimate intracellular fate. Cellular trafficking mechanisms for particles that 
prompt inflammatory cascades facilitate chronic inflammatory endpoints. My lab has 
already shown significant alterations in hemolysis and biodistribution as a function of NP 
porosity (21, 22). Nonporous materials resided mostly in the spleen while porous 
materials were found in kidney (22). If certain mechanisms elicit specific localizations, 
they may also initiate different inflammatory cascades, due to differing interactions with 
the biological environment. Surface modifications, such as PEGylation, can impact 
inflammatory mediated results, as was shown in Chapter 5. Finally, silica itself, while 
nondegradable, cannot be cleared from the host tissue, and could initiate long-term 
fibrosis as a part of a host chronic response. Increased levels of immunological cells as a 
result of nanoparticle administration within tissues at 4 weeks described in Chapter 4 
helps to support that nondegradable NP materials initiate acute inflammatory 
mechanisms. Inflammatory initiation may be resolved with degradable silica particles, 
which would be resorbed and cleared. To test this, I propose to exploit established 
methods to adjust silica nanoparticle curvature and develop new methods to adjust SNP 
porosity and degradability. 
Chapters 3-5 and my lab’s collaborative efforts illustrate in vivo and in vitro 
evidence supports primary uptake via phagocytic systems and accumulation in RES 
organs as a result nanoparticulate insults on tissue, or encapsulation within thrombus, 
initial events of inflammatory mediated chronic response (17, 19, 23-26). Chapter 3 and 5 
also suggest that after phagocytic internalization, particles are trafficked to autophagic 




death and dysfunction appear to result from injurious response to the mitochondria and 
consequent ROS production. I propose that combinations of these intracellular processes 
initiate inflammatory cascades, leading to increased levels of gene expression and local 
induction of fibrosis responses. However, I cannot yet connect these mechanistic 
complications to develop requisite deeper understandings of how each process initiates 
another. Additionally, neither my lab nor I has yet to expand this understanding to 
specific NP surface characteristics, or to propose routes to induce or avoid specific 
cascades and mechanisms within these processes using NP designs. Additionally, I have 
not yet expanded these observations to other nanomaterials or examination of degradation 
products, to see if the results from these studies are universally applicable. As such I 
proposed to add the evaluation of PLGA particles, gold nanorods and G3.5 dendrimers to 
selected studies. I believe that the utilization of PLGA, as a polymer used in FDA-
approved products, gold nanoparticles, currently in phase 2 clinical trials, and 
dendrimers, used extensively in preclinical studies, will help to supply clinical 
applicability and devolve platform development. Here, I propose strategies to assess how 
NPs are taken up, trafficked and influence phagocytic cellular responses in vitro. I 
propose to utilize neutrophils, macrophages and dendritic cells as model systems for NP 
processing. I aim to identify inflammatory gene and protein expression resulting from 
variations in NP surface modifications, NPs themselves and degradation products, in 
order to address reductions in local levels of inflammation. I also propose to assess local 
levels of autophagy and connect NP surface characteristics that initiate these 
mechanisms. Additionally, I propose to analyze the relative levels of blood component 




ways to mitigate thrombotic plugs. The ultimate goal is to connect intracellular uptake 
and trafficking to downstream cascades. Based on observations in Chapters 3 and 5, I 
propose that autophagic encapsulation induces mitochondrial damage and subsequent 
inflammatory gene induction. I also propose to investigate levels of protein adsorption 
and what proteins may initiate inflammatory mediation, utilizing 2D gel methods specific 
inflammatory proteins (TNF-alpha, IL-1beta, IL-6, IL-8, IL-2, IL-4, IL-5) can be 
investigated. I propose to correlate these levels of adsorption to levels of activation of the 
same proteins via quantification using western blots, ELISA and their subsequent gene 
regulation by qPCR. I propose to correlate these degrees of adsorption to the relative 
level of inflammatory mediation events, and believe that surface modifications can 
substantially influence protein as well as inflammatory events. I also believe that these 
two events will be directly correlated, due to protein interactions with the inflammatory 
biological environment. Additionally, I propose to assess the levels of in vitro and in vivo 
degradation, as well as degradation products and their associated toxicity.  
Traditional chronic particle-associated inflammatory disease states, such as 
mesothelioma, pneumoconiosis, asbestos and silicosis, present 10-15 years after 
environmental particulate exposure. Gold, zinc and titanium particles have shown 
responses similar to silicosis (27, 28), suggesting that local nanoparticle encapsulation 
initiates acute inflammatory events that progress to chronic disease states due to the lack 
of NP resorption and clearance of the material. Currently, no long-term studies evaluate 
particles residence in tissues and what effects that residence has on the ultimate tissue 
inflammatory states. It is possible that NP residence induces autoimmune disorders. My 




events, fibrosis, and infiltration of PMNs suggesting downstream inflammatory cascades 
(22, 26, 29-34). This dissertation and my lab’s collaborative efforts in vitro evidence 
support this theory (17-19, 21, 23, 26, 32). Because of this I propose to investigate how 
NPs and their surface modifications initiate local chronic responses and progression 
through the phases of chronic inflammation. I also propose to expand selected 
experiments with PLGA particles, dendrimers and gold nanomaterials. I believe that 
degradation products will not cause the same levels of activation as whole nanoparticles. 
I propose to study mechanisms used for pathogen processing such as autophagy that 
initiate local fibrosis and increased levels of inflammation. I propose to test for chronic 
inflammation with CD-1 mice models to assess local infiltration of innate and adaptive 
immunological cells including but not limited to PMNs, T cells, and B cells, degree of 
fibrosis, local levels of inflammatory gene, cytokine and chemokine expression. I also 
propose to assess local levels of tissue autophagy to correlate with our previous findings. 
Ideally, one should seek to correlate mechanistic studies to suggest how and why certain 
specific surface functionalities present with specific chronic inflammatory mechanisms. 
The ultimate goal is to understand how these NP materials can be designed and modified 
to reduce inflammatory mediated events. 
 
6.2.1 Outline of future experiments 
6.2.1.1 Synthesis and characterization  






6.2.1.1.1 Surface curvature 
Monodispersed silica spheres with diameters of 50,500 nm (35) should be 
prepared by hydrolysis of tetraethyl orthosilicate (TEOS) in the presence of water and 
ammonia in ethanol (36). Silica colloidal sphere sizes should be controlled by changing 
ammonium concentration at fixed TEOS and water concentrations (35). Smaller silica 
nanoparticles should be prepared using a similar procedure (37). Surface curvature should 
be modified systematically with these preparative methods. Pegylated gold nanoparticles 
of 50nm size will be synthesized/characterized as described by Bergen et al. (38), 
pegylated PLGA nanoparticles should be synthesized and characterized as described by 
Velcia et al. (39) and dendrimers should be purchased from dendritic and prepared as 
described in our lab previously (30, 31, 40). 
 
6.2.1.1.2 Porosity and roughness  
As my lab’s collaborators have shown (41, 42), NP pore shape and size in silica 
nanoparticles are controlled by the size and nature of the porogen organic groups and by 
organic templates used during the nanoparticle formation. To establish relationships 
between the toxicity of silica nanoparticles and their porosity, one should prepare SNPs 
with different pore sizes and shapes, and with different porosities. To distinguish the 
effects of porosity based on altered adsorption of various biological molecules inside the 
pores from the effects based on the increased nanoparticle roughness, one should prepare 
SNPs with solid cores and mesoporous shells (43) and SNPs with varying degrees of 
surface roughness (44). The nanoparticle porosity should be examined using transmission 




be calculated from nitrogen adsorption/desorption isotherms. 
 
6.2.1.1.3 Surface PEGylation 
One should surface modify SNPs with a 5000 Da PEG with a terminal free amine, 
which will be conjugated to a N-hydroxysuccinimide (NHS) activated silane (Nanocs, 
Japan) via a reductive amidation chemistry. Following the conjugation, SNPs should be 
centrifuged and washed to remove excess reagents. Polymer conjugation to the surface 
will be confirmed by hydrodynamic radius measurements, Fourier transform infrared 
spectroscopy (FTIR) to confirm the presence of the PEG chains on the surface, and by 




As shown by my lab’s collaborators previously, novel approaches can be used to 
destabilize silica by incorporating cleavable organic linkers into SNPs (42). One should 
expand the set of linkers and will vary linker content in order to control the SNP 
degradability. These degradable silica nanoparticles should be characterized by scanning 
electron microscopy (SEM), dynamic light scattering (DLS) and TGA. The key 
characteristics to be examined will be SNP size, size distribution and composition. The 
latter is particularly important for toxicity prediction. While the starting materials for the 
synthesis are of intrinsically low toxicity (45-47), one should validate residual solvents 
within SNPs using TGA coupled with mass spectrometry (TGA-MS). If solvents are 




temperature. SNP degradability studies as a function of the cleavable linker structure and 
content should be followed by measuring the amounts of the resulting product, Si(OH)4, 
spectrophotometrically as a molybdenum blue complex (48). With this organosilica NP 
series in hand, one should perform degradation studies as a function of pH to obtain 
kinetic and thermodynamic data for the degradation process. 
 
6.2.1.1.5 Additional characterization of SNPs 
Since nanoparticles have the propensity to agglomerate depending on surface 
properties, one should utilize dynamic light scattering to evaluate the aggregation in cell 
culture media containing serum proteins. One should also use confocal microscopy to 
characterize aggregate localization and size within cells. Zeta-potentials will be measured 
for as-synthesized SNPs as a function of pH and also after equilibrating SNPs with cell 
culture media. The particles should be monitored for endotoxin contamination using LAL 
assay kits. 
 
6.2.1.1.6 Anticipated results, potential pitfalls, and alternative 
strategies 
In the event that SNPs do not degrade rapidly enough or not in response to sharp 
transitions in pH, one should augment destabilization by incorporating biodegradable, 
biocompatible polymer, poly(L-lactic acid), PLLA, as previously described (49). One 
should then study the influence of poly(L-lactic acid) molecular weight and amount on 
SNP degradation rates (49). One should incorporate PLLA also if insufficient porosity is 




produce increased changes in biological activity, triangular and cube-like silica 
nanoparticles should be prepared using reported procedures (50).   
 
6.2.1.2 Investigation of effects on cellular and protein inflammatory 
mediated mechanisms. 
6.2.1.2.1 NP stability in cell culture medium 
One should evaluate NP aggregation and stability in physiological conditions with 
DLS and UV measurements. Particles should be suspended in DMEM and mouse serum 
at 50 and 100 ug/mL and the hydrodynamic diameter and OD should be estimated at 37 
°C. All measurements should be performed in triplicate. I believe both nondegradable 
and degradable particles should be stable under these conditions.  
 
6.2.1.2.2 Degradation in vitro 
One should assess the relative levels of degradation of SNPs by enclosing known 
amounts (by weight) in dialysis bags (MW cut-off ~10000 Da) incubated in buffer 
solutions of pH values 4, 7.4, and 10. For determination of NP weight and size loss, NP 
samples will be removed from dialysis tubing medium at 1 day, 1 week, 1, 2, 4, 6 and 12 
months. Weight differences should be measured between samples at zero time and time 
removed represent weight loss over time t. Recovered solid residues should then be 







6.2.1.2.3 Degradation in vitro 
One should assess the relative levels of degradation of the silica nanoparticles by 
enclosing known amounts (by weight) in dialysis bags (cellulose membranes with a MW 
cut-off ~10000 Da). These bags should be incubated in several buffer solutions of pH 
values 4, 7.4, and 10. For the determination of the weight loss and size reduction from the 
nanoparticles, samples should be removed from the incubation medium at 1 day, 1 week, 
1, 2, 4, 6 and 12 months. The solid residues should be weighed and the weight difference 
between the sample at zero time and time removed will represent the weight loss 
occurring until time t. The solid residues should then be dissolved in buffer and size will 
be analyzed via DLS, TEM and flow field fractionation to see the relative size, 
topography and degradation mechanisms (51). The degradation products should also be 
tested for associated toxicity via standard proliferation assays and in selected 
immunological processes. One should capture degradation products and assess toxicity 
and enhancement of inflammatory activation. 
 
6.2.1.2.4 Immune cell processing 
Blood-derived neutrophils are isolated by density centrifugation (Ficoll-Plaque 
Plus, Amersham) and purified from contaminating erythrocytes as described (52). Their 
production of superoxide anion upon NP incubation is used as an indicator of neutrophil 
activation, measured spectrophotometrically at 550nm by following ferricytochrome c 
reduction. PBMC should be cultured to produce monocyte-derived DC as described (53). 
Cells will be seeded; 2 hours later nonadherent cells will be removed. Adherent PBMC 




days. Monocytes should be obtained from whole CD-1 mouse blood utilizing a density 
gradient centrifugation and isolated utilizing anti-CD14 microbead. These should then be 
cultured for 6 days in RPMI-1640 supplemented with 20% FBS and 100 ng/mL of 
macrophage colony stimulating factor at a density of 1.5x105 per cm2. Inflammatory 
mediated cells should be obtained by culturing cells for an additional 72 hours in RPMI 
1640 supplemented with 5% FBS and 100 ng/mL of LPS plus 20 ng/mL of IFN-gamma 
(54, 55). 
  
6.2.1.2.5 Cell viability and proliferation 
WST-1 assay should be used to assess the relative proliferative capacity and 
mitochondrial function. A base level of cellular toxicity should be assessed via a standard 
WST-1 (4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate) 
assay. Cells should be exposed to a range of concentrations (.0001-1000 ug/mL) of SNPs 
for 72 hours. IC50 values can be calculated using GraphPad Prism (La Jolla, CA). To 
assess plasma membrane integrity, cells should be exposed to various concentrations of 
NPs for 24 hrs and assayed for lactate dehydrogenase (LDH) or leakage with the 
CytoScan LDH leakage cytotoxicity assay (G-Bioscience, Madison, WI). Maximum 
LDH is assessed via total control cell lysis induced by 0.1% Triton X-100, and a diluted 
series of LDH supplied with the kit will be utilized as positive control. Degradation 







6.2.1.2.6 Cellular uptake 
SNP uptake by cultured cells is visualized by confocal microscopy. Cells should 
be incubated for 24 h with 50 µg/ml FITC-labeled SNPs. Cell nuclei should be stained 
with DRAQ5 (Biostatus Ltd.). Fluorescent images of live cells should be captured using 
confocal laser scanning microscopy. Laser beam intensity and photodetector sensitivity 
should be kept constant in order to compare relative fluorescence intensities between 
experiments. Z-stacks should be collected and used for 3D reconstruction and 
visualization of intracellular particle localization. Flow cytometry should be used to 
quantify SNP uptake. Cells should be grown and incubated with 75 µg/ml FITC-labeled 
SNPs for various time points (0.5, 1, 2, 4, 6, 12 and 24 h). Following incubation, analysis 
should be performed on a FACSCalibur (BD Biosciences, Germany). Emitted light 
resulting from FITC-labeled NPs should be detected and background fluorescence of 
unlabeled cells subtracted. Cells without any NP addition will be negative controls in 
every measurement. Data analysis should be performed with BD CellQuest Pro (BD 
Biosciences, Germany). 
 
6.2.1.2.6 Co-localization in intracellular compartments 
The co-localization of SNPs with acidic and basic lysosomes, as well as 
autophagosomes by cultured cells should be assessed by confocal microscopy. Cells 
should be grown and incubated for 24 hrs with 50 µg/ml FITC-labeled NPs. Lysosomes 
should be stained with 2.5 µM LysoSensor Yellow/Blue DND-160 or 50 µg/mL 
Transferrin Alexa Fluor 546 (Invitrogen Corp., Carlsbad, CA). Fluorescent images of live 




6.2.1.2.7 Transmission electron microscopy (TEM) 
Cell uptake of SNPs by cultured cells will be assessed by TEM. Cells should be 
seeded on 1x1 cm ACLAR plastic. After an overnight incubation, 50 µg/mL of SNPs 
should be added and cells incubated for 24 hr after which cells should be fixed. Cells 
should be stained with uranyl acetate for 45 min at room temperature and TEM images 
should be taken with a Phillips TECHAI F2 TEM (Hillsboro, USA) at an accelerating 
voltage of 80 kV.  
 
6.2.1.2.8 Protein adsorption 
A 2-D PAGE gel of the protein containing supernatants should be run before and 
after adsorption to nanoparticles (56, 57). 2-D PAGE separates proteins with respect to 
their isoelectric point in the first dimension and their molecular weight in the second 
dimension (58-61). The gels should be stained for proteins using high affinity 
quantitative silver staining. It has been shown that the 2-D PAGE adsorption method can 
analyze which plasma proteins simultaneously bind to particles both in vivo and in vitro 
(58, 60). The gel after adsorption should be compared to standards and specific spots 
should be excised and characterized individually. While gross surface adsorption should 
be determined via ellipsometry, circular dichroism, SPR, and optical waveguide 
lightmode spectroscopy, the specific proteins adsorbed to the surface should be 
determined from the  2-D gel excised spots via NMR, FTIR, MS, or Western blotting 
similar to previous procedures (62-65). Correlations between adsorption and Western 
blot/ELISA analysis should be determined, specifically one should investigate the 




quantify the degree of adsorption and correlate that to the relative activation of 
inflammatory mediated mechanisms. 
 
6.2.1.2.9 Assessment of inflammatory cytokine production 
 Fresh blood from CD-1 mice (6-8 weeks old) should be drawn into an 
appropriate anticoagulant-containing polypropylene container using gravity flow to 
prevent cell damage due to shear. Collected blood should be diluted to 25% with 
plasmalyte, a physiological dilutent used during surgical procedures. Aliquots (1 ml) of 
the blood should be added to 24-well cell culture plates. Stock concentrations of SNPs 
will be added to the blood (100 µL of synthesized SNP added to 1 mL of blood). The 
blood with the test compound should be incubated at 37 oC for 15 min. Following the 
initial incubation, 10 µg/mL of LPS (as a control treatment) and NPs below IC50 
concentration should be added. The plate should be incubated for 2 h with shaking on an 
orbital shaker at 37°C. After incubation, plates should be spun down at 1300g and plasma 
extracted for inflammatory cytokine analysis using capture ELISA methods (BD 
Biosciences). For Inflammatory Capture ELISA (TNF-alpha, IL-1beta, IL-6, IL-8, IL-2, 
IL-4, IL-5) 96-well polystyrene microtiter plates should be coated with anti-inflammatory 
cytokine capture antibodies overnight at 4oC. One hundred µl of plasma extracted from 
the same whole blood method should be added to the respective wells and incubated at 
room temperature for 1 h. Samples should be aspirated and incubated with inflammatory 
cytokine detection antibody conjugated to a horseradish peroxidase substrate for 1 h. 
Antibody solutions should be aspirated and the plate washed, developed with 3,3',5,5'-




6.2.1.2.10 Western blot and ELISA assessment of cell  
inflammatory and autophagic activation 
Relative levels of LC3-I and II (traditional autophagic markers), MIP1, MIP2, 
MCP, iNOS (traditional inflammatory markers) should be assessed utilizing standard 
western blot and ELISA techniques. Cells should be lysed with Radio-
Immunoprecipitation Assay (RIPA) buffer supplemented with protease inhibitor cocktail 
(Sigma) and sodium dodecyl sulfate polyacrylamide gel electrophoresis should be 
performed. Protein immunobloting should be performed via gel transfer to PVDF 
membranes. The membrane should be blocked and incubated with primary antibodies 
(Novus Biologicals) for 1 hr and then with peroxidase-conjugated secondary stabilized 
goat anti-rabbit antibodies (Pierce) for 1 hr. Proteins should be detected with western 
blotting. One should include degradation products of degradable silica systems, PLGA 
particles, gold nanorods and G3.5 dendrimers within this examination.  
 
6.2.1.2.11 Inflammatory gene profiling 
My lab’s collaborators have considerable experience using the Agilent microarray 
platform (20) but RNAseq allows for more thorough gene expression analysis. Therefore, 
it is proposed to utilize RNAseq to generate transcriptional profiles of primary human 
cells exposed to nontoxic SNP doses. Following cell viability analysis, nontoxic amounts 
of NPs should be dosed to macrophages, dendritic cells and neutrophils. Total RNA 
should be collected following ~4 hrs of incubation with NPs (Qiagen RNeasy minikit 
protocol RNA), quantified (Nanodrop spectrophotometer), and assessed for quality. 




as monitored using the Experion (Bio-Rad) analyzer to ensure high quality RNA is used 
for the expression analysis. One should utilize Illumina TruSeq RNA sample preparation 
to generate barcoded sample libraries. Supervised strategies should be used to identify 
genes with greatest significant differences among NP treatments and compared to 
untreated controls. Since RNAseq has considerable costs, a focus should be on ensuring 
reasonable sequencing depth. A maximum of 8 multiplexed samples per HiSeq 2000 lane 
to ensure that the depth of sequencing should be sufficient (currently, typical results from 
one HiSeq lane at our institution is between 150-200 million reads or approximately 7.5 
to 10 billion bases, so for 8 multiplexed samples, we anticipate >16 million 
reads/sample). The samples should be processed using the Genomic Analyzer Pipeline 
and mapped to the genome using GNUMAP. The differential gene expression profiles are 
used for pathway analysis where a focus on gene ontology, transcriptional regulation 
(TRANSFAC) and KEGG analysis of the differentially expressed genes should be 
accomplished with GATHER(66). Degradation products of degradable silica systems, 
PLGA particles, gold nanorods and G3.5 dendrimers will be included within this 
examination. 
 
6.2.1.2.12 Validate select genes by quantitative PCR 
Microarray expression analysis is generally a semiquantitative method. Hence 
select genes that may serve as potential biomarkers will be evaluated by quantitative PCR 
procedures. Should the transcriptional profiling identify genes involved in inflammatory 





6.2.1.2.13 Platelet aggregation 
Platelet-rich plasma (PRP) and platelet-poor plasma (PPP) should be prepared 
from citrated CD-1 mice, 6 - 8 weeks old (67). Various concentrations (50-500 µg/mL) of 
blank nanoparticles should be incubated at 37°C for 10 min with PRP containing 106 
platelets/ml under constant stirring. Platelet aggregation in the presence of various 
nanoparticle concentrations should be measured turbidimetrically from absorbance at 
500nm. Collagen (2 ug/ml) and epinephrine (2.5 µmol/L) should be used as positive 
controls. Platelet aggregation by the positive controls added to PRP (106 cells/ml) should 
be measured in the absence or presence of NPs. 
 
6.2.1.2.14 Neutrophil activation studies 
Neutrophils should be isolated by density centrifugation (Ficoll-Plaque Plus, 
Amersham) and purified from contaminating erythrocytes as described previously (68). 
The production of superoxide anion upon NP incubation with neutrophils is used as an 
indicator of neutrophil activation and measured spectrophotometrically at 550nm by 
following ferricytochrome c reduction (68). The reduction of ferricytochrome c as a 
result of NP incubation with neutrophils should be carried out in the presence and 
absence of superoxide dismutase (SOD; free radical scavenger). The superoxide 
production should be determined in supernatants from AU550 of samples without SOD 
minus samples with SOD. The results obtained from NP suspensions should be presented 
with respect to the amounts of superoxide production from neutrophil incubation with 
phorbol 12-myristate 13-acetate (PMA; positive control). The criteria for selection of 




than 5% of positive controls (in both platelet aggregation and neutrophil activation). 
 
6.2.1.2.15 Thrombin assays 
Platelet-rich plasma (PRP) should be obtained via centrifugation of whole mouse 
blood for 20 min at 150 x g. Prior to PRP isolation the whole blood will need to be 
incubated with SNP samples for 30 min or 4 hr. A Synergy HT multi Detection 
Microplate Reader (Bio-Tek Instruments, Winooski, USA) will be utilized to determine 
thrombin generation at excitation/emission wavelength of 360 nm/460 nm.  
 
6.2.1.3 Investigation of chronic inflammatory mechanisms in 
vivo as a function of NP surface properties 
6.2.1.3.1 Animal models and treatments 
CD-1 mice, 6 - 8 weeks old, should be purchased from Jackson Laboratories 
(USA). Synthesized SNPs should be injected via tail vein into these mouse models at 20 
mg/kg (a concentration previously showing acute toxicity and fibrosis as well as 
physiologically relevant in drug delivery applications (35 mg/kg, Nanomedicine: 
Nanotechnology, Biology, and Medicine 8 (2012) 212–220) (21, 29, 53)). Saline should 
be utilized as a negative control and crystalline silica known to induce silicosis as a 
positive control. Each treatment method should have 10 mice per time point, for a total of 
280 mice; 5 mice should be utilized to assess histology/immunohistochemistry and for 
protein, RNA and DNA assessment and 5 for biodistribution. At Day=0, mice receive 
intravenous injection of NPs at maximum concentration in 25 µL of media 




by CO2 asphyxiation. One should include degradation products of degradable silica 
systems, PLGA particles, gold nanorods and G3.5 dendrimers within this examination to 
ensure universal applicability, but reduce assessment to 2-, 24- and 60- week time points 
to reduce animal sacrifice increasing animals by 90 for a total of 370 mice. Large 
numbers of animal cohorts are necessary since these experiments have previously been 
unperformed and we are unable to complete a proper power analysis.  
 
6.2.1.3.2 Histology, foreign body response and immunological  
cell infiltration  
Five mice from each time point and treatment will be utilized. Primary 
accumulation organs (lung, spleen, kidney, liver) should be excised and placed in 
histological cassettes, fixed in formaline-free zinc fixative (BD PharMingen, San Diego, 
USA) for 48 hours. Tissue should be embedded in paraffin, stained with hematoxylin and 
eosin, masson’s trichrome to assess the level of macrophage fusion or presence of foreign 
body giant cells and extent of local fibrosis. The fusion of local macrophages should be 
determined by counting total numbers of cells with fused nuclei, with foreign body giant 
cells defined as having three or more nuclei. Immunohistochemical analysis should be 
performed with the sliced paraffin-embedded blocks, the paraffin should be removed 
from the tissue sections utilizing EZDeWax solution (Biogenex Lab, San Ramon, CA). 
Staining should be done with F4/80 and CD11b (for macrophages), CD3 (for T cell 
infiltration), B220 (for B cell infiltration), IL-3, IL-4, IL-10 and TGF-beta 
(immunoregulatory cytokines and chemokines), IL-6, TNF-alpha, IFN-gamma, MCP-1 




QS (Vector Laboratories) and observed under the microscope. In gross blinded 
pathological examination one should look for hard nodules, with enlarged lymphatic 
nodes. Statistical significance should be determined using one way ANOVA with 
Bonferroni’s multiple comparison post test (p<0.05). 
 
6.2.1.3.3 Accumulation, residence and degradation rates of SNPs 
Five mice from each time point and treatment should be utilized to assess the 
relative level of accumulation over time of silica in residence organs. Inductively coupled 
plasma mass spectrometry should be utilized to quantify silica retention in tissues and 
blood. After sacrifice, blood should be collected using a heparinized needle from the 
inferior vena cava and the animals should be perfused with at least 20 mL of saline by 
cardiac puncture. Blood and organs such as the liver, spleen, lungs, heart and kidneys 
should be collected and weighed. Each sample should be refluxed in 4 ml of fresh trace-
metal grade aqua regia at 90 °C for 24 hrs, and then dried at 130 °C. Subsequently, 
samples should be dissolved in 4 ml of 5% trace-metal grade nitric acid before 
quantification of silica content by ICP-MS against a silica internal standard. Statistical 
significance should be determined using one way ANOVA with Bonferroni’s multiple 
comparison post test (p<0.05). The relative level of degradation of the newly developed 
silica nanoparticles should be assessed via increased clearance rates.  
 
6.2.1.3.4 PK analysis for early degradation of silica nanomaterials  
CD-1 mice, 6 - 8 weeks old, will need to be purchased from Jackson Laboratories 




particles) should be injected into these mouse models at 20 mg/kg (a concentration 
previously evaluated to show acute toxicity and fibrosis and is significantly less than 
recent therapeutic levels of in vivo treatments of silica (35 mg/kg, Nanomedicine: 
Nanotechnology, Biology, and Medicine 8 (2012) 212–220) (21, 29, 53)), saline should 
be utilized as a negative control and 50 nm Stöber nanoparticles, as a positive control. 
Each treatment method should have 5 mice per time point, with a total of 90 mice. At 
Day=0 mice receive intravenous injection of NPs at maximum concentration in 25 µL of 
solution which should be approximately 20 mg/kg. At 0, 1, 12, 24, 48, and 72 hours mice 
cohorts should be euthanized by CO2 asphyxiation. Blood and major organs should be 
collected and ICP-MS should be utilized to assess relative levels of silica accumulation. 
Metabolic cages should be utilized to extract and quantify the concentration excreted 
through renal or hepatic means. The relative level of degradation of the newly developed 
silica nanoparticles can be assessed via increased clearance rates.   
 
6.2.1.3.5 Phases of chronic inflammation 
The phase of chronic inflammation should be evaluated utilizing analysis from the 
histological slides outlined above. Since limited to no evidence has been provided for 
nanoparticle chronic evaluation, one will assess the levels based on previously reported 
microspheres (69). One should assess local/chronic inflammation characterized by the 
pre-defined inflammatory phases outlined below (69). A significant temporal variation in 
the acute, chronic and developed granulation, foreign body and fibrous encapsulation 





6.2.1.3.5.1 Phase 1. One should look for minimal inflammatory reaction within 
the first 2 weeks of treatment with the presence of PMNs, leukocytes, lymphocytes, 
plasma cell and monocytes. One should expect to see edema, transient myositis and 
initial injury or damage to local tissue due to deposition of the particles. High levels of 
monocytes will infiltrate and adopt local macrophage phenotype. 
6.2.1.3.5.2 Phase 2. The persistence of this phase depends on the length of time of 
residence of NPs in the tissue. One should look for creation of foreign body giant cells or 
highly activated macrophages, as well as the presence of the initial stages of fibrosis and 
infiltration of fibroblasts. Staining for collagen should also be done at this point to assess 
the local levels of fibrous capsule formation. One should also assess the local levels of 
neoangiogenesis and formation of blood capillaries. I believe, as happens in microparticle 
cases, that we will see this development within 4-20 weeks after the initial acute phase 
reaction. 
6.2.1.3.5.3 Phase 3. Enhancement of the fibrous capsule will take place with large 
increases in local inflammatory response, including increased neovascularization, 
collagen deposition, and fibroblast infiltration. The rate of NP degradation will facilitate 
the time length that NPs reside within this phase. I propose that it is possible with 
nondegradable systems to continue to maintain this phase for the animal’s life due to the 
inability to secrete the local nanomaterials. During each phase, at least two people should 
assess local histological sections, utilizing a scoring system to assess the levels of 
infiltration, extent of collagen deposition and levels of local vascularization. One should 
utilize a blind evaluation with a rating system of - = no infiltration and ++++ will = 




ANOVA with Bonferroni’s multiple comparison post test (p<0.05).  
 
6.2.1.3.6 Connecting fibrosis and autophagic activation  
6.2.1.3.6.1 Immunohistochemistry and Western blot. Five mice should be used 
from each time point. One should stain for autophagic markers (i.e., LC3 transition from I 
to II), to verify autophagy at each time point. Sections should be washed with phosphate-
buffered saline (PBS; pH 7.4) and blocked. They should be incubated overnight at 4°C 
with primary antibody and the following day the slices should be incubated for 2 h with 
fluorochrome-coupled secondary antibody at room temperature. A confocal microscope 
should detect the following autophagic immunohistochemistry markers: anti-
microtubule-associated protein 1 light chain 3, anti- beclin-1, anti-caspase-3 and anti-p62. 
Western blot should be run on digested samples with similar primary markers to quantify 
levels in tissue over time to back correlate autophagic markers to phases of chronic 
inflammation and levels of fibrosis. Statistical significance should be determined using 
one way ANOVA with Bonferroni’s multiple comparison post test (p<0.05). 
6.2.1.3.6.2 Real time PCR analysis. One should further refine the induction of 
inflammatory genes that are obtained from aim two and assess the local tissue levels for 
inflammatory and fibrotic markers to help correlate stages of inflammation to fibrotic 
levels. Statistical significance should be determined using one way ANOVA with 
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Figure A.1: RAW 264.7 cellular viability profiles after 72 hour 
incubation with various concentrations of silica nanoconstructs. The 
values of 3 different experiments are shown. Proliferative functional 
alteration was not observed up to approximately 50 ug/mL at which 
point there was a rapid fall off in proliferation, suggesting a threshold 





Figure A.2: A549 cellular viability profiles after 72 hour incubation 
with various concentrations of silica nanoconstructs. The values of 3 
different experiments are shown. Proliferative functional alteration 
was not observed up to approximately 50 ug/mL at which point there 





Figure A.3: Mode of cell death induced in A549 cells after 24 hours 
of incubation with 500 µg/mL of silica nanoparticles. Annexin V 
(green) staining provides evidence of apoptotic cell death and PI (red) 
staining provides evidence of necrotic cell death. The combination of 
the two dyes is usually indicative of late stage apoptosis or necrosis. 
Representative single plane confocal images of: A) Control; B) 












Figure A.4: Relative levels of activated caspase 3 in silica nanoconstruct 
treated A549 cells. Statistically only adipocyte (positive control) showed 
a relative change in caspase activation when compared to control. All 
other treatments provide the same relative fluorescence due to cell 
treatment and washing. The star indicates a statistically significant 





Figure A.5: Assessment of modes of silica nanoparticle uptake by confocal imaging. 
Modes of nanoparticle uptake were assessed by co-incubating transferrin with each 
nanoconstruct and analyzing the relative co-localization of the two. Transferrin (red) 
and 50 µg/mL construct (green) were co-incubated for ~4 hours. Nuclei (blue) of cells 
were stained with DRAQ5 following incubation. A) Cylinders in RAW 264.7; B) 









Figure A.7: RAW 264.7 cells incubated with 50µg/mL of worms: green corresponds 
to FITC labeled particles; blue corresponds to basic lysosomal compartments; red 
corresponds to acidic lysosomal compartments; orange corresponds to colocalization 





Figure A.8: Western blot images of expressed proteins Atg9a, Beclin and Atg5 in both 
A549 and RAW 264.7 cell lines. Tamoxifen and Rapamycin were utilized as positive 
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Figure B.1: TEM images of silica nanoparticles used in this study. A: Spheres, B: 







Figure B.2: Confocal images of 50 µg/mL silica nanoconstruct uptake after 24 
hours of incubation in RAW264.7 (left) and A549 cells (right). Cell nucleus in 
pink and particles in green A and D) Worms; B and E) Cylinders; C and F) 





Figure B.3: Confocal image analysis of preliminary uptake of nanoparticles 
within primary cells. 3a: Primary macrophage confocal image (membrane stained 
red) uptake of silica nanoparticles (green).  A and B) Alveolar macrophages 
treated with 75 µg/mL of spherical and worm like nanoparticles, respectively. C 
and D) Tissue macrophages treated with 75 µg/mL of spherical and worm like 
nanoparticles, respectively. Alveolar macrophages (A and B), as this figure 
demonstrates when correlated to our FACS analysis in Figure 4.1, there is a 
greater degree of nanoparticle uptake when compared to tissue macrophage 
uptake where much of fluorescence was associated with the cell membrane (C 
and D).  It is also important to note that macrophages treated with spherical 
nanoparticles (A and D) when compared to worm like nanoparticles (B and D) 
appear to have a greater degree of nanoparticle uptake (at this time point, 1.5 
hours).  This suggests a phenotypic and geometric implication. 3b: Confocal 
image of uptake of silica nanoparticle constructs in alveolar epithelial cells; 
limited uptake of silica nanoconstructs was observed in primary epithelial cells 
similar to what is observed in FACS results presented in Figure 4.1b. Particles 
(green) at a concentration of 50µg/mL were incubated with primary alveolar 
epithelial cells for two hours, following incubation to help with cellular 
visualization of the cell membrane stained with Rhodamine-WGA (red) and 
nucleus stained with DAPI following cellular fixation; A) Cylinder incubation, B) 






Figure B.4: Vialight assay, assessing the relative ATP level in metabolically 
active cells.  4a and 4b: Vialight assay, assessing the relative ATP level in 
metabolically active cells.   In 4a, macrophages exhibit a varied response. When 
exposed to high concentrations of silica nanoparticle constructs they exhibit a 
degree of toxicity while they appear to tolerate lower concentrations. As shown in 
4b, alveolar epithelial cells show very little decrease in cell viability when 
exposed to silica nanoparticle constructs 4c:  RAW 264.7 macrophages exhibit a 
varied response. When exposed to high concentrations of silica nanoparticle 
constructs they exhibit a degree of toxicity while tolerating lower concentrations.  
4d: A549 epithelial cells show very little decrease in cell viability when exposed 
to silica nanoparticle constructs.  Please note: graphs are represented as 






Figure B.5: Time dependent fluorescence uptake of silica nanoparticles. 5a and 
5b) All time points tested were of 75 µg/mL in RAW 264.7 cells and A549 cells 
respectively. A gradual increase in concentration uptake was observed in cells 
until a concentration threshold was achieved. Above this threshold cells no longer 
took up nanoparticles. Please note: graphs are represented as percentage of 
control or the background provided by FACS analysis of cells incubated without 







Figure B.6: Uptake of nanoparticles as a function of temperature in model cell 
lines. The graph provides confirmation of energy dependent mechanisms of 
uptake. Please note: graph is represented as percentage of uptake at 37 degrees of 
the respective nanoparticle at 4 degrees. So at 4 degrees RAW 264.7 cells exhibit 





Figure B.7: ATP in metabolically active cells following treatment with uptake 
inhibitors. Caveolin dependent endocytosis was assessed utilizing Nystatin at a 
30 minute pre-incubation at 20 µg/mL. Clathrin dependent endocytosis was 
assessed utilizing a 30 min pre-incubation with either 100 µmol of 
Dansylcadaverine or 10 µg/mL of Chlorpromazine. Clathrin and caveolin 
independent endocytosis were assessed utilizing a 30-minute pretreatment with 
30 µg/mL Monensin. Phagocytosis and macropinocytosis were assessed utilizing 
a 1-hr incubation with 10 µmol or 10 nmol concentrations of Wortmannin or a 





























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure B.8: Quantitative assessment of nanoparticle uptake by flow cytometry. 
An additional lower concentration of wortmannin was tested to discern between 
phagocytic and macropinocytic uptake. However, very little differences between 
the two concentrations were observed. Please also note: graphs are represented as 
percentage of uptake or the background provided by FACS analysis of cells 






Figure B.9: Uptake and association of cylindrical particles are similar to worm-
like particles. A) Actin staining with cylindrical treatment in RAW 264.7 cells, B) 
Dextran staining with cylindrical treatment in RAW 264.7 cells, C) Transferrin 
staining with cylindrical treatment RAW 264.7 cells, and D) TEM images of 
cylindrical treatment RAW 264.7 cells. Note: graphs are represented as 
percentage of uptake or the background provided by FACS analysis of cells 






Figure B.10: Microscopy of nanoparticle uptake in A549 cells. A549 data are included 
to supplement the RAW 264.7 data outlined in the paper. Due to similarities of the 
images, these were excluded from the text of the paper included as Chapter 4. 
